<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:cik1690384="http://biocrudetechnologiesusaInc.com/20210630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_cik1690384_biocrudetechnologiesusaInc.com_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20210101_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001690384 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityCentralIndexKey">0001690384</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="AsOf2021-06-30" id="xdx2ixbrl0065" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="AsOf2020-12-31" id="xdx2ixbrl0066" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2021-06-30" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-04-012021-06-30" id="xdx2ixbrl0113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0114" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0115" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-04-012021-06-30" id="xdx2ixbrl0143" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0144" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0145" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0146" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2021-04-012021-06-30" id="xdx2ixbrl0183" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0184" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0185" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0235" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0236" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik1690384:SubscriptionReceivable" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik1690384:SubscriptionReceivable" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik1690384:SubscriptionReceivable" contextRef="From2021-01-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik1690384:SubscriptionReceivable" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik1690384:SubscriptionReceivable" contextRef="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="From2021-04-012021-06-30_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik1690384:ForgivenessAccruedInterest" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik1690384:BeneficialConversionFeatureDiscountRelatedToIssuanceOfConvertibleDebt" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik1690384:BeneficialConversionFeatureDiscountRelatedToIssuanceOfConvertibleDebt" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik1690384:StockIssuedForServices" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik1690384:ForgivenessAccruedInterest" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="cik1690384:ForgivenessAccruedInterest" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cik1690384-20210630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik1690384:TotalEquityAttributableToEquityShareholdersOfTheCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik1690384:TotalEquityAttributableToEquityShareholdersOfTheCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik1690384:TotalEquityAttributableToEquityShareholdersOfTheCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik1690384:TotalEquityAttributableToEquityShareholdersOfTheCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cik1690384:TotalEquityAttributableToEquityShareholdersOfTheCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_BiocrudeHKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">cik1690384:BiocrudeHKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_LoanPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cik1690384:LoanPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690384</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 10pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 14pt Times New Roman, Times, Serif"><b>U.S.
SECURITIES AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_90D_edei--DocumentType_c20210101__20210630_zDHyDVf11nPd"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Mark
One)</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--DocumentQuarterlyReport_c20210101__20210630_ztwnkALtUMea"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
the quarterly period ended <span id="xdx_908_edei--DocumentPeriodEndDate_c20210101__20210630_zFe7GF0M61li"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 30, 2021</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">or</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_edei--DocumentTransitionReport_c20210101__20210630_zW4EdmPFIwyc"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
Transition Report under Section 13 or 15(d) of the Exchange Act</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the Transition Period from ________to __________</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number: <span id="xdx_90F_edei--EntityFileNumber_c20210101__20210630_zUJbVDBwCz8e"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityFileNumber">000-55818</ix:nonNumeric></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 24pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityRegistrantName_c20210101__20210630_z72jYoWdxoy6"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityRegistrantName">BioCrude Technologies USA, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><i>(Exact Name of Registrant as Specified
in its Charter)</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 50%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20210101__20210630_z92xNDc8FSg4"><span id="xdx_90F_edei--EntityAddressStateOrProvince_c20210101__20210630_zPm1BMmrY1G7"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Nevada</ix:nonNumeric></ix:nonNumeric></span></span></b></span></td>
    <td style="width: 1%; text-align: center; line-height: 107%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 49%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20210101__20210630_zzmi7TLnPJE4"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityTaxIdentificationNumber">81-2924160</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><i>(State of incorporation)</i></span></td>
    <td style="text-align: center; line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><i>(I.R.S. Employer Identification No.)</i></span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20210101__20210630_zFKSk32DEbfl"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressAddressLine1">1255 Phillips Square</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20210101__20210630_zabVqlvsGtA6"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressAddressLine2">Suite 605</ix:nonNumeric></span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center"><b><span id="xdx_903_edei--EntityAddressAddressLine3_c20210101__20210630_zFOxse7yQPpf"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressAddressLine3">Montreal</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressCityOrTown_c20210101__20210630_zpOZjQRwEdf5"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressCityOrTown">Quebec</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressCountry_c20210101__20210630_zjHBO0VXgJq9"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Canada</ix:nonNumeric></span>
<span id="xdx_903_edei--EntityAddressPostalZipCode_c20210101__20210630_zhL1hNR9oynh"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressPostalZipCode">H3B 3G5</ix:nonNumeric></span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center"><i>(Address of principal executive
offices)</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_90D_edei--CityAreaCode_c20210101__20210630_zuwfnAkdHHte"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:CityAreaCode">514</ix:nonNumeric></span>-<span id="xdx_90E_edei--LocalPhoneNumber_c20210101__20210630_zM97bMY4FJB5"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:LocalPhoneNumber">840-9719</ix:nonNumeric></span></b>&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><i>(Registrant&#8217;s telephone number
including area code)</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 34%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Title of Class</span></td>
    <td style="width: 1%; text-align: center; line-height: 107%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Trading Symbol</span></td>
    <td style="width: 1%; text-align: center; line-height: 107%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Name of each exchange on which registered</span></td></tr>
<tr style="background-color: #CCEEFF">
    <td>&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td>&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the issuer (1) filed all reports required to be filed by Section13 or 15(d) of the Exchange Act of 1934
during the past 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Yes&#160;&#9744;&#160;&#160;&#160;
<span id="xdx_904_edei--EntityCurrentReportingStatus_c20210101__20210630_zqFytBCtjn24"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityCurrentReportingStatus">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_907_edei--EntityInteractiveDataCurrent_c20210101__20210331_zSh5Xyy4BNh7" style="display: none; font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2021-01-012021-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>
</span><span style="display: none; font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;an accelerated filer&#8221; and &#8220;smaller
reporting company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
    <td style="width: 40%; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Large Accelerated Filer</span></td>
    <td style="width: 10%; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td>
    <td style="width: 40%; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">AcceleratedFiler</span></td>
    <td style="width: 10%; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td></tr>
<tr>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityFilerCategory_c20210101__20210630_zZF83wiUkqH1"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-Accelerated Filer</ix:nonNumeric></span></span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Smaller Reporting
    Company</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--EntitySmallBusiness_c20210101__20210630_z0SlL0gKWKR3"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
<tr>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Emerging Growth
    Company</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20210101__20210630_zlQDj8RovQAd"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Yes&#160;&#9744;
&#160;&#160;&#160;<span id="xdx_900_edei--EntityShellCompany_c20210101__20210630_ztGj4ZA1ovZk"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">As of <span>June 30, 2021</span>,
the issuer had <span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_c20210630_zCco0gOuFBIc"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,710,386</ix:nonFraction> </span>shares of common stock issued and outstanding.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 107%">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Page</span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td colspan="3" style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><b>PART I &#8211; FINANCIAL INFORMATION</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 10%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext">Item 1.</span></td>
    <td style="width: 80%; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><a href="#a_002">Financial Statements- Unaudited</a></span></td>
    <td style="width: 10%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext">Item 2.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><a href="#a_003">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</a></span></td>
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">8</span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext">Item 3.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><a href="#a_004">Quantitative and Qualitative Disclosures about Market Risk</a></span></td>
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">30</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext">Item 4.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><a href="#a_005">Controls and Procedures</a></span></td>
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">30</span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td colspan="3" style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><b>PART II &#8211; OTHER INFORMATION</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: center; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext">Item 1.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><a href="#a_007">Legal Proceedings</a></span></td>
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext">Item 1A.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><a href="#a_008">Risk Factors</a></span></td>
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext">Item 2.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><a href="#a_009">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext">Item 3.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><a href="#a_010">Defaults Upon Senior Securities</a></span></td>
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext">Item 4.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><a href="#a_011">Submission of Matters to a Vote of Security Holders</a></span></td>
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext">Item 5.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><a href="#a_012">Other Information</a></span></td>
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext">Item 6.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><a href="#a_013">Exhibits</a></span></td>
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="a_001"></span>PART I &#8211; FINANCIAL INFORMATION</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span id="a_002"></span><span style="text-decoration: underline">ITEM 1</span>. FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BIOCRUDE TECHNOLOGIES USA, INC.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(EXPRESSED IN US DOLLARS)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b>&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_305_111_z0j14F9nt4Q1" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_499_20210630_zYzkTpqFPvmk" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_49D_20201231_zpxgkJvneZM7" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">UNAUDITED <br /> June 30,<br /> 2021</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">AUDITED<br /> December 31, <br /> 2020</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_zv85ea0rrvi9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="9" style="text-decoration: underline; font-weight: bold; text-align: center">ASSETS</td></tr>
<tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_zY3CgC20VsFj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--Cash_i02I_maAzU5l_zhJyES8ZTUXk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Cash</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,412</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,971</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzU5l_zAigdars5iqb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property, plant and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,048</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,697</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--Assets_iTI_mtAzU5l_z5CWaB1OvJq2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,460</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,668</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zaFaa98hlPT5" style="vertical-align: bottom; background-color: White">
    <td colspan="9" style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</td></tr>
<tr id="xdx_40D_eus-gaap--LiabilitiesCurrentAbstract_i01B_zc3jEksw2Azl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maLz9V5_zXJvn2hJyr6i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable and accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,172</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccountsPayableRelatedPartiesCurrent_i02I_maLz9V5_zGrIoL1hPyu1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable and accrued liabilities - related parties (Note 6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,017</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,727</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--ConvertibleDebtCurrent_i02I_maLz9V5_zqudQFZGTWoj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible notes (Note 3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0065">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0066">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LoansPayableCurrent_i02I_maLz9V5_zmUwFR7yESvi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loans payable (Note 4)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,671</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,169</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--Liabilities_iTI_mtLz9V5_maLASEz2Pd_zXCMhB7KRwR8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">TOTAL LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,860</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">278,296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--StockholdersEquityAbstract_iB_zRNlBzmM9Ok8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">STOCKHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--CommonStockValue_i01I_maSEzW3J_zWAAd3mWW9K3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Common stock, $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_c20210630_pdd" title="Common stock, par value (in dollars per share)"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pdd" title="Common stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20210630_pdd" title="Common stock, authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_c20201231_pdd" title="Common stock, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20210630_ziL3mPUxZQZ3" title="Common stock, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,710,386</ix:nonFraction></span> and outstanding (December 31, 2020 - <span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20201231_zv9EFTw6ELD6" title="Common stock, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,621,336</ix:nonFraction></span>)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,711</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,622</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_i01I_maSEzW3J_za8Si0xuKC9h" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,523,756</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,167,646</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_i01NI_di_msSEzW3J_zzvgpYNZJkV4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Subscription receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_maSEzW3J_zHFnua5OgB9j" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,660</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,654</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEzW3J_zaT33MbrIAB6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt">Deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,660,918</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,343,939</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">))</td></tr>
<tr id="xdx_409_eus-gaap--StockholdersEquity_i01TI_mtSEzW3J_maLASEz2Pd_zm4XuxAS2M1g" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">TOTAL STOCKHOLDERS&#8217; DEFICIT ATTRIBUTALBLE TO &#160; EQUITY SHAREHOLDERS OF THE COMPANY</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,791</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">147,017</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_404_eus-gaap--MinorityInterest_i01I_maLASEz2Pd_zFHESqYE0qH1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;NON-CONTROLLING INTEREST</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,609</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,611</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtLASEz2Pd_zwyVZuNVsM66" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,460</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,668</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral
part of these consolidated financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BIOCRUDE TECHNOLOGIES USA, INC.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FOR THE THREE AND SIX MONTHS ENDED
JUNE 30, 2021 AND 2020</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(EXPRESSED IN US DOLLARS)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>


<table cellpadding="0" cellspacing="0" id="xdx_308_113_zLLX40SfwDQg" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20210401__20210630_zvUL3whC1cn6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20200401__20200630_z1pCHGKHgZEf" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20210101__20210630_zgBKBSUZxcVi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20200101__20200630_z5GQDZUn6CW5" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the three months ended</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the six months ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2020</td></tr>
  <tr id="xdx_401_eus-gaap--Revenues_maOILzzz4_maOILzH04_zGgmMQEKwfw3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">REVENUE</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0113">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0114">&#8212;</span></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0115">&#8212;</span></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0116">&#8212;</span></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingExpensesAbstract_iB_z0V0qtPG8A6l" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_i01_maOILzLPv_zghYl0aGfpjb" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt 20pt; width: 40%; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,158</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,955</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">314,853</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,396</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpenses_i01T_mtOILzLPv_msOILzzz4_msOILzH04_zPaxwecGds93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0 0 2.5pt 30pt; text-align: left">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,158</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,955</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">314,853</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,396</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_iT_mtOILzH04_maPLzALS_zOHm5VjEUJ7e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">LOSS FROM OPERATIONS</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">152,158</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,955</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">314,853</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,396</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestExpense_iN_di_msPLzWDC_msPLzUnW_msPLzALS_zumxsX00BUke" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 20pt; text-align: left">Interest expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,025</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,240</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,126</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,483</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_msPLzWDC_msPLzUnW_msPLzALS_zoStBlPBIjij" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt 20pt; text-align: left">Income tax expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0143">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0144">&#8212;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0145">&#8212;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0146">&#8212;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProfitLoss_iT_mtPLzALS_maOCILBzLw7_maOCILBzEbb_maOCILBzXMS_zTOtiedReHyj" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">NET LOSS</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">153,183</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,195</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">316,979</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,879</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_iB_zSz4PH69W0ig" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">OTHER COMPREHENSIVE LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_i01_maOCILBzLw7_maOCILBzEbb_maOCILBzXMS_zyMUtJXW32bl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 20pt; text-align: left">Exchange differences on translating foreign operations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--ExchangeDifferencesOnTranslatingNoncontrollingInterest_i01_msOCILBzLw7_msOCILBzEbb_msOCILBzXMS_zEh9sjeehUz5" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt 20pt; text-align: left">Exchange differences on translating non-controlling interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="cik1690384:ExchangeDifferencesOnTranslatingNoncontrollingInterest" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik1690384:ExchangeDifferencesOnTranslatingNoncontrollingInterest" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik1690384:ExchangeDifferencesOnTranslatingNoncontrollingInterest" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="cik1690384:ExchangeDifferencesOnTranslatingNoncontrollingInterest" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeLossBeforeTax_i01_mtCz4e6_mtOCILBzLw7_mtOCILBzEbb_mtOCILBzXMS_zXGEBka1Krhf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">TOTAL COMPREHENSIVE LOSS</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">153,189</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,068</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">316,971</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,906</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_iB_znBn4rWStt6i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">NET LOSS ATTRIBUTABLE TO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i01_maPLzMvX_zC7HtPJao9Uk" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 20pt; text-align: left">Equity shareholders of the Company</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">153,183</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,195</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">316,979</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,879</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_i01_msPLzMvX_z3PW0gUskJ0k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt 20pt; text-align: left">Non-controlling interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0183">&#8212;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0184">&#8212;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0185">&#8212;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0186">&#8212;</span></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProfitLoss_i01_zOqnKOjr7dZg" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">NET LOSS</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">153,183</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,195</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">316,979</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,879</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_iB_zhMzsogdJN0a" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">TOTAL COMPREHENSIVE LOSS ATTRIBUTABLE TO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_i01_maOCILBzcjm_zNfmimuU8y8a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 20pt; text-align: left">Equity shareholders of the Company</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">153,187</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,106</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">316,973</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,898</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_i01_msOCILBzcjm_z4Mo3eUVfKc3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1pt 20pt; text-align: left">Non-controlling interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr>
  <tr id="xdx_406_ecustom--OtherComprehensiveIncomeLossBeforeTax1_i01_zUWA6QOQXUWa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">TOTAL COMPREHENSIVE LOSS</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="cik1690384:OtherComprehensiveIncomeLossBeforeTax1" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">153,189</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="cik1690384:OtherComprehensiveIncomeLossBeforeTax1" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,068</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="cik1690384:OtherComprehensiveIncomeLossBeforeTax1" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">316,971</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="cik1690384:OtherComprehensiveIncomeLossBeforeTax1" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,906</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EarningsPerShareBasicAndDiluted_zwn0hg0hNZbl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss per common share&#160;&#160;&#160;basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2021-04-012021-06-30" format="ixt:numunitdecimalin" decimals="INF" sign="-" unitRef="USDPShares">0,00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">)</td></tr>
  <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_z0PqtpukDffk" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted average number of common shares outstanding&#160;&#160;&#160;basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,604,735</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,492,243</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,604,735</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,492,243</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td></tr>
  </table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt">See accompanying
notes to unaudited interim consolidated financial statements</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BIOCRUDE TECHNOLOGIES USA, INC.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF CHANGES
IN STOCKHOLDERS&#8217; DEFICIT</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><b>(EXPRESSED IN
US DOLLARS)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_114_zw4NssRyimb5" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; DEFICIT (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number of
    shares</b></span></td><td>&#160;</td>
    <td colspan="3" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z2JKWHhxjBL3" style="text-align: center">&#160;&#160;&#160;&#160;<span style="font: 10pt Times New Roman, Times, Serif"><b>Par Value</b></span></td><td>&#160;</td>
    <td colspan="3" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zB9e6GFvZsee" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Additional
    Paid-in Capital</b></span></td><td>&#160;</td>
    <td colspan="3" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_z8eXFGSl0kLa" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Accumulated
Other Comprehensive Income</b></span></td><td>&#160;</td>
    <td colspan="3" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zWPr7J6Msfn4" style="text-align: center">&#160;&#160;&#160;&#160;<span style="font: 10pt Times New Roman, Times, Serif"><b>Deficit</b></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_custom--TotalEquityAttributableToEquityShareholdersOfTheCompanyMember_zDsv5Wc5rj0e" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Total equity</b></span> <span style="font: 10pt Times New Roman, Times, Serif"><b>attributable to</b></span> <span style="font: 10pt Times New Roman, Times, Serif"><b>equity</b></span> <span style="font: 10pt Times New Roman, Times, Serif"><b>shareholders</b></span> <span style="font: 10pt Times New Roman, Times, Serif"><b>of the Company</b></span></td><td>&#160;</td>
    <td colspan="3" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zX7JWDjeHYt" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Non-
    controlling interest</b></span></td><td>&#160;</td>
    <td colspan="3" id="xdx_4BB_zr1KWIMZ6k29" style="text-align: center">&#160;&#160;&#160;&#160;<span style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_43B_c20210101__20210331_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zj2wChytxDig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%">Balance at December 31, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRx9vYtBvcR1" title="Beginning balance (in shares)" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,621,336</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,622</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,167,646</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,654</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,343,939</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">147,017</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,611</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">148,628</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left; padding-bottom: 2.5pt">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_zPzTbdOHtoG7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock issued for services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zba5pZBcZMb9" title="Stock issued for services (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,550</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">66,183</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0235">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0236">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">66,200</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">66,200</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--SubscriptionReceivable_pp0p0_zA5vzjK91YR" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Subscription receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0243">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0244">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik1690384:SubscriptionReceivable" contextRef="From2021-01-012021-03-31_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0248">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="cik1690384:SubscriptionReceivable" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_zJ8MRQr7Swy8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock issued for cash</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUbv08YdFGtb" title="Stock issued for cash (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">169,957</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0254">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-03-31_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">170,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">170,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit_iN_pp0p0_di_znYcOxyrE58g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Foreign currency translation loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" contextRef="From2021-01-012021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" contextRef="From2021-01-012021-03-31_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" contextRef="From2021-01-012021-03-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">14</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_pp0p0_zx7CxMHu3Y1l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">163,796</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">163,796</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">163,796</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20210401__20210630_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zOt9vsimy1Di" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Balance at March 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCqQg32XeRa6" title="Beginning balance (in shares)" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,680,386</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,681</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,403,786</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,664</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,507,735</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-03-31_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,604</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-03-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,607</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,211</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_zUN4GTMpOAm3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock issued for services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrntVZuN9O9g" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">119,970</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_iP3us-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pp0p0_z1DI31oXgJH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock issued for convertible debts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_zruy833j4oR2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock issued for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit_iN_pp0p0_di_zQzZjDoQy80f" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Foreign currency translation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" contextRef="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" contextRef="From2021-04-012021-06-30_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" contextRef="From2021-04-012021-06-30_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyTaxExpenseBenefit" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_pp0p0_z2Xp9e7ZPnWd" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">153,183</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">153,183</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">153,183</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20210401__20210630_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zWMfPLZ3LRQ1" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balance at June 30, 2021</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN4ZmqTRa4M" title="End balance (in shares)" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,710,386</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,711</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,523,756</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,664</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,660,918</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-06-30_custom_TotalEquityAttributableToEquityShareholdersOfTheCompanyMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,791</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-06-30_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,609</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">59,400</ix:nonFraction></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">)</td></tr>
  </table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes to unaudited interim
consolidated financial statements</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BIOCRUDE TECHNOLOGIES USA, INC.</b>&#160;&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FOR THE THREE &amp; SIX MONTHS ENDED JUNE
30, 2021 AND 2020</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(EXPRESSED IN US DOLLARS)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_112_z8H14wZ7bIMk" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_49C_20210101__20210630_zxhBpYohpkyc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">UNAUDITED<br /> June 30, 2021</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_49B_20200101__20200630_zUIFlpyR2Szh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">UNAUDITED<br /> June 30,
    2020</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_z0d0ZUvEPb92" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i01N_di_msNCPBUzB5R_zhrlGiBJ8jLk" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Net loss</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">316,979</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,480</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_404_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_z4xfpujax9qb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AccretionExpense_i02_maNCPBUzB5R_z77BgP1uUMpe" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Accretion and interest expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccretionExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccretionExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,484</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--AdjustmentForAmortization_i02_maNCPBUzB5R_z6kTisbruBE6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt">Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,649</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_maNCPBUzB5R_zXwTFvpl06G4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Stock issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,198</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_ecustom--ForgivenessAccruedInterest_i02_maNCPBUzB5R_zsk2wlGaZYJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Forgiveness accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i02N_di_msNCPBUzB5R_zmyn8Z78C3K5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,781</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">239</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zk4PuKUZ9fYg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02_msNCPBUzB5R_zKzRq3t9TnUk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_maNCPBUzB5R_zCUyBo3B7sZ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Accounts payable and accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,228</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,258</ix:nonFraction></td><td style="text-align: left"></td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsPayableRelatedParties_i02_maNCPBUzB5R_zTJ0fh7DWhC" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Accounts payable and accrued liabilities - related party</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">88,710</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">35,860</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtNCPBUzB5R_maCCERCzGGB_z664Yh2pcvm2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">236,724</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,540</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_z8LjDJ6EMRI5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ProceedsFromConvertibleDebt_i01_maCzFR1_maNCPBUz1ng_zzrnl6hq8Vk2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Proceeds from issuance of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_maCzFR1_maNCPBUz1ng_ztIEutGZJPH4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Proceeds from private placement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--ProceedsFromRepaymentsOfShortTermDebt_i01_maCzFR1_maNCPBUz1ng_zzEOVGNhRQK1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">(Repayment) Proceeds of loans payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,835</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUz1ng_maCCERCzGGB_zkyO5i366Wm1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">207,165</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_i01B_zh7g118UHjH7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i02N_di_msCzw5k_msNCPBUzWmZ_msNCPBUz7Ky_z6J8zCp96Ml5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Purchase of property, plant and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i02T_mtNCPBUzWmZ_maCCERCzGGB_z7IP1NOB5evg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash used in financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--EffectOfExchangeRateOnCashAndCashEquivalents_maCzSis_maCCERCzGGB_maCCERCz5W8_zJQ5WIbpgZ74" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of exchange rate changes on cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzGGB_mtCCERCz5W8_zwdbfGolzsPa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CHANGE IN CASH DURING THE PERIOD</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,559</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">290</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zs4Gnp7QPOjh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CASH BEGINNING</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,971</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">305</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zWqglNadAd9k" style="vertical-align: bottom; background-color: White">
    <td>CASH ENDING</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,412</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zDKOzr2dtK3i" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--IncomeTaxesPaidNet_i01_zpLiuqs3WG35" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Cash paid for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--InterestPaidNet_i01_zxBmmUdbJuve" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zhWr7FMevdBj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Noncash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--BeneficialConversionFeatureDiscountRelatedToIssuanceOfConvertibleDebt_i01_z2V6S72eLzGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Beneficial conversion feature discount related to the issuance of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DebtConversionOriginalDebtAmount1_i01_zF0oVf9cE8Z2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Conversion of convertible debt to common stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--StockIssuedForServices_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Stock issued for services</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="cik1690384:StockIssuedForServices" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--ForgivenessAccruedInterest_i02_zSWA9b1JwRge" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Forgiveness accrued interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0435">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to unaudited interim
consolidated financial statements</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BIOCRUDE TECHNOLOGIES USA,
INC.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zQv2FdvNMXa7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">NOTE 1</span> &#8211; <span id="xdx_825_zdHblpz163Ze">ORGANIZATION AND BASIS OF PRESENTATION</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Nature of Operations</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Biocrude Technologies USA, Inc. (the
&#8220;Company&#8221;) was incorporated under the laws of the State of Nevada on December 29, 2015. The Company&#8217;s principal
business objective is to provide resource management expertise and services, catering to commercial, municipal, and industrial
customers, primarily in the areas of solid waste management and recycling services.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Interim Financial Statements</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited interim consolidated financial
statements of the Company have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;)
for interim financial information and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).
They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein,
there have been no material changes in the information disclosed in the notes to the financial statements for the year ended December
31, 2020 included in the Company&#8217;s 2020 annual report on Form 10-K, filed with the SEC. The unaudited interim consolidated
financial statements should be read in conjunction with those financial statements included in Form 10-K. In the opinion of management,
all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made.
Operating results for the six-month period ended June 30, 2021 are not necessarily indicative of the results that may be expected
for the year ending December 31, 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going Concern</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s consolidated financial
statements are prepared on a going concern basis in accordance with United States generally accepted accounting principles (&#8220;US
GAAP&#8221;) which contemplate the realization of assets and discharge of liabilities and commitments in the normal course of business.
The Company has not generated operating revenues to date and has accumulated losses of $<span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20210630_zrQuTNGCd0el" title="Accumulated losses"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,660,918</ix:nonFraction></span> since inception. The Company
has funded its operations through the issuance of capital stock, convertible debt, loans, and advances from related parties. Management
plans to raise additional funds through equity and/or debt financings.&#160;There is no certainty that further funding will be
available as needed. These factors raise substantial doubt about the ability of the Company to continue operating as a going concern.
The Company&#8217;s ability to continue its operations as a going concern, realize the carrying value of its assets, and discharge
its liabilities in the normal course of business is dependent upon its ability to raise new capital sufficient to fund its commitments
and ongoing losses, and ultimately on generating profitable operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80B_eus-gaap--SignificantAccountingPoliciesTextBlock_zI4rhNv5xArk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2 &#8211; <span id="xdx_828_zKDqRAzW09y7">SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zTpfRKaDGU3j" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_861_zeIL8hl2NP8c"><span id="xdx_862_zU8tHroCjeNa">Basis of presentation and Principles
of Consolidation</span></span></span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements
and related notes are presented in accordance with US GAAP and are presented in United States dollars.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial
statements include the accounts of its <span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20210630__srt--OwnershipAxis__custom--BiocrudeHKMember_zgbWtkdS7Vie"><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="AsOf2021-06-30_custom_BiocrudeHKMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span>% owned subsidiary, Biocrude Technologies (Hong Kong) Limited (&#8220;Biocrude HK&#8221;).
All significant inter-company transactions and balances have been eliminated upon consolidation.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_849_eus-gaap--UseOfEstimates_zhKQv1wDcLb5" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_864_zxml5yF24Hg1"><span id="xdx_86A_zMSco9RDCN0h">Use of Estimates</span></span></span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements
in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Significant areas requiring management&#8217;s estimates
and assumptions include determining the fair value of transactions involving shares common stock.&#160;Actual results could differ
from those estimates.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zjD2QYRnRk9b" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_869_zHDcQhhs8kO2">Fair Value Measurements</span></span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company adopted the provisions of
ASC Topic 820, &#8220;Fair Value Measurements and Disclosures&#8221;, which defines fair value as used in numerous accounting pronouncements,
establishes a framework for measuring fair value and expands disclosure of fair value measurements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair value of certain
financial instruments, including cash and cash equivalents, payables to related parties, and accounts payable and accrued expenses
are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 820 defines fair value as the exchange
price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes
a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. ASC 820 describes three levels of inputs that be used to measure fair value:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23F_zm4JMm8w0tba" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 7; Value: 1 -->
    <div id="xdx_237_zBmlcfaplYf9" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_235_zRgGaWCR6a2h" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_237_zaWeExSxe6M7" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_235_zmKeQozbgpcl" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zJi5pCGtRHje" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - quoted prices in active markets
for identical assets or</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - quoted prices for similar
assets and liabilities in active markets or inputs that are observable</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - inputs that are unobservable
(for example cash flow modeling inputs based on assumptions)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s financial assets
and liabilities are subsequent measured at amortized cost, but their carrying amount approximates their fair value due to the short
period of time until maturity.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_849_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zyqJ72Me5LLc" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_862_zYuLToiDfidg">Foreign Currency Translation and
Transaction</span></span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s presentation currency
is the U.S dollar. The functional currency of Biocrude USA and Biocrude HK is U.S dollar and Hong Kong dollar, respectively. Assets
and liabilities of the foreign operations are translated to the U.S dollar using the exchange rate at period end, and income, expenses
and cash flow items are translated using the rate approximates the exchange rates at the dates of the transactions (i.e., the average
rate for the period). All resulting exchange differences recognized directly in other comprehensive income (loss).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Transactions in currencies other than
the entity&#8217;s functional currency are recorded at the rates of exchange prevailing at the dates of the transactions. At each
statement of financial position date, monetary assets and liabilities are translated using the period end foreign exchange rate.
Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. Non-monetary assets
and liabilities that are stated at fair value are translated using the historical rate on the date that the fair value was determined.
All gains and losses on translation of these foreign currency transactions are included in profit or loss.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zMw4NZJ4cfie" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86B_zR8AnnXsPrTj">Cash and cash equivalents</span></span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents consist of
cash balances and highly liquid instruments with an original maturity of three months or less. As at June 30, 2021, the Company
does not have cash equivalents.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z58yvnsHmvwk" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86C_zpxKmcFSitTk">Property, plant and equipment</span></span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Property, plant, and equipment are recorded
at cost and depreciated to its estimated residual values using the straight-line method over its estimated useful lives of <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630_zfyUSKj0dSrf"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">8</ix:nonNumeric></span> years.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_842_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zstX5lMUDsTj" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_867_zJkkFYYfFgKg">Share-based Expense</span></span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 718, &#8220;<i>Compensation &#8211;
Stock Compensation</i>&#8221;, prescribes accounting and reporting standards for all share-based payment transactions in which
employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and
other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees,
including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair
values. That expense is recognized over the period during which an employee is required to provide services in exchange for the
award, known as the requisite service period (usually the vesting period).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for stock-based
compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, &#8220;<i>Equity &#8211;
Based Payments to Non-Employees.&#8221;</i> Measurement of share-based payment transactions with non-employees is based on the
fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued.
The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance
completion date.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_849_eus-gaap--IncomeTaxPolicyTextBlock_zEDhHs5ipaC1" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86D_zldBP42rADra">Income Taxes</span></span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income for the years in which those differences are expected
to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income
statement in the period that includes the date of enactment. Additionally, ASC 740: Income Taxes, requires the Company to recognize
in its financial statements the impact of a tax position that is more likely than not to be sustained upon examination based on
the technical merits of the position.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:LessorLeasesPolicyTextBlock"><p id="xdx_84F_eus-gaap--LessorLeasesPolicyTextBlock_zkJnZ4IQxXE9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86D_zrlwAFMLhfXj">Leases</span></span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Effectively January 1, 2018, the Company
adopted ASC Leases which requires a lessee to recognize the assets and liabilities that arise from leases, including operating
leases. Under the new requirements, a lessee will recognize in the balance sheet a liability to make lease payments (the lease
liability) and the right-of-use asset representing the right to the underlying asset for the lease term. For leases with a term
of twelve months or less, the lessee is permitted to make an accounting policy election not to recognize lease assets and lease
liabilities by class of underlying assets. The Company did not enter into any significant operating leases for the six months period
ended June 30, 2021 and did not have any significant leases as at December 31, 2020. Adoption of this standard does not have material
impact on the Company&#8217;s interim consolidated financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zWsj3DSHiMg1" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_866_zoL8ZomvJe75">Earnings Per Share Information</span></span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB ASC 260, &#8220;Earnings Per Share&#8221;
provides for calculation of &#8220;basic&#8221; and &#8220;diluted&#8221; earnings per share. Basic earnings per share includes
no dilution and is computed by dividing net loss available to common shareholders by the weighted average common shares outstanding
for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an
entity similar to fully diluted earnings per share. Basic and diluted loss per share were the same, at the reporting dates, as
there were no common stock equivalents outstanding.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_238_zr9wyPFQEdWi" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 8; Value: 1 -->
    <div id="xdx_235_zsXz2CJG9HH5" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23C_zRiRQx0upG6a" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div id="xdx_23A_zyrSH7OChV4l" style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" id="xdx_23D_zncC8D1POxBk" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td id="xdx_23A_zbXlgacjQ9H3" style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_ztomc3ONa221" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zSyu4G85f19a" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 &#8211; <span id="xdx_823_z6icnmDw2iDf">CONVERTIBLE NOTES</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As at June 30, 2021, there are <span id="xdx_908_eus-gaap--ConvertibleDebt_iI_do_c20210630_zfv4GKH9LiP8" title="Convertible loans"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2021-06-30" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> outstanding
convertible loans.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="cik1690384:LoansPayableTextBlock"><p id="xdx_800_ecustom--LoansPayableTextBlock_zPWbUzB4wO0f" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 &#8211; <span id="xdx_821_zCRqYLUcGP1g">LOANS PAYABLE</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As at June 30, 2021, the Company has
loans payable of $<span id="xdx_907_eus-gaap--LoansPayable_c20210630_pp0p0" title="Loans payable"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">110,856</ix:nonFraction></span> (December 31, 2020 &#8211; $<span id="xdx_905_eus-gaap--LoansPayable_c20201231_pp0p0" title="Loans payable"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">126,481</ix:nonFraction></span>) in principal and accrued interest of $<span id="xdx_90D_eus-gaap--InterestPayableCurrent_c20210630_pp0p0" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,815</ix:nonFraction></span> (December 31, 2020
- $<span id="xdx_908_eus-gaap--InterestPayableCurrent_c20201231_pp0p0" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,688</ix:nonFraction></span>) outstanding. These loans bear an average interest rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanPayableMember_zNixIH7kinfg"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2021-01-012021-06-30_custom_LoanPayableMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>%, are unsecured and have extended maturities until December
31, 2022. Included in the balance of loans payable as at June 30, 2021, $<span id="xdx_901_eus-gaap--LoansPayable_iI_pp0p0_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_z5YeUmsDCqPl" title="Loans payable"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2021-06-30_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,383</ix:nonFraction></span> (December 31, 2020 - $<span id="xdx_90E_eus-gaap--LoansPayable_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_pp0p0" title="Loans payable"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2020-12-31_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,291</ix:nonFraction></span>) was due to a director
of the Company.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zxVT4qC2wdI7" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 -&#160;<span id="xdx_82F_z37vyssSsXG4">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As at June 30, 2021, the &#8220;CEO&#8221;
of the Company and a director had advanced the Company a cumulative $<span id="xdx_908_eus-gaap--ProceedsFromRelatedPartyDebt_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Advances from related parties"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2021-01-012021-06-30_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,017</ix:nonFraction></span> (December 31, 2020 - $<span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Advances from related parties"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2020-01-012020-12-31_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">104,727</ix:nonFraction></span>) net of repayments for
the payment of the Company&#8217;s operating expenses. These amounts are unsecured, without interest and payable on demand and
are included in accounts payable and accrued liabilities &#8211; related parties.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zC5Uds8prp1j" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">NOTE 6</span> &#8211;<span id="xdx_824_zm7BLmRaVfEi"> SHARE CAPITAL</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue up
to <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20210630_z7jLGDr2tYSl" title="Common stock, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000,000</ix:nonFraction></span> shares of common stock at par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210630_z0hlL0Uawl89" title="Common stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. As at June 30, 2021, the Company had <span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20210630_pdd" title="Common stock, outstanding"><span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20210630_zdsyfPzH9404" title="Common stock, issued"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,710,386</ix:nonFraction></ix:nonFraction></span></span> (December 31,
2020 - <span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_c20201231_pdd" title="Common stock, outstanding"><span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20201231_zATNEsjZoev9" title="Common stock, issued"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,621,336</ix:nonFraction></ix:nonFraction></span></span>) shares of common stock issued and outstanding, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In Q2 2021, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDKUWg1dbXLf" title="Stock issued for services, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock, with a fair value of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20210401__20210630_zPFNjhA66Yjc" title="Stock issued for services, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,000</ix:nonFraction></span>, for services rendered..</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_z4GHonDjr0m9" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 7</span> &#8211;&#160;<span id="xdx_820_zFMmMPA62o23">SUBSEQUENT
EVENTS</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no subsequent events.</p>

</ix:nonNumeric><p id="xdx_814_zerTdiZjLicb" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_003"></span><span style="text-decoration: underline">ITEM 2.</span> MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Forward-Looking Statements</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This Form 10-Q includes &#8220;forward-looking
statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included or incorporated by reference
in this Form 10-Q which address activities, events or developments which the Company expects or anticipates will or may occur in
the future, including such things as future capital expenditures (including the amount and nature thereof); finding suitable merger
or acquisition candidates; expansion and growth of the Company&#8217;s business and operations; and other such matters are forward-looking
statements. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its
perception of historical trends, current conditions and expected future developments, as well as other factors it believes are
appropriate under the circumstances. However, whether actual results or developments will conform with the Company&#8217;s expectations
and predictions is subject to a number of risks and uncertainties, including general economic, market and business conditions;
the business opportunities (or lack thereof) that may be presented to and pursued by the Company; changes in laws or regulation;
and other factors, most of which are beyond the control of the Company.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These forward-looking statements can
be identified by the use of predictive, future-tense or forward-looking terminology, such as &#8220;believes,&#8221; &#8220;anticipates,&#8221;
&#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; or similar terms. These
statements appear in a number of places in this Filing and include statements regarding the intent, belief or current expectations
of the Company, and its directors or its officers with respect to, among other things: (i) trends affecting the Company&#8217;s
financial condition or results of operations for its limited history; (ii) the Company&#8217;s business and growth strategies;
and, (iii) the Company&#8217;s financing plans. Investors are cautioned that any such forward-looking statements are not guarantees
of future performance and involve significant risks and uncertainties, and that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors. Such factors that could adversely affect actual results
and performance include, but are not limited to, the Company&#8217;s limited operating history, potential fluctuations in quarterly
operating results and expenses, government regulation, technological change and competition.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Consequently, all of the forward-looking
statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results
or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected
consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking
statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>General Business Development</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company was formed on August 4,
2015 in the State of Nevada, under the name of &#8220;BioCrude Technologies, Inc. On November 8, 2016, the Company received its
&#8220;Certificate of Amendment to Articles of Incorporation&#8221; pursuant to NRS 78.385 and 78.390 to its request for a name
change from &#8220;BioCrude Technologies, Inc.&#8221; to &#8220;BioCrude Technologies USA, Inc.&#8221;, whilst doing business as
&#8220;BioCrude Technologies, Inc.&#8221;, as well. All of the afore-stated have been filed with SEC as part of the Company&#8217;s
S-1(/A) registration statement(s).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Business Strategy</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is a resource management
expertise and services provider, catering to commercial, municipal, and industrial customers, primarily in the areas of solid waste
management and recycling services.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude Technologies USA, Inc. has
developed efficient, cost-effective, and environmentally friendly products, processes and systems for the reformation of waste
material, waste management and creation of renewable energy.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The versatility and potential of the
BioCrude Technologies USA, Inc. has been demonstrated by the many uses that our R&amp;D department has already tested and verified.
The avenues they have explored include sustainable and cost-efficient methods that will enlarge composting and biomethanation yields
and rates of decomposition while increasing output and providing a higher quality of end product. Their focus is on waste treatment
protocols for Municipal Solid Waste (&#8220;MSW&#8221;), cellulose, all organic waste and all manure types; renewable energy sources
such as biogas, ethanol and biodiesel; waste water treatment, and multiple other applications.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">One very important area that BioCrude
Technologies USA, Inc. excels in is the reformation of MSW into renewable energy and marketable end-by-products, using its intrinsic
intellectual property and know how in its &#8220;Integrated Municipal Solid Waste to Energy Proposed Complexes&#8221; for municipal
applications. Understanding the non-homogenous nature and characteristics of the waste, we can define distinct processes to optimally
handle the procurement of the varied categories of waste (MSW can be classified into organics, fuels, recyclables, inerts and others),
once segregated with an efficient separation process and materials recovery facility (&#8220;MRF&#8221;). There is no intellectual
property protection as of yet. BioCrude will be filing for certain Intellectual property and know how protection via a patent for
&#8220;Integrated Municipal Solid Waste to Energy Systems&#8221;. In addition to patent applications, the Company will apply for
trademark protection where appropriate.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The long-term vision of the organization
is to be a world leader in the management of solid waste. Our business model will be to transform solid waste streams into renewable
energy resources and marketable by-products. Conventionally, people, entities, etc.&#8230;, view solid waste streams as not only
worthless refuse requiring monetary resources in order to get rid of. BioCrude, on the contrary, views this so-called refuse &#8220;as
a valuable commodity&#8221;, with a negative product cost, i.e., PRODUCT COST is ZERO, with an implicit REVENUE received PER UNIT
OF WASTE given for disposal (people, governments will pay entities/companies in order to get rid of the undesired waste, in the
form of a &#8220;Tipping&#8221; or &#8220;Gate&#8221; fee. <b>Global competition for limited resources is, the Company believes,
creating significant business opportunities <span style="text-decoration: underline">for companies</span> that can sustain and extract value in the form of renewable energy
and other marketable by-products, i.e., fertilizer, raw materials (primary feedstock for building materials), etc.&#8230;, from
resources previously considered an irretrievable waste stream.</b> BioCrude&#8217;s business strategy has been firmly tied to creating
a sustainable resource management model and the Company continues to be rooted in these same tenets today. Each day the Company
strives to create long-term value for all stakeholders: customers, employees, communities, and shareholders, by helping customers
and communities manage their resources in a sustainable and financially sound manner.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company intends to achieve successful
market penetration, with distinction, in numerous segments of the industry, generating escalating positive cash flows on an annual
basis so that the Company becomes a competitive leading participant in the industry. Management will look to have its Integrated
Municipal Solid Waste to Energy Complexes widely implemented across Africa, Asia, the Balkans and North America with a view to
expanding to other international markets (Latin America), while continuing to pursue Concession Agreements under private license/joint
ventures and other conventional arrangements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Municipal Solid Waste Management is
the collection, transport, processing (waste treatment), recycling or disposal of waste materials, usually ones produced by human
activity, in an effort to reduce their effect on human health or local aesthetics or amenity.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Municipal Solid Waste Management (&#8220;MSWM&#8221;)
is a major responsibility for local government. It is a complex task which requires appropriate organizational capacity and cooperation
between numerous stakeholders in the private and public sectors.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The first goal of MSWM is to protect
the health of the population, particularly that of low-income groups. Other goals include promotion of environmental quality and
sustainability, support of economic productivity and employment generation.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Waste-to-energy (&#8220;<b>W2E</b>&#8221;)
or energy-from-waste (&#8220;<b>EfW</b>&#8221;) is the process of creating energy in the form of electricity or heat from the incineration
of waste source.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Conventional Municipal Solid Waste Management
employs one or more of the following processes:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Waste prevention, including reuse of products</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Recycling, including composting</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Combustion with energy recovery</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Disposal through land-filling</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><img src="image_001.jpg" alt="" style="height: 236px; width: 406px" /></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Landfilling is one of the most common
ways of municipal solid waste disposal in developing countries.&#160;Air pollutants emitted from landfills contributes to the emission
in the atmosphere of greenhouse gases and cause&#160;serious problems to human health.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Methane emissions from landfills are
a serious environmental global concern, as it accounts for approximately 15% of current greenhouse gas emissions.&#160;Landfilling
is a significant contributor to greenhouse gas emissions (GHG) accountable for approximately 5% of total GHG releases which consists
of methane from anaerobic decomposition of solid waste and carbon dioxide from wastewater decomposition.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The past 20 years has seen a change
in how we look at our environment. There has been a greater understanding of the economic, social and environmental risks of not
managing waste.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The main drivers of the W2E market are
environmental factors, regulations and legislation and economic factors.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"><b>&#160;<span style="text-decoration: underline">Environmental Factors</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Stern report, published in 2006,&#160;created
an authoritative and eye-opening scientific report on the challenges of climate change. The report highlighted the need to decarbonize
the power sector by 60% and reduce CO<sub>2</sub> emissions by 80% of current levels to ensure increases in&#160;global temperature
do not exceed two degrees Celsius.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"><b><span style="text-decoration: underline">Regulations and Legislation</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Scientific evidence, public awareness
and increased levels of participation in environmental campaigning have led to governments&#8217; worldwide implementing regulations
and legislation. Examples include:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 24px; font-family: Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">EU Landfill Diversion Directive</span></td></tr>
<tr style="vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">recycling targets</span></td></tr>
<tr style="vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">climate change regulations</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 35.7pt; text-align: justify; text-indent: -17.85pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Nota Bene</span>: It is only in the
last two decades that governments world wide have been working together to come to a consensus of standardized, environmentally
friendly waste management directives, in order to become recognized and implemented practices.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b><span style="text-decoration: underline">Economics</span></b></span></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Economic drivers to developing the waste
and renewable energy sector have included:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">waste disposal and landfill gate fees/landfill tax</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">penalties/avoidance schemes (e.g., landfill allowance schemes and fines, carbon trading)</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">energy prices</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"><b><span style="text-decoration: underline">Waste to Energy Market
Size and Trend</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Renewable Energy: </b>According to
the most recent data available from the International Energy Agency, global waste to energy power production from municipal and
industrial wastes increased from 283 terawatt hours to 383 terawatt hours, a 35% increase over that period. In-depth analyses of
the global market, forecasts the market will increase from approximately $27 billion in 2018 to $450 billion by 2030.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><img src="image_002.jpg" alt="" style="height: 177px; width: 274px" /></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>MSW Management (Tipping/Gate fees):
</b>As long as there are people in our world, there will be waste generation. Depending on the demographics of people clusters
(nations), the amount of waste generated on a per capita (person) basis can vary from 0.6 kg (persons in destitute third world
countries (e.g., Niamey [Niger], Juba [South Sudan], Freetown [Sierra Leone], Port-au-Prince [Haiti])) to 1.8 kg (advanced societies
with flourishing economies (e.g., New York City [US], Toronto [Canada], Paris [France], Dubai [UAE]) per person per day. With an
approximate current world population (census 2020) of 7.8 billion persons, there is a minimum quantum (weighted average) of about
6,000,000 tons of waste generated on a per day basis. Depending on the national budget for the level of waste management treatment
implemented by a certain nation, analyses of the global market, forecasts the market will increase from approximately $45 billion
in 2020 to $60 billion by 2030.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Nota Bene</span>: The Market potential
for Waste Management is not only &#8220;HUGE&#8221;, but at its infancy stage, ready to &#8220;EXPLODE&#8221;, with few credible
corporations, capable of servicing same!</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><img src="image_003.jpg" alt="" style="height: 165px; width: 259px" /></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Source </b>: http://www.waste-management-world.com</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Competition</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The market for Waste-to-Energy is dominated
manly by Germen, French, American and British companies. Ex.: AE&amp;E Group GmbH, Axpo Kompogas AG, Babcock &amp; Wilcox Volund
A/S, Bedminster International Ltd., BiogenGreenfinch, BTA International GmbH, Community Power Corporation, CNIM, Covanta Holding
Corporation, EcoCorp Inc., Keppel Integrated Engineering Ltd., North American Power Group Ltd., Organic Waste Systems NV, STRABAG
Umweltanlagen GmbH, Veolia Environmental Services, Waste Management Inc., and Wheelabrator Technologies Inc., among others.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Nota Bene</span></b>: If you compare
the technology of the <b>Competition</b> in <b>juxtaposition</b> to <b>BioCrude&#8217;s (further elaborated upon, hereinunder,</b>
you will be able see why &#8220;<b>BioCrude is the logical choice for the present and the future</b>&#8221;.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt"><b><span style="text-decoration: underline">Defining Waste Management
for Municipal Applications</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: -18pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The provision of municipal solid waste
services is a costly and troubling problem for local authorities everywhere. In many cities, service coverage is low, resources
are insufficient, and uncontrolled dumping is widespread, with resulting environmental and health related problems, which are recognized
worldwide, and cannot be neglected! Moreover, substantial inefficiencies are typically observed. Typically, worldwide, governmental
waste management ordinance, surprisingly enough, encompasses inefficient waste collection, landfilling until over exhaustion, and
incineration<b>.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Out of concern for the quality of life
of their residents, local municipalities bear primary responsibility for waste management. Municipalities will work with other
municipal levels to identify the best collection, transportation, treatment and disposal methods for their respective jurisdictions.
This includes identifying suitable sites for municipal, or regional waste management facilities, and managing and operating collection,
transportation and treatment systems. To increase the environmental and economic efficiency of waste management, local municipalities
will be responsible for planning waste management infrastructure and systems at the urban community and regional county municipality
levels.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Biocrude, with its upgraded technologically
advanced systems, can improve quality of environment, ergo, life.</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Waste management planning, as well as
the production of renewable energy resources, are vital issues facing any city or municipality today. We are at a time where all
level of governments recognize the importance and need for waste management. Be it for financial, environmental, or health issues.
Room for improvement exists for the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Reduction, and eventually, the elimination of landfilling, as opposed to over exhausting (substituting proposed landfill sites with other forms of development (commercial, industrial, residential, agricultural, and community developments, amongst others &#8211; real estate value).</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Reduction of Greenhouse Gases, and environmental pollutants with reference to ground and surface water contamination <b>(percolation of contaminated leachate)</b> alongside with the elimination of odors.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Further enhanced separation process for MSW, which could prelude to a more optimal recycling program.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Nota Bene</span></b>: Landfilling
is NOT a solution (contaminates the land forever, cost of construction, waste creation), but a deferral of a problem for future
generation to handle. In essence, it is what it is; a PRACTICE that has been utilized for the longest period of time! Nothing more!</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The myth that landfilling is a cost-effective
solution is what it is; a myth. There are long term ramifications, especially when the landfills are not proper &#8220;Scientific
Landfills&#8221; (environmental implications; rainfall, leachate, percolation, contamination (soil and water table). Even the fact
that, if a Scientific Landfill is deployed (with membrane linings) at an astronomical cost (the cost of construction of a Scientific
landfill, which could host approximately 2,000 TPD of waste for 25 years could costs approximately 100 MUSD), after a few earth
tremors or shifting of land, the membrane could crack, or over time, the membrane will deteriorate, thus yielding the same negative
environmental impacts, only deferred in time.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Another issue to address is the continual
use of landfills. As time goes on, and waste is continuously generated by the populous and its activities, more and more landfills
have to be created, to a point where a good part of the country will become a cemetery for garbage. Municipalities/governments
must plan to integrate their waste management from a strategic and financial perspective.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>BioCrude, having set as its objective
the &#8220;PROFITABILITY&#8221; of the activities inherent within the realms of this sector, whilst building business relationships
and addressing social implications within the collectivity&#8217;s / communities that BioCrude is called upon to serve, beyond
the environmental and social implications, and beyond the business imperatives, has set as one of its priorities, the optimization
of waste management and, treatment thereof, all in conformity to the boundaries of economies, efficiency and adherence to environmental
wellbeing initiatives.</b> BioCrude has been involved in the R&amp;D of Environmental Technologies, both process and product based,
whereby it has enhanced and optimized conventional technology, thus giving credence to environmental, economic, social and technological
well-beings, too numerous to mention (all can be referenced, in its entirety, within BioCrude&#8217;s Integrated MSW-Energy Proposal.
Shortlists of the aforesaid well-beings are summarized herein under:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Secure, cost effective long-term processing capacity for recyclables and organics.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Improvement of effectiveness and efficiency of current waste systems/practices.</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Elimination of MSW from going to landfills.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Procurement of Renewable Energy and Marketable by-products (fertilizer, primary feedstock for building materials, etc.&#8230;) from the exploitation of the calorific value inherent within the realms of the MSW</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Reduction of Greenhouse Gases and other environmental pollutants emitted into the atmosphere.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">6.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Municipalities do not have to undergo cost of implementation; privatized via BOOT (Build, Own, Operate &amp; Transfer), whereby BioCrude Technologies USA, Inc. will be lobbying to get the MSW, Land, Sewage treated Effluent and Resale of Electricity Concessions (with Sovereign Guaranties from the Ministry of Finance of the Government in question).</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 24px; line-height: 107%">&#160;</td>
<td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">7.</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Due to the profitability of the proposal, significant savings could be passed onto the Municipalities, to reduce their day to day on going expenses for Municipal Waste Management, for the duration of the BOOT (30 years), by approximately 50% per annum, via MSW Tipping (Gate) Fees (favorably outbidding the competition and still having better bottom lines than same) and the Transport of the MSW to neighboring cities/provinces (states), without forgetting to mention the reduced GHG emissions from the substitution effect of BioCrude&#8217;s Integrated MSW to Energy proposal from landfilling and/or incineration. This surplus in savings can be used for other municipal social and infrastructural programs.</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%">&#160;</td>
<td style="line-height: 107%">&#160;</td>
<td style="text-align: justify; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%">&#160;</td>
<td>8.</td>
<td>Employment opportunities are created during the EPC (Engineering, Procurement &amp; Construction) phase of the project (a few hundred jobs) and for the day-to-day operations of the project (approximately 86 jobs per shift per 2,000 TPD Plant plus 11 persons for administration X 3 shifts per day, equating to a total quantum of a minimum of 269 persons).</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">9.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The proposed solution is an integrated MSW management system based on energy recovery that respects the norms of a Clean Design Mechanism (&#8220;CDM&#8221;) inherent within the realms of article 12 of the Kyoto Protocol (&#8220;UNFCCC&#8221;) or any future proposed legislation regarding same, and qualifies for Carbon Emissions Reduction Credits (&#8220;CER&#8217;s&#8221;).</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Municipal Solid Waste</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">All solid waste generated in an area
except industrial and agricultural wastes, typically from residences, commercial or retail establishments. Sometimes includes construction
and demolition debris and other special wastes that may enter the municipal waste stream. The EPA (1998c) defined municipal solid
waste as &#8220;a subset of solid waste and as durable goods (e.g., appliances, tires, and batteries), non-durable goods (e.g.,
newspapers, books, and magazines), containers and packaging, food wastes, yard trimmings, and miscellaneous organic wastes from
residential, commercial and industrial non-process sources.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The MSW can be classified in the following
categories:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">a)</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Organics</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">b)</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Fuels</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">c)</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Recyclables</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">d)</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Inerts</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">e)</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Miscellaneous</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 71.7pt; text-align: justify; text-indent: -17.85pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Each category has its own distinct composite
classification. To achieve an optimal Waste to Energy procurement, one has to analyze separately the inherent category contributions
to energy yield and its correlated technological process of extraction in obtaining same in the most economical sense available;
thus, the importance of segregating the MSW into the appropriate categories of distinct feedstock is of principal importance for
optimal performance in the appropriate technological processes.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In BioCrude&#8217;s MSW-Energy initiative,
BioCrude Technologies USA, Inc. incorporated the following technologies in the Integrated Municipal Waste Processing (Waste to
Energy) Complex in order to optimize the treatment process in an environmentally friendly manner by whilst optimizing the Revenue
Model of same, and in turn, pass some of the savings back to the municipalities while still earning an impressive bottom line in
juxtaposition to what the competition has to offer with regards to landfilling and incineration:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Separation of Waste Facility (Materials Recovery Facility)</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Refuse Derived Fuel (&#8220;RDF&#8221;) Plant in order to handle the fuels of the MSW and produce Energy with an ash by-product</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Bio-Methanation Plant in order to handle the organic fraction of the MSW (OFMSW) to produce Energy with a fertilizer by-product</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Composting Facility (maximum 50 TPD) in order to handle a percentage of the OFMSW alongside with the small particles (plastics, ceramics...) that could not be efficiently separated within the separation process of the MSW (fuels in the Bio Methanation plant (plug flow digester) inhibit the process). The economies are no longer apparent in Composting facilities surpassing the 50 TPD capacities.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Power Plant</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 35.7pt; text-align: justify; text-indent: -17.85pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 35.7pt; text-align: justify; text-indent: -17.85pt"></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 35.7pt; text-align: justify; text-indent: -17.85pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">With BioCrude&#8217;s Integrated MSW
to Energy proposal/initiative, BioCrude attempts to service each category of the MSW in order to optimally utilize all renewable
resources from same to procure renewable energy and marketable by-products (fertilizer, ash, etc.).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">It is very important to note that the
Separation Process of the MSW into the appropriate feedstock categories for each distinct process (organics for biomethanation
(as well as for composting), and polymer based hydro-carbons and cellulose based products for RDF process) is of the utmost importance.
Failure to do so can lead to complications and inevitable failure of each process in question. Evidence of Success and failure
stories (especially with biomethanation plants, whereby the feedstock generated from MSW (organic fraction) had traces of more
than 10% of polymer based products and/or inerts, thus inhibiting and/or limiting the viability of same) as can be found all over
the world, and each outcome, in essence, can be summarized by Plant Technology Implementation and Feedstock Preparation (do not
mix up technology viability with technology implementation and operation).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span style="text-decoration: underline">Nota Bene</span></i></b>: With
gasification and/or incineration (mass burn), MSW is dumped into the boiler &#8220;as is&#8221; and combusted at temperatures ranging
from 800 &#8211; 12000C (minimum; plasma arc gasification temperatures range from 7,000 &#8211; 10,0000C). All waste is burned
yielding an approximate net yield of energy for reuse (after self-consumption) of 30 &#8211; 40%. The organic fraction of the MSW
(OFMSW) is burned, whereby the fertilizer potential via a biomethanation process (cooking) is substituted for an ash from the gasification/incineration
process (es). Let us not even entertain what happens to the methane potential of same via gasification/incineration in lieu of
biomethanation; LOST! Bottom line, &#8220;<b>Potential Revenues</b>&#8221; lost and operational costs of gasification/incineration
processes are increased dramatically, up to the point where one has to substitute more energy (fuel) in order to sustain continuity
of operation and/or to substitute the self-consumption energy requirements of the processes when the varying calorific value of
a sample of the waste is deficient for same. One can do their own sensitivity analysis to evaluate same and come to their own conclusions!
BioCrude&#8217;s Integrated MSW-Energy Solution evolves from first principles of Science, Chemistry, Engineering, Economics and
Common Sense!</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The <b>Organics</b> portion of the MSW
is treated via a <b>biomethanation</b> process, whereby all methane gas is extracted for the eventual realization of renewable
energy creation, and a fertilizer procured as an additional by-product, which can be marketed to the agricultural industry.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The <b>polymer-based</b> (hydro-carbon chain), cellulose
and textiles portion of the MSW will be treated via an <b>RDF</b> process (a derivative of gasification, but with the incorporation
of a Materials Recovery Facility (MRF) [Separation process], where we have the luxury of operating at lower temperatures (350 &#8211;
400<sup>0</sup>C) because of the separation of the MSW, i.e. lower temperatures reflects less operational self-consumption, hence
more outputs (energy) for resale), whereby the thermal combustion will generate renewable energy and the by-product of ash can
be marketed to the construction industry for the following purposes:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Concrete production, as a substitute material for Portland cement and sand</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Embankments and other structural fills (usually for road construction)</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Grout and Flowable fill production</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Waste stabilization and solidification</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Cement clinkers production - (as a substitute material for clay)</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Mine reclamation</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Stabilization of soft soils</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Road sub base construction</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">As Aggregate substitute material (e.g. for brick production)</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Mineral filler in asphaltic concrete</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Agricultural uses: soil amendment, fertilizer, cattle feeders, soil stabilization in stock feed yards, and agricultural stakes</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Loose application on rivers to melt ice</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Loose application on roads and parking lots for ice control</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Other applications include cosmetics, toothpaste, kitchen counter tops, floor and ceiling tiles, bowling balls, flotation devices, stucco, utensils, tool handles, picture frames, auto bodies and boat hulls, cellular concrete, geopolymers, roofing tiles, roofing granules, decking, fireplace mantles, cinder block, PVC pipe, Structural Insulated Panels, house siding and trim, running tracks, blasting grit, recycled plastic lumber, utility poles and cross arms, railway sleepers, highway sound barriers, marine pilings, doors, window frames, scaffolding, sign posts, crypts, columns, railroad ties, vinyl flooring, paving stones, shower stalls, garage doors, park benches,</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 35.7pt; text-indent: -17.85pt">&#160;</p>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 35.7pt; text-indent: -17.85pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The fly ash can also be marketed to
the agricultural industry for the following purposes:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify; line-height: 107%">&#160;</td>
    <td style="width: 24px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">It improves permeability status of soil</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Improves fertility status of soil (soil health) / crop yield</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Improves soil texture</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Reduces bulk density of soil</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Improves water holding capacity / porosity</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Optimizes pH value</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Improves soil aeration and reduces crust formation</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Provides micro nutrients like Fe, Zn, Cu, Mo, B, Mn, etc.</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Provides macro nutrients like K, P, Ca, Mg, S etc.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 107%; width: 24px">&#160;</td>
    <td style="text-align: justify; line-height: 107%; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Works as a part substitute of gypsum for reclamation of saline alkali soil and lime for reclamation of acidic soils</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Surface cover of bio reclaimed vegetated ash pond get stabilized and can be used as recreational park</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Ash ponds provides suitable conditions and essential nutrients for plant growth, helps improve the economic condition of local inhabitants</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Works as a liming agent</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Helps in early maturity of crop &amp; improves the nutritional quality of food crop</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Reduces pest incidence</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There is a definite market for the fly
ash by-product; the industry players in the global market place have to be clearly identified for the realization of commercialization.
BioCrude can even offer this ash by-products pro-bono to the industry or landfill, for there is no environmental hazard of same.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The recyclables can be easily sold to the recyclable industry
milieu (metals, glass, ceramics, etc.)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The balance of the inerts (Construction
and Demolition Debris, gravel, sand, bricks, etc.) can either be landfilled with no negative environmental impacts, or crushed
and given to companies specializing in the fabrication of construction materials (if a market is identified, BioCrude can offer
them these by-products (crushed or uncrushed).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">BioCrude&#8217;s Integrated MSW
to Energy Complex for Municipal Applications</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude&#8217;s solution of an Integrated
Municipal Solid Waste to Energy complex is in line with the present trends in the Municipal Solid Waste (&#8220;MSW&#8221;) industry
and the main advantage of same is that it is comprised of a Materials Recovery Facility (&#8220;MRF&#8221;) and different modular
waste treatment processes (Composting, Bio-methanation and Refuse Derived Fuel (&#8220;RDF&#8221;)) and a power station, in order
to treat the MSW and procure renewable energy and other marketable by-products (compost, ash and certain recyclables) with the
added implication of practically zero-landfill policy (less certain inerts which have zero negative environmental impact, if landfilled).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The material components (modules) of
an Integrated Municipal Solid Waste to Energy Complex are detailed as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Entrance to complex</b>: Kiosk and weighbridge (reception/departure and weighing of garbage trucks (pre-and-post deposit of MSW at the MSW Storage facility).</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>MSW Storage facility</b>: Closed and properly ventilated warehouse facility for receiving and storing just in time (JIT) 3 days&#8217; inventory of MSW. MSW is moved from the storage facility and moved via machinery and conveyor belts to the Materials Recovery facility.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Materials Recovery facility (MRF)</b>: a properly ventilated facility that houses different types of machinery/equipment (either procured from suppliers or built in-situ according to plan specifications) requisite for different facets of the separation process of the MSW into the distinct categories of the waste (organics, hydro-carbon polymer based, cellulose, inerts, miscellaneous (batteries, cadavers, etc.&#8230;)) and prepare same as the distinct feedstock for the different waste treatment processes (Composting, Biomethanation and Refuse Derived Fuel (RDF)), as well as separate the recyclables for resale and the inerts (elements of construction and demolition debris that are not recyclable) for landfilling or to be crushed and given/sold (negligible in nature in comparison to the revenue model established by the tipping fees, and resale of electricity and compost) to the secondary markets for the manufacturing of building materials.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Composting facility</b>: A portion of the land concession will host a type of composting system (Windrow [with procured mechanical mixing machinery (trucks) like compost turners or tub/horizontal grinders] or Static Aerated Piles [aeration system such as installed perforated piping to ensure steady oxygen supply (forced air) for the microorganisms and to reduce moisture content]), depending on BioCrude&#8217;s evaluation of the waste analysis. A fertilizer will be procured, dried and stored in a warehousing facility for by-products.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Biomethanation facility</b>: Modular digesters are constructed in series and synchronized in operation in order to receive organics and process same to extract and capture the methane gas which will be piped to the Biogas &#8211; RDF power plant (will be combusted for the procurement of renewable energy) and in addition, yield a cured fertilizer which will be dried and stored in the warehousing facility for by-products.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">6.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>RDF facility</b>: A refuse derived fuel system (gasification derivative) will be procured and installed. The RDF facility will receive the hydro-carbon polymer and cellulose based waste products that will be used to make RDF pellets (compressed and dried) that will be used as the feedstock for combustion within same to generate renewable energy within the Biogas &#8211; RDF power plant.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">7.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>RDF &#8211; Biogas power plant</b>: will be procured and installed within a certain section of the Complex with a dedicated Distributed Control System (DCS) for the MSW-Energy (RDF &amp; Biogas based) power plant &amp; fuel processing plant (controls &amp; instrumentation for the boiler and turbine, instrumentation for the balance of the power plant and control room).</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">8.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Internal roads</b>: will be constructed within the complex for vehicle/truck transport/passage within the complex.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">9.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Green Belt</b>: will be developed for aesthetic purposes and municipal environmental conformities.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><img src="image_004.jpg" alt="" style="height: 545px; width: 369px" /></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Business Model</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s business model is
designed to create a profitable revenue stream through the direct acquisition of Concession Agreements from different Governments
for the implementation of BioCrude&#8217;s integrated MSW-Energy Complexes. Our products, processes and services, marketed to the
relevant target audience, enable us, to generate multiple revenue streams and consistent profitability derived from the high gross
profit inherent within the realms of our proprietary products, services and applications.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">By acquiring the necessary Concession
(MSW, Land and Supply of Treated Effluent) and Power Purchase Agreements (PPA), from the respective governmental authorities of
a certain country, with Sovereign Guarantees (with right of subrogation), the Company will develop its Integrated Municipal Solid
Waste to Energy Complex, under &#8220;<b>BOOT&#8221;</b> (Build, Own, Operate &amp; Transfer) basis.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The following contractual understandings are the key prerequisite
elements for establishing a mutual meeting of the minds, by and between BioCrude Technologies USA, Inc. and the governmental authorities
of a municipality/country, for the successful realization of BioCrude&#8217;s MSW-Energy Complexes:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>MSW Concession</b> for the guaranteed delivery of MSW to the Complex with an implied base tipping fee per tonne (&#8220;Put or Pay&#8221;) with annual escalations for the term (30 years) of the project with an option of renewal for an additional term (30 years) and Sovereign Guarantees from the Minister of Finance endorsing same.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Land Lease Concession</b> for the delivery of the required amount of land for project term (30 years), at an annual symbolic lease rate of $1/amount of land delivered/annum, with an option of renewal for an additional term (30 years).</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Supply of Treated Effluent Concession </b>whereby the governmental authorities will supply the necessary treated water in order to fulfill the operational requirements of the MSW to Energy complex at a negligible symbolic annual rate for the term of the project with an option of renewal for an additional term (30 years).</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px; line-height: 107%">&#160;</td>
<td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
<td><b>Power Purchase Agreement (PPA)</b> [resale of procured electricity to the Power Corporation of the country in question], whereby the Power Corporation of a certain country will buy back the electricity produced by the MSW to Energy Complex at a base rate per kW-hr (&#8220;Take or Pay&#8221;), with annual escalations for the term (30 years) of the project with an option of renewal for an additional term (30 years) and Sovereign Guarantees from the Minister of Finance endorsing same. &#160;</td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%"></td></tr></table>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="line-height: 107%; width: 24px">&#160;</td>
<td style="line-height: 107%; width: 24px">&#160;</td>
<td><p style="margin-top: 0; margin-bottom: 0">&#160;</p>
    <p style="margin-top: 0; margin-bottom: 0">&#160;</p></td></tr>
<tr style="vertical-align: top">
<td>&#160; &#160; &#160;</td>
<td>5.</td>
<td>Assistance from the Appropriate Governmental Ministries and Municipalities in obtaining all necessary permits and clearances for the Construction and Operation of the MSW-Energy Complex (stipulations in contracts).</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Nota Bene</span></b>: Depending on
country policy on foreign investment, the Company may request or be granted an exemption of taxes, levies, duties and all other
relevant taxes applicable to the importation of all plant, materials, equipment and rolling stock for the Construction of the MSW-Energy
complex, from the appropriate Ministries, related thereto.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the aforesaid Concession agreements
have to be granted at the same time in order for BioCrude to successfully realize the development (Engineering, Procurement and
Construction) and operation of the MSW to Energy complex (the &#8220;Sovereign Guarantees&#8221; and right of subrogation are critical
and paramount for the funding requirements of the MSW to Energy complex).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Target Market </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The global Waste to Energy segment of
the waste management industry is the target market BioCrude addresses. Management is confident it will succeed in having its integrated
systems and processes widely implemented across Africa, Asia, the Balkans, the GULF and North America with a view to expanding
to other international markets (Latin America). The Company&#8217;s first step in penetrating its target market has been taken
with the signing of Concession Agreements with the country of the Union of the Comoros (Autonomous Island of Grande Comore); signed
January 11, 2016.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Strategies of the Company </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude&#8217;s strategy is designed
to create a &#8220;PROFITABLE&#8221; revenue stream through the direct acquisition of Concession Agreements from different Governments,
for the implementation of BioCrude&#8217;s integrated MSW-Energy Complexes, or through the establishment of unique and strategic
alliances via licensing arrangements and/or joint ventures within the industry milieu.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude has developed what we believe
is a highly effective marketing strategy, built on a proactive direct marketing campaign with Government, large corporate facility
management that target the sector for waste product treatment and reformation. <b>The Company believes that this will result in
a development of a marketing and distribution network with extensive coverage of the Company&#8217;s target market at a minimal
expense, allowing the Company to reach profitability.</b> We believe that our marketing strategy will permit us to generate an
extensive customer/end user base; however, there can be no assurance that our estimate regarding acceptance of our products and
services will be correct.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s long-term strategy
is to create economically beneficial uses for waste streams through resource transformation solutions. Since the value of marketable
by-products (commodities; renewable energy, fertilizer, primary feedstock for building materials, etc.&#8230;), after processing
costs, is a significant and absolute amount, in juxtaposition to disposal options (ZERO), such as landfilling or incineration,
the Company believes this strategy is effective long-term. The Company believes that as carbon taxes or cap and trade systems are
implemented and the demand for commodities rises, economics will further favor this strategy. The Company is also focusing on lowering
the cost of resource transformation solutions by reducing its recycling processing operating costs, examining ways to mitigate
commodity price fluctuations (forward contracts for marketable by-products), and developing new processing technologies. These
steps will help to build an effective business model at lower commodity pricing levels.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is focused on four main
areas to improve the performance of base operations and hence, increase cash flow generation. They are Pricing initiatives, Cost
controls and operating efficiencies, Integrated Waste to Energy development initiatives with long term Concession Agreements and,
Asset Management.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude has developed a number of Lobbying
(Sales/Solicitation) programs and the standardization of same. We believe that the pricing logic used in our fee structures, with
implied &#8220;<b>Put or Pay</b>&#8221; and &#8220;<b>Take or Pay</b>&#8221; provisions for the supply of feedstock and resale
of outputs (renewable energy), respectively, is not only reasonable, but competitive. We expect to continue to add valued ameliorations
to our structured fee-based pricing of products and services. The goal of our pricing program is to generate price increases in
excess of CPI, whilst being competitive in nature. BioCrude will derive revenues from a combination of commodity sales (Marketable
by-products &#8211; fertilizer and energy resale), carbon credits (CER&#8217;s under the auspices of a &#8220;<b>Clean Development
Mechanism</b>&#8221; (CDM project)) and tipping (gate) and material processing fees. Fluctuations in commodity pricing are managed
by a number of risk mitigation strategies including: financial hedging instruments (transfer of foreign exchange risk), floor prices,
forward sales contracts, and index purchases. The goal is to optimize and stabilize the revenue stream, while still being competitive,
net of cost of operations, and generate consistent positive cash flows.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continues to search for
the best continuous improvement practices and programs as solutions to then implement as part of its corporate governance. The
goals of these practices and programs are to enhance customer service, increase safety for employees, and to reduce operating and
administrative costs. The Company has implemented continuous improvement strategies, and as such, as of date, the Company has introduced
select operating efficiency initiatives in safety, productivity, maintenance, customer service, environmental compliance, and procurement.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Prior Activities of BioCrude Canada</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Within certain countries, if an entity
wants to pursue certain specialized works, it is recommended that the entity establish a presence within same (establish a corporation
with a civic address). As an example, in 2009, this was done in Romania with the anticipation that BioCrude Canada would be successful
in acquiring the concession agreements from the governmental authorities of Romania. BioCrude was not successful in meeting its
objective in Romania for same and stopped its lobbying works for the pursuit of said engagement by and between the Governmental
authorities of Romania and BioCrude for the implementation of BioCrude&#8217;s proposed MSW to Energy complex in Romania, closed
its preliminary office and the corporation became dormant.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Since July 2008, BioCrude Canada has
taken the initiative to market and promote its intellectual property and specialized technical expertise throughout the market
place, both nationally and globally (we have introduced our technology to Governments and major Conglomerates in the Waste to Energy
sector) in over 30 Countries worldwide, whereby BioCrude has successfully opened up dialogue with Governmental Authorities and
respectable corporations for near future contractual negotiations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In December, 2007, Jaipuria Advanced
Technologies, Inc. (http://www.jaipuria-group.com and http://www. smvjaipuria.com/waste.php) of India, and BioCrude Canada, announced
their formation of a new division dedicated to Waste Reformation and Energy Procurement for the purpose of pursuing contracts in
India. In many areas of the country, waste management and energy shortages are a serious problem. With Jaipuria&#8217;s construction
and large project experience, and with the use of the intellectual property supplied by BioCrude in terms of waste management and
production of renewable energy, we have, in January, 2008, submitted a bid, in response to a tender for a Waste to Energy plant
(2,000 TPD) in Okhla and Tymarpur, India (we were not the selected candidate) and Indore, India (Collection and Treatment of municipal
waste; 600 TPD; we were not the selected candidate).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During this time, we have also negotiated
with &#8220;Pepsi Co India&#8221; to build a 50 TPD prototype in the city of Panipat, India, in a strategic joint venture alliance.
A few months later, Pepsi Co India&#8217;s New President/CEO had a change of corporate venue and put aside the Waste to Energy
initiative. Ever since then, BioCrude Technologies, Inc. (Canada) decided not to pursue any more works in India.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, through its commercialization
efforts, has established good relationships with governments and ministries in more than 70 countries in North America, Latin America,
Asia, Africa and Europe and received a positive reception when presented with its waste to energy solution for their waste management
dilemmas. This produced dozens of Letters of Interest, submitted to BioCrude, by different divisions of Governments (federal/municipal)
from different countries, worldwide.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 57pt; text-align: justify; text-indent: -57pt">2009 &#8211;
2020 - <b><span style="text-decoration: underline">Marketing and Commercialization</span></b>: BioCrude presented its waste to energy solution to governments and ministries
from USA, Canada and Mexico in North America, Costa Rica, Panama, Ecuador, Argentina, Peru, Brazil, Dominican Republic, Haiti,
Colombia, Venezuela, Guatemala, Honduras, Jamaica, El Salvador, Cuba, Uruguay, Bahamas and Trinidad &amp; Tobago in Latin America,
China, Hong Kong, Mongolia, Kazakhstan, Vietnam, Indonesia, Philippines, India, Bangladesh, and Pakistan in Asia, Kingdom of Saudi
Arabia, United Arab Emirates, Kuwait, Qatar, Jordan, Oman, and Bahrain in the Middle East, Portugal, Luxembourg, Belgium, Hellenic
Republic, Malta, Corsica, Albania, Bulgaria, Romania, Serbia, FYROM (Macedonia), Spain, Montenegro, Kosovo, Belarus, Ukraine, Georgia,
Latvia, Armenia, amongst other countries, in Europe, Ivory Coast, Burkina Faso, Ghana, Togo, Senegal, Benin, Angola, Niger, Guinea,
Mali, Uganda, Burundi, Rwanda, Morocco, Tunisia, Algeria, Egypt, Libya, Kenya, Ethiopia, Democratic Republic of the Congo (Kinshasa),
Republic of the Congo (Brazzaville), amongst other countries in Africa.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 57pt; text-align: justify; text-indent: -57pt"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Pricing initiatives</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude has developed a number of sales/solicitation
programs and the standardization of the sales/solicitation process and standardized the sales/solicitation process. We believe
that the pricing logic used in our fee programs, with implied &#8220;<b>Put or Pay</b>&#8221; and &#8220;<b>Take or Pay</b>&#8221;
provisions for the supply of feedstock and resale of outputs (renewable energy), respectively, is reasonable and competitive. We
expect to continue to add to our fee-based pricing through additional administrative fees, recycling fees, late charges and further
improvements to our existing fee structures. The goal of our pricing program is to generate price increases in excess of CPI. BioCrude
will derive revenues from a combination of commodity sales (Marketable by-products &#8211; fertilizer and energy resale), carbon
credits (CER&#8217;s under the &#8220;<b>Clean Development Mechanism</b>&#8221; established pursuant to article 12 of the &#8220;<b>Kyoto
Protocol</b>&#8221; (CDM project)) and tipping fees paid for material processing. Fluctuations in commodity pricing are managed
by a number of risk mitigation strategies including: financial hedging instruments (transfer of foreign exchange risk), Sovereign
Guarantees, floor prices, forward sales contracts, index purchases, and tipping fees. The goal is to smooth revenue, net of cost
of products purchased, and generate consistent cash flows.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cost controls and operating efficiencies</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continues to search for
the best practices throughout the entire organization and then implements these solutions through standardized continuous improvement
programs. The goals of these programs are to enhance customer service, increase safety for employees, and to reduce operating and
administrative costs. The Company has implemented continuous improvement strategies and the introduction of select operating efficiency
initiatives in safety, productivity, maintenance, customer service, environmental compliance, and procurement.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Integrated Waste to Energy development
initiatives with long term Concession Agreements</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude excels is the reformation of
MSW using its intrinsic intellectual property as well as its expertise in Integrated Waste to Energy Processing Complexes. BioCrude
has and will continue to invest time, effort and valuable resources in the pursuit of Governmental Concession (MSW, Land, Supply
of Treated Effluent and Power Purchase Agreements (PPA)) Agreements, for the duration of twenty-five to thirty years, for the implementation
of same. The essence of the Concession Agreements, not only guarantees the MSW and implied tipping fees, related thereto (with
annual indexing), but the resale of the marketable by-products (energy to grid via PPA) for the duration of the term, with Sovereign
Guarantees. Investments in Waste to Energy facilities position the Company well for the evolution of the industry from waste management
to resource management.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Company milestones and plan of execution</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the past 10 years, BioCrude has
developed a reputation in waste management, a result of R&amp;D of Environmental Technologies (both process and product based)
whereby it has enhanced and optimized conventional technologies, augmented by its fungal technology that increases the rate of
decomposition of organics. This led to the development of efficient, cost-effective, and environmentally friendly products, processes
and systems for the reformation of waste material and the creation of renewable energy and marketable by-products.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude&#8217;s MSW to Energy initiative
is, by definition, an &#8220;en suite&#8221; of waste management and energy procurement, whereby the latter is a marketable byproduct
derived from the intrinsic processes of the treatment of the MSW by procuring the necessary constituent feedstock (primary material)
to produce the renewable energy in the modular section for power generation of the Integrated MSW to Energy complex. In order to
realize an integral MSW to Energy complex, as defined in the &#8220;Business Model&#8221; of the registration statement, all Concession
Agreements (guarantee of MSW supply, Land and Supply of Treated Effluent) as well as a Power Purchase Agreement must be contracted
concurrently, for they are &#8220;ALL&#8221; necessary constituent elements for the development of an integrated MSW to Energy
complex i.e., you cannot have some or most of the agreements (Concessions/PPA) in place, but must have &#8220;ALL&#8221; in place,
at the same time, simply because of the nature of the project in question.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude&#8217;s revenue model is based
on revenue generation from the following: i) the operation of MSW to Energy complexes (tipping fees, resale of renewable energy,
resale of other marketable by-products (compost, recyclables) and potential carbon credits, ii) Joint Venture license fees, whereby
the prospective Joint Venture partner will buy a license from BioCrude (payment to be effected immediately after signature) for
their participation in the consortium and will infuse its prorated share of equity capital for the potential MSW to Energy complex,
and iii) EPC (&#8220;Engineering, Procurement &amp; Construction) management fees (general contracting fees, approximately 20%
of the capital cost of the project).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to realize an integrated MSW
to Energy complex, as defined in the &#8220;Business Model&#8221;, all Concession Agreements (guarantee of MSW supply, Land and
Supply of Treated Effluent) as well as a Power Purchase Agreement must be contracted concurrently, for they are &#8220;ALL&#8221;
necessary constituent elements for the development of an integrated MSW to Energy complex.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to acquire the concessions
for Biocrude waste management (MSW to Energy), major lobbying must be done in all levels of government and ministries (e.g., Biocrude&#8217;s
waste management project is an environmental project thus requiring the intervention of the Ministry of Environment, renewable
energy is procured, hence requiring the intervention of the Ministry of Energy/Power and Power Corporation (usually crown corporation),
the municipalities usually are responsible for the granting of the MSW, Land and Supply of Treated Effluent Concessions and the
Ministry of Finance is responsible for the signing of the Sovereign Guarantees, and in some instance, countries might have other
intervening governmental agencies).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude has positioned itself, through
its continual lobbying efforts (ongoing), for potential Joint Ventures (JV) with certain governments (countries/clients). Should
any of these Joint Ventures prove to be realized because of the persistent lobbying activities, not only will BioCrude be able
to realize the EPC management fee for the development of the MSW to Energy complex(es), but it will also receive its prorate share
(50%) of the revenue stream of the developed MSW to Energy complex(es), with similar time frame frequencies as mentioned above,
as well as a license fee (BioCrude already submitted offers) immediately following signature of the Joint Venture engagement and
the Concession and Power Purchase agreements. BioCrude anticipates, that if the prospective JV partner(s) take the initiative to
implement (not only entertain) a waste management solution for their country, possible engagement can be realized within 6 to 12
months following that initiative (being cognizant of bureaucracy and red tape procedures of government).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of BioCrude&#8217;s marketing
strategy, BioCrude invests time, effort and resources in order to prepare tailor made prefeasibility studies, presentations &amp;
educational literature for municipalities worldwide, and sends corporate delegations to these places for presentation of same,
at no expense to these governmental institutions. This attribute of BioCrude&#8217;s direct marketing campaign has proven to be
very successful. Governments worldwide were not only receptive, but appreciative of BioCrude&#8217;s formal and professional address.
These efforts have given BioCrude a profound understanding of the challenges faced by governments at all levels in their dealings
with waste management issues.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A vote of confidence has been bestowed
to BioCrude by the governmental authorities of the Autonomous Island of Grande Comore on its proposed integrated waste management
solution for the Autonomous Island of Grande Comore through the awarding of the necessary Concession Agreements (delivery of MSW,
Land and Supply of Treated Effluent) for 30 years (with a renewal option of 30 years) with Sovereign Guarantees for the implementation
(design, build, finance and operate) of a 700 TPD Municipal Solid Waste to Energy Complex, in the city of Moroni, Autonomous Island
of Grande Comore, Union of the Comoros. Furthermore, a Power Purchase Agreement has been signed with the &#8220;Le Gestion de l&#8217;Eau
et de l&#8217;&#201;lectricit&#233; aux Comores (MA-MWE)&#8221; whereby same will buy back all procured renewable energy from
the MSW to Energy complex for the term of the Concessions (and renewal option).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude, subject to its contractual
engagement with the Government of the Autonomous Island of Grande Comore for the implementation of a 700 TPD MSW to Energy complex
in Moroni, Grande Comore, through the financing provisions of the MSW to Energy project, will earn the EPC management/general contracting
fee of approximately twenty percent (20%) of the capital cost of the MSW to Energy project (prorated over the duration of the construction
period), i.e., commencing within 6 to 8 months from these presences.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Nota Bene</span></b>: For the Union
of the Comoros, the Company is still awaiting documents from the Federal Governmental Authorities stating that the Federal Government
is the new Intervening Party to the Concession(s) agreements previously signed with the Governorate (province; autonomous region)
of Moroni, after the outcome of the Federal Referendum, whereby through same, contracting and economic powers are transferred from
the Governorate (Province) level to that of Federal level. The Referendum outcome favored the Federal Government over that of the
Governorate (Autonomous) Region of Moroni, i.e., authorizing documents are still pending.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude, as well, is looking at approximately
24 to 26 months (development time frame for the realization of MSW to Energy complex) before it can start generating absolute,
guaranteed revenues from the operation of the MSW to Energy complex(es) (tipping fees/fees from the resale of marketable by-products
(compost, ash, primary feedstock for building materials (inerts), recyclables, etc.&#8230;), resale of renewable energy and carbon
emission reduction credits [CERs]), servicing the waste management needs of the Government of the Union of the Comoros, as per
the provisions and stipulations of the contractual engagements with the government (with implied sovereign guarantees), for a minimum
guaranteed term of 30 years (and an option for an additional 30 years).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude is evaluating additional options
for funding (capital markets, financial institutions, contracting companies, pension funds, etc.&#8230;amongst other financially
engineered hybrid scenarios thereof) and has already opened up dialogue regarding same. BioCrude has received a term sheet for
the funding of the MSW to Energy project for the Union of the Comoros, ergo, BioCrude will shortly be able to commence works for
ground breaking and start receiving its (Engineering, Procurement and Construction) EPC management fee as its first projected revenue
stream on a prorate schedule subject to a disbursement schedule in accordance to the terms and stipulations of the expected offer
of funding.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude, with confidence, aims to be
a leader in waste management, having set as its objective, the profitability inherent within the realms of the activities issued
of this sector, while building business relationships and social implications within the collectivity&#8217;s/communities that
BioCrude is called upon to serve, beyond the environmental and social implications, and beyond the business imperatives.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude has adopted a directive, as
part of its corporate governance, to routinely undertake innovative strategic planning initiatives in order to design and implement
integrated solid waste systems that are responsive to dynamic demographic and industrial growth needs of municipalities. Strategic
planning starts with the formulation of long-term goals based on the local urban needs, followed by a medium and short-term action
plan to meet these goals. The strategy and action plans should identify a clear set of integrated actions, responsible parties
and needed human, physical and financial resources as part of the waste management solution.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude has not only demonstrated its
proven ability to open up dialogue and develop relationships with the various divisions of Governments worldwide (Administrative
and Technical) but has also developed confidence in same for potential and eventual engagement. BioCrude&#8217;s Public Relations
and Business Development divisions have demonstrated their lobbying abilities as highly effective, efficient and productive in
yielding results and establishing goodwill for BioCrude.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At present, the provisioning for waste
treatment and &#8220;<b>green</b>&#8221; reformation of these products into renewable energy sources is regionalized and within
a given geographic region of operations, can be competitive. However, we believe that there are no other entities that provide
turnkey solutions targeted to all types and sizes of users. However, there are waste treatment providers that may elect to enter
into this designated market if our model is successful. We compete on the basis of engineering uniqueness, quality, cost-effectiveness
and the increasingly comprehensive and specialized nature of our services, along with the expertise, technology and professional
support we offer. While we believe that we will have a competitive cutting-edge advantage by being the most specialized in the
market, there can be no assurance that our assumptions regarding our competitive position will be proven correct.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We will require additional capital to
meet our liquidity needs. Currently, the Company has determined that its anticipated monthly cash flow needs should not exceed
$30,000 per month for twelve months following the filing date of these financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s projected capital
needs and its projected increase in expenses are based upon the Company&#8217;s projected acquisition of Municipal Solid Waste,
Land and Supply of Treated Effluent Concessions and Power Purchase Agreements (&#8220;PPA&#8221;) per facility interests over the
coming twelve months; however, in the event that the full offering proceeds are not raised, the Company would acquire the Municipal
Solid Waste, Land and Supply of Treated Effluent Concessions and PPA per facility at a slower pace and/or focus its energies on
the refinement of existing properties to maximize their productivity. The Company&#8217;s success does not depend on a scheduled
acquisition and therefore it has flexibility to scale back its expenses to meet actual sources of cash.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We anticipate that we will receive sufficient
proceeds from investors through this offering, to continue operations for at least the next twelve months; however, there is no
assurance that such proceeds will be received and there are no agreements or understandings currently in effect from any potential
investors. It is anticipated that the Company will receive increasing revenues from operations in the coming year; however, since
the Company has a short history of revenues, it is difficult to anticipate what those revenues might be, if any, and therefore,
management has assumed for planning purposes only that it may need to sell common stock, take loans or advances from officers,
directors or shareholders or enter into debt financing agreements in order to meet our cash needs over the coming twelve months.
The Issuer has no agreements or understandings for any of the above-listed financing options.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Use of Proceeds section includes
a detailed description of the use of proceeds over the differing offering scenarios of 100%, 75%, 50% and 25%. As the Company&#8217;s
expenses are relatively stable, not incorporating elements of severe force majeure, the Company believes it can fund its present
operations with projected revenues together with offering proceeds under any of the offering scenarios. The Company will consider
raising additional funds during 2021 through sales of equity, debt and convertible securities, if it is deemed necessary.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s belief is based
on its business model, which in turn is based on assumptions, which may prove to be incorrect. As a result, the Company&#8217;s
financial resources may not be sufficient to satisfy its capital requirements for this period, and may need to raise additional
funds. If additional funds are raised through the issuance of equity, equity-related or debt securities, such securities may have
rights, preferences or privileges senior to those of the rights of the common stock and the Company&#8217;s shareholders may experience
additional dilution. Management cannot be certain that additional financing will be available on favorable terms, when required,
if at all. If adequate funds are not available or not available on acceptable terms, the Company may not be able to fund its expansion,
promote its brand as desired, take advantage of unanticipated acquisition opportunities, develop or further enhance and/or optimize
its products and services or respond to competitive pressures.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude&#8217;s revenue model is based
on revenue generation from the following: i) the operation of the MSW to Energy complexes (tipping fees, resale of renewable energy,
resale of other marketable by-products (compost, recyclables) and potential carbon credits, ii) Joint Venture license fees, whereby
the prospective Joint Venture partner will buy a license from BioCrude (payment to be effected immediately after signature) for
their participation and will infuse its prorated share of equity capital for the potential MSW to Energy complex, and iii) EPC
(&#8220;Engineering, Procurement &amp; Construction) management fees (general contracting fees, approximately 20% of the capital
cost of the project). In essence, these fees have to be paid regardless, and BioCrude management will execute and capture remuneration
for same.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Hereunder is a schedule of events (agenda)
for the realization (full execution) of the MSW to Energy project in Moroni, Autonomous Island of Grande Comore (inclusive: contract
realization process), in order for BioCrude to start realizing revenues as an ongoing concern, not taking into account any prospective
joint ventures in the works.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Different facets and schedule of
events for the pursuit and realization of MSW to Energy projects (excluding lobbying activities)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Contract Conclusion, Engineering,
Procurement&amp; Construction</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>A. Signature of the following Accords
necessary for the realization of the MSW-Energy Complex in Moroni, Autonomous Island of Grande Comore</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">1.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Deed of Assignment Agreement (&#8220;Protocol of Engagement&#8221;) by and between the Government of the Autonomous Island of Grande Comore and BioCrude Technologies USA, Inc. Contract was signed January 11, 2016.</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%">&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">2.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">The signing of the Concession Agreement for the Municipal Solid Waste, Land Lease Agreement and Agreement for the supply of treated Municipal Water on January 11, 2016</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%">&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">3.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">The signing of the Power Purchase Agreement (PPA) with the &#8220;Le Gestion de l&#8217;Eau et de l&#8217;&#201;lectricit&#233; aux Comores (MA-MWE)&#8221; [ Power Corporation of the Autonomous Island of Grande Comore] on January 11, 2016</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%">&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">4.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Opening of a new Comorian Corporation (in the country in question) totally owned by BioCrude Technologies USA, Inc., opening of bank account and execution of all party obligations contained in the Deed of Assignment. This was done on January 12, 2016</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%">&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">5.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Reception of letter from new governmental administration of the Autonomous Island of the Grande Comore (after elections on May 2016) reaffirming their initiative and will to fully respect and execute the engagements signed on January 11, 2016; August 25, 2016</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%">&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">6.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Site selection (site Identification and legal designation (Cadastral, Lot, etc. ...)) for the MSW-Energy Complex, preparation of legal documents to annex same to the Land Lease Agreement and Assignment of selected parcel of land to BioCrude, as per the stipulations of the Land Concession agreement on November 12, 2016.</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%">&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">7.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Incorporating agreed to amendments and/or modifications to the contractual engagements of January 11, 2016 into the new agreements replacing those of January 11, 2016: December 9, 2016.</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%">&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">8.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; color: black">Granting of a Treasury Guarantee to BioCrude from the governmental administration of the Autonomous Island of the Grande Comore, as per the stipulations of the Concession and Power Purchase Agreements: December 10, 2016</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>(Fully executed; timeline:&#160;</b>it took approximately
8 months<b>)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>B. Organizational Matrix: Construction, Management, Operations
and Maintenance of Project</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Flowchart of management staff</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px; line-height: 107%">&#160;</td>
<td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Organization of the Waste Management (Collection, Transportation, Sorting and Treatment)</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="line-height: 107%; width: 24px">&#160;</td>
<td style="line-height: 107%; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
<td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Flowchart of Engineering, Procurement and Construction</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%">&#160;</td>
<td style="line-height: 107%">&#160;</td>
<td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%">&#160;</td>
<td>4.</td>
<td>Flowchart of Operations Complex and Maintenance</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Flowchart for the influx of feedstock and the out flux (distribution) of by-products</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">(<b>Fully executed; timeline:&#160;</b>The
tasks identified above in B are part and parcel of the submitted preliminary proposal, which included the &#8220;<b>Prefeasibility
Study &amp; Detailed Project Report</b>&#8221; and the &#8220;<b>Business Plan (with financial metrics)</b>&#8221;, to the Governmental
Authorities of the Autonomous Island of Grande Comore (September 2015) for the realization of the Concession and Power Purchase
Agreements in accordance to the provisions of the Deed of Assignment pursuant to a Public-Private Partnership (PPP)).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>C. Project implementation plan for
the Integrated Municipal Solid Waste to Energy Complex</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Opening of the office in Moroni, Autonomous Island of Grande Comore:&#160;expected completion date September 2021</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Recruitment and training of human resources in Moroni, Autonomous Island of Grande Comore (for engineering, management, operation and maintenance):&#160;expected completion date September 2021 (preliminary core)</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Recruitment of human resources in Canada (for key management positions):&#160;expected completion date September 2021</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Preliminary Engineering:&#160;completed in preliminary proposal (generic)</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Analysis of Municipal Solid Waste:&#160;expected completion date September 2021</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">6.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Study of the site and soil studies:&#160;expected completion date October 2021</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">7.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Detailed Engineering plans:&#160;expected completion date October 2021</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">8.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Detailed plan of the development strategy of the complex:&#160;expected completion date October 2021</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">9.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Hiring of project manager(s) and subcontractors (either through reference or through tender):&#160;expected completion date September 2021</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Recruitment of Material and Equipment specialist suppliers, via reputation in the market place or tender:&#160;expected completion date October 2021</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>(Timeline:&#160;</b>6 to 8 months from time = present)</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>D. Human Resource List for Project Implementation</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Project management</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Structural Engineers</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Electrical Engineers</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Mechanical Engineers</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">6.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Environmental Engineers</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">7.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Geological Engineers&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">8.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Designers&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">9.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Architects&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Planners</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">11.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Buyers</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">12.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Supply Agents</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">13.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Cost Controllers</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">14.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Training Coach</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>(Timeline:&#160;</b>2 to 4 months from time = present<b>)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>E. Development and implementation of the EPC project guide
(Engineering, Procurement and Construction)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Program Implementation Plan (<b>Project Execution Plan</b>&#160;&#8221;<b>PEP</b>&#8221;)&#160;Completed</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Preparation of studies and preliminary engineering plans&#160;Completed</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Preparation of studies and detailed engineering design&#160;3 months following task D</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Planning and timetable for the project (Gantt Chart)&#160;3 months following task D</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Obtaining permits and governmental approvals and clearances for the construction and operation of the complex&#160;2 months following submission of detailed engineering plans to the related Governmental Agencies of the Union of the Comoros (timeline provision in agreements and signed off by the Governmental Authorities of the Union of the Comoros)</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">6.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Construction&#160;10 to 14 months following the execution of E.5. above incorporating a startup synchronization period of approximately 1 to 2 months</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">7.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Operation and Maintenance Complex&#160;NA for Development timeline</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>F. Project Management and Control: Project Implementation
Plan (PIP)</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">A preliminary feasibility study and a detailed report of the complex&#160;Completed</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Strategic planning and economic analysis&#160;Completed</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The selection of the field&#160;Completed</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Preliminary engineering&#160;Completed</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Economic analysis and project risks</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The estimate of the total capital investment as well as operating and maintenance costs</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The preliminary assessment of environmental impact and permitting requirements</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The technology research, analysis and conceptualization</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Reliability analysis&#160;Completed</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td>
        <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">6.</p></td>
    <td>
        <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The technology selection, project configuration
and sizing&#160;Concurrently with task E.3. and its timeline</p></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px; line-height: 107%">&#160;</td>
<td style="width: 24px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">7.</span></td>
<td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The studies and engineering plans for the environmental permitting&#160;Concurrently with task E.3. and its timeline</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%">&#160;</td>
<td style="text-align: justify; line-height: 107%">&#160;</td>
<td style="text-align: justify; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="line-height: 107%">&#160;</td>
<td>8.</td>
<td>Research Techniques&#160;Concurrently with task C and its timeline</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">9.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The strategy and planning for the reduction of emissions of greenhouse gases (GHG)&#160;Concurrently with task C and its timeline</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of the Clean Design Mechanism documents for submission to the CDM program (literature and the detailed report for project compliance with the standards and requirements established by the UNFCCC)&#160;Concurrently with task C and its timeline</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">11.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Carbon capture and storage&#160;Concurrently with task C and its timeline</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">12.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The carbon credit analysis&#160;Concurrently with task C and its timeline</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">13.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Energy efficiency&#160;Concurrently with task C and its timeline</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">14.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The analysis of the applicable regulations&#160;Concurrently with task C and its timeline</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">15.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The economic and financial analysis (Business Plan) for the preparation of the application for funding&#160;Completed; we have already opened up dialogue with an EPC firm for not only engaging same for the EPC works, but also financing same under the proviso of BioCrude subrogating its right to the Sovereign Guarantees; waiting for proforma proposal from EPC firm</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">16.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The selection for the companies to carry out the civil works, and procure materials and equipment required for the development of the project (initiate works)&#160;Completed; we have already opened up dialogue with an EPC firm for not only engaging same for the EPC works, but also financing same under the proviso of BioCrude subrogating its right to the Sovereign Guarantees; awaiting proforma proposal from EPC firm</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">17.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The management and supervision of the project&#160;10 to 14 months; duration of EPC works</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">18.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The operation and maintenance of the MSW-Energy complex&#160;NA for Development timeline</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">19.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The invoice, receipt and payment collection&#160;NA for Development timeline</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">20.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Organization of briefings to the public&#160;NA for Development timeline</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b></b></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>G. Environmental Impacts Analysis</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>The evaluation process:</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The assessment of critical elements used in the development of the project, emissions harmful to the environment, leaching into soil, drainage, etc.&#8230;</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Potential erosion, the effects of the use and release of public waters on the tributaries, the adjacent ecological systems to the site, etc.&#8230;</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The number of vehicles (trucks, cars, etc.&#8230;) and emissions of pollutants</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The energy used in the complex and cooling of various buildings</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Materials used for the manufacture of the floor</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">6.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Building materials used for roofs</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">7.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Management and treatment of municipal solid waste (MSW)</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">8.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The quality of water and air</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">9.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The negative environmental impacts and mitigation, thereof</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">10.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Analysis of existing site and the impact of adverse effects thereon, for the development of the MSW-Energy complex so as to minimize the impact thereof</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">11.</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Effect of development on sensitive regional systems sent by either air or by ground water systems</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(Fully executed; timeline:</b>&#160;Part
and parcel of the submitted preliminary proposal (&#8220;<b>Prefeasibility Study &amp; Detailed Project Report</b>&#8221; incorporating
an &#8220;<b>Environmental Impact Analysis</b>&#8221;) to the Governmental Authorities of the Autonomous Island of Grande Comore
for the realization of the Concession and Power Purchase Agreements in accordance to the provisions of the Deed of Assignment pursuant
to a Public-Private Partnership (PPP); the Environmental Impact Analysis was acceptable to the Governmental Authorities of the
Autonomous Island of Grande Comore, hence no caveats, provisions or stipulations related thereto are within the signed contractual
agreements).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Planning and Timetable for the Project</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Summary forecast for the following tasks of the project
planning encompasses a timeline of 6 to 8 months:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Analysis of the composition and characteristics of municipal solid waste,</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Study and preparation of plans for the preliminary engineering,</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Study and preparation of detailed plans of Engineering.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Summary forecast for the Construction
&amp; synchronization of different modules in the MSW to Energy complex of the project planning encompasses a timeline of 16 to
18 months (incorporating approximately 4 months for project preparation for ground breaking ceremony).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Material Agreements</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have filed (with SEC as part of the
Company&#8217;s S-1(/A) registration statement(s)) our Material Agreements (the Deed of Assignment pursuant to a Public-Private
Partnership (PPP), the Power Purchase Agreement (PPA), and MSW, Land and Supply of Treated Effluent Concession Agreements), with
SEC as part of the Company&#8217;s S-1(/A) registration statement(s), respectively by and between the Governmental Authorities
of the Grande Comore and BioCrude.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">January 2016 &#8211; <b>Concluded Engagements</b>:
signed Deed of Assignment pursuant to a Public-Private Partnership (PPP), MSW, Land and Supply of Treated Effluent Concession Agreements
and a Power Purchase Agreement (PPA), by and between the Government of the Autonomous Island of Grande Comore and BioCrude Technologies
USA, Inc., for the implementation of the first Waste to Energy complex in the municipality of Moroni, which are as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Deed of Assignment pursuant to a Public-Private Partnership (PPP):</b> exclusively assigning the rights of waste management treatment to BioCrude via the inter-related specific concession vehicles, all defining protocol and mode of engagement as well as rights, interests and obligations of each engaging entity for the term of engagement (30 years) with an option of renewal for an additional term (30 years). Contract was signed January 11, 2016 and amended on December 9, 2016.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 93pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 93pt; text-align: justify; text-indent: 36pt"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 93pt; text-align: justify; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>MSW Concession* </b>for the guaranteed delivery of MSW to the Complex with an implied base tipping fee per ton of MSW (&#8220;<b>Put or Pay</b>&#8221; for the minimum MSW guarantee of 700 TPD) with annual escalations for the term (30 years) of the project with an option of renewal for an additional term (30 years) and Sovereign Guarantees from the Minister of Finance endorsing same. Contract was signed January 11, 2016 and amended on December 9, 2016.</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;&#160;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Land Lease Concession</b> for the delivery of the required amount of land for project term (30 years), at an annual symbolic lease rate of $1/amount of land delivered/annum, with an option of renewal for an additional term (30 years). Contract was signed January 11, 2016 and amended on December 9, 2016.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Supply of Treated Effluent Concession </b>whereby the governmental authorities will supply the necessary treated water in order to fulfill the operational requirements of the MSW to Energy complex at a negligible symbolic annual rate for the term of the project with an option of renewal for an additional term (30 years). Contract was signed January 11, 2016 and amended on December 9, 2016.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Power Purchase Agreement (PPA)*</b> [resale of procured electricity to the Power Corporation of the country in question], whereby the Power Corporation of a certain country will buy back the electricity produced by the MSW to Energy Complex at a base rate per kW-hr (&#8220;<b>Take or Pay</b>&#8221; for all of the renewable energy procured less the self-consumption needs of the MSW-Energy complex), with annual escalations for the term (30 years) of the project with an option of renewal for an additional term (30 years) and Sovereign Guarantees from the Minister of Finance endorsing same. Contract was signed January 11, 2016 and amended on December 9, 2016.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">*<b>A Revolving Letter of Credit (RLC)</b>,
replenished quarterly (for the duration of the term of the contractual engagements) will be issued by the Governmental Authorities
of the Autonomous Island of the Grande Comore (a temporary Treasury bond has been issued to BioCrude on December 10, 2016, which
will be replaced by the RLC), as per the provisions and stipulations of the contractual engagements (submitted to the SEC), as
a default payment mechanism guarantee, in the event of nonpayment of the tipping fees or for the purchase of the renewable energy,
which can immediately, after default, be drawn upon, to remedy default. The face value of the RLC is to cover the tipping fees
and resale of electricity payments for a whole year, multiplied by a factor of 1.5.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">* On July 27, 2017, the Governmental
Authorities of the Autonomous Island of the Grande Comore have issued to BioCrude a &#8220;<b>Treasury Bond</b>&#8221;, with supporting
literature (indenture, resolutions, etc.&#8230;; as filed with SEC as part of the Company&#8217;s S-1(/A) registration statement(s),
as well as other in other Form filings) baring a face value of twenty million United States Dollars (20,000,000 USD), in lieu of
a &#8220;Revolving Letter of Credit (RLC)&#8221;, replenished quarterly (for the duration of the term of the contractual engagements),
as per the provisions and stipulations of the contractual engagements (Concessions and Power Purchase Agreements). This Treasury
Bond serves as a default payment mechanism guarantee, in the event of nonpayment of the Governmental Authorities of the Autonomous
Island of the Grande Comore&#8217;s financial contractual obligations (tipping fees and/or fees due for the purchase of the renewable
energy), which same can immediately, after default, be executed upon by BioCrude, to remedy default.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Nota Bene</span></b>: The parties
(the Governmental Authorities of the Grande Comore and BioCrude), following discussions, agreed to enforce amendments discussed
and reflect same within the agreements and agreed to sign these new agreements, as amended, on December 9, 2016, replacing all
of the agreements signed on the 11<sup>th</sup> of January 2016. The principal points of amendment were to incorporate the identified
land concession which was assigned to BioCrude, by governmental decree, on November 12, 2016 and to reflect the new governmental
administration that was elected into office as the representatives for the Governmental divisions of the Grande Comore that engaged
with BioCrude.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the Union of the Comoros, the Company
is still awaiting documents from the Federal Governmental Authorities stating that the Federal Government is the new Intervening
Party to the Concession(s) agreements previously signed with the Governorate (province; autonomous region) of Moroni, after the
outcome of the Federal Referendum, whereby through same, contracting and economic powers are transferred from the Governorate (Province)
level to that of Federal level. The Referendum outcome favored the Federal Government over that of the Governorate (Autonomous)
Region of Moroni, i.e., authorizing documents are still pending.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Nota Bene</span>: </b>The following
contractual attributes are intrinsic to the aforesaid contractual (Concessions) agreements:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Contracts are backed by Government Sovereign Guarantees</b></span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Law and Jurisdiction of Dispute Arbitration (Canada)</b></span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Law of Contract execution immunized against change of law with Grandfather clause </b></span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Government issuance of (USD 20 Million) Treasury Bond; covers any interim financial defaults &#8211; replenished quarterly</b></span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Government payments are in US dollars (foreign exchange rate risk eliminated)</b></span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Zero Income Taxes, VAT&#8217;s and no levies &amp; duties of imported materials, equipment, rolling stock, etc.&#8230; for duration of contract (30 years)</b></span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Assignment of contracts/change of control clauses benefiting BioCrude (to its discretion)</b></span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Land Lease Concession: Symbolic $1 US per 25 hectares per year, for 30 years (term), and for additional 30-year renewal term (no escalations / changes)</b></span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Supply of Effluent Concession: Symbolic $1 US per 7,000 kL of Effluent (water) per day, for 30 years (term), and for additional 30-year renewal term (no escalations / changes)</b></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Supply of primary feedstock (waste): 700 tons per day not only at zero cost, but at either a &#8220;gate fee&#8221; [government pays BioCrude this tipping fee]</b></span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Government buys back all procured renewable energy (net of self-consumption of complex) via a Power Purchase Agreement for the duration of the 30-year term and renewal option thereof</b></span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>BioCrude is beneficiary of all Certified Emissions Reduction Credits (CERs) due to the MSW to Energy project</b></span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>BioCrude&#8217;s management and its Joint-Venture Partner, China Machinery Industry Construction Group Inc. (SINOCONST), have BONIFIDE credentials to execute the Engineering, Procurement, and Construction (&#8220;EPC&#8221;) of the MSW to Energy project, as well as the management of the operations to same*</b></span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">* On April 4th, 2017, China Machinery
Industry Construction Group Inc.&#8217;s (SINOCONST) and BioCrude Technologies, Inc. have signed a strategic Partnership (JV) Agreement
which embodies the understood exclusive engagement by and between the participants of the JV Consortium (SINOCONST and BioCrude)
for any present and future Waste to Energy Project(s) acquired by any party worldwide. SINOCONST will be responsible for the EPC
works (for the development of the Project(s) [Design and Build]) as well as securing the financing for the Project(s), while BioCrude
will be the operator (Operation and management).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">China
Machinery Industry Construction Group Inc. (SINOCONST), is one of the earliest large state-owned construction enterprises in
China, having Class A general construction contracting certification and Class A design certification approved by the
Ministry of Housing and Urban-Rural Development, and having AAA credit standing and foreign trade license granted by the
Ministry of Commerce. SINOCONST has passed the certification of ISO9001 Quality Management System, ISO14001 Environmental
Management System and GB/T 28001 Occupational Health and Safety Management System. Presently, SINOCONST has 15 wholly owned
subsidiaries, 4 Business Division divisions, 19 branch companies, 8 joint-stock companies and 1National Exemplary Technician
Institute. It boasts more than 10,000 employees, including 3,000 various engineers.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the past 60 years since its establishment,
SINOCONST has successively undertaken hundreds of large and medium key projects involving different sectors, such as machinery,
automobile, building materials, metallurgy, electric power, chemical, petroleum, electronics, light industry, broadcasting &amp;
TV, environmental protection, municipal, public and civil buildings etc., with projects performed throughout the country. SINOCONST
has made great contribution to China&#8217;s industrial development and modernization.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">SINOCONST will be responsible for the
EPC works (for the development of the Project(s) [Design and Build]) as well as securing the financing for the Project(s), while
BioCrude will be the operator (Operation and management). Both SINOCONST and BioCrude will engage with SPV&#8217;s/SPE&#8217;s,
with Contract (Project) Agreements and Operation and management Agreements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As a caveat for securitizing payment
of the contract price for Engineering, Procurement and Construction (&#8220;EPC&#8221;) works, via the financing mechanism established
by SINOCONST, JV Consortium will set up &#8220;Special Purpose Vehicle&#8217;s/Entity&#8217;s&#8221; (&#8220;SPV/SPE&#8221;) for
each and every acquired Project. The JV Consortium&#8217;s mission and ethos for creating an SPV/SPE of each well-defined Project
is to enable direct securitization of financially engineered loans (and other receivables) against direct assets. SINOCONST&#8217;s
association (equity participation) into every SPV/SPE will be provisional, in a sense where same will have a certain stake in the
shareholdings (Common Stock) of the SPV/SPE (as defined in the Capital Structure of the SPV/SPE, as referenced below and in the
Memorandum and Articles of Association of same, refer to Annex I), until such time that the loans vested for the development (Design,
Building of Project by SINOCONST) of the Project are fully paid back by the JV Consortium from the proceeds of the receivables
(for services rendered to client by the Project (SPV/SPE)), and all shares of Common Stock held by SINOCONST are transferred (sold
to BioCrude for Project loan(s) repayment, only) to BioCrude as full and final settlement for the loan (that paid for the contract
price of said development to SINOCONST). As part and parcel to the securitization of the loans in the SPV/SPE, BioCrude shall assign
and/or subrogate its rights to its assets of that distinct Project (Concessions and Power Purchase Agreements, Sovereign Guarantees,
Revenues of Operation, etc.&#8230;) to the SPV/SPE (&#8220;JV Consortium&#8221;), and same shall be subject to Charges (Mortgage,
privilege, etc..) for financing (funding), only.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 4, 2017, SINOCONST and BioCrude
have commissioned the services of B &amp; W INT&#8217;L SECRETARY LIMITED (Honk Kong, China) [law firm] to establish an SPV/SPE,
&#8220;<b>BioCrude Technologies, (Hong Kong) Limited</b>&#8221; [JV Corporation], as the development vehicle for the MSW to Energy
project for the Autonomous Island of the Grande Comore, Union of the Comoros (BioCrude Technologies, (Hong Kong) Limited; filed
as an exhibit with the SEC). The &#8220;SPV/SPE&#8221; possesses the following characteristics:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Memorandum and Articles of Association</b>: &#8220;The Companies Ordinance (Cap. 622) [Hong Kong, China]&#8221; for &#8220;Private Company Limited by Shares&#8221; is utilized as the base Memorandum and Articles of Association and enhanced / modified as per the terms, conditions and stipulations of the JV Agreement by and between SINOCONST and BioCrude (&#8220;<b>Memorandum and Articles of Association</b>&#8221;; filed as an exhibit with the SEC).</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Organization and Capital Structure</b>: as per the stipulations of the Memorandum and Articles of Association, and modified to reflect the following, as well:</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">BioCrude will account for seventy
percent (70.0%) of the total issued and outstanding shares of Common Stock at an issue price of 1 HKD per share for an aggregate
issue price of 700 HKD, and at Closing Date;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">SINOCONST will account for
thirty per cent (30.0%) of the total issued and outstanding shares of Common Stock, at an issue price of 1 HKD per share for an
aggregate issue price of 300 HKD, and at Closing Date and issued only once financing (funding) for the Project has been put in
place, and will be holder of same until such time that financing (funding) has been paid back, in full, whereby all shares of Common
Stock will have been transferred to BioCrude, as full and final settlement for loan repayment and shares of Common Stock acquisition.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><b><span style="text-decoration: underline">Nota Bene</span></b>: The
financing (funding) secured by SINOCONST for the Project and accepted by the JV Consortium will bare an amortization of approximately
five (5) years, with a negotiated mechanism for the repayment schedule of principal and interest. Every year end (from the beginning
of operations of the Project, i.e., after project completion in accordance to the terms, conditions and stipulations of SINOCONST&#8217;s
engagement (Contract (Project) Agreement) with SPV/SPE), relative to the amount of capital paid down from the original outstanding
loan on that year, a pro rata amount of shares of Common Stock will be given (transferred) back to BioCrude in that year, until
the full repayment of the loan, whereby the balance of the shares of Common Stock outstanding as shareholdings of SINOCONST are
transferred back to BioCrude, and BioCrude is one hundred per cent (100.0%) shareholder of all of the issued and outstanding shares
of Common Stock.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Management (Board of Directors, Officers)</b>: as per the stipulations of the Articles of Association, modified to reflect the terms, provisions and stipulations of the JV Agreement by and between BioCrude and SINOCONST.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 4th, 2017, SINOCONST&#8217;s
General Manager of the Group Business Development Department, Mr. Zhou Tao, and BioCrude Technologies (Comoros), LTD. [Hong Kong
SPV established by SINOCONST and BioCrude, as a JV Partnership], Chairman and CEO, Mr. John Moukas, have signed a Construction
(EPC) Contract Agreement which embodies SPV&#8217;s engagement of SINONST to Design, Construct, and Finance BioCrude&#8217;s Municipal
Solid Waste (MSW) to Energy Complex in the municipality of Moroni, Autonomous Island of the Grande Comore, Union of the Comoros,
to treat MSW and procure renewable energy and other marketable by-products (organic fertilizer, ash, primary feedstock for building
materials, etc.&#8230;) within the conforms of BioCrude&#8217;s acquired Concession and Power Purchase Agreements, as well as
BioCrude&#8217;s Deed of Assignment pursuant to a Public-Private Partnership with the Governmental Authorities of the Autonomous
Island of Grande Comore, Union of the Comoros.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 1, 2017, BioCrude, in joint
with SINOCONST (&#8220;JV Consortium&#8221;), have had a work session (in Beijing, China) with China Export and Credit Insurance
Corporation (&#8220;SINOSURE&#8221;), to clarify particulars regarding BioCrude&#8217;s Municipal Solid Waste (MSW) to Energy Complex
(&#8220;Project&#8221;) in the municipality of Moroni, Autonomous Island of the Grande Comore, Union of the Comoros, more particularly,
the Concessions and Power Purchase Agreements and the Deed of Assignment pursuant to a Public &#8211; Private Partnership. Thereafter,
BioCrude and SINOCONST, on behalf of BioCrude Technologies, (Hong Kong) Ltd (&#8220;SPV/SPE&#8221;), have submitted an application
to SINOSURE requesting loan insurance for the Project. As part and parcel to the loan insurance application, an independent third-party
feasibility study for the Project was requested. The JV Consortium has taken the initiative to solicit same for the execution of
the required works.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 5, 2017, JV Consortium,
on behalf of SPV/SPE, had a work session (in Beijing, China) with the Industrial and Commercial Bank of China Limited (&#8220;ICBC&#8221;),
and shortly therewith, submitted to same, an application for funding for BioCrude&#8217;s Project. We are awaiting feedback regarding
the indicative terms and conditions (&#8220;term sheet&#8221;) for the Project funding.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 5, 2017, BioCrude received
from ICBC, the indicative terms and conditions (&#8220;term sheet&#8221;) for the Project funding (term of validity was six months).
On April 8, 2018, BioCrude received from ICBC, a renewal of the &#8220;term sheet&#8221;, extending the term of validity for another
six months.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On January, 2018, BioCrude, in joint
with SINOCONST (&#8220;JV Consortium&#8221;), have commissioned out the works related to the feasibility study of the Municipal
Solid Waste (MSW) to Energy Complex (&#8220;Project&#8221;) in the municipality of Moroni, Autonomous Island of the Grande Comore,
Union of the Comoros, to China International Electronic Commerce Center (&#8220;CIECC&#8221;), an independent engineering firm
in China, acceptable to SINOSURE&#8217;s shortlist of accredited and acceptable suppliers for same.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 23, 2018, BioCrude, in joint
with SINOCONST (&#8220;JV Consortium&#8221;), had a work session (in Beijing, China) with CIECC. CIECC had requested that all of
BioCrude&#8217;s literature be translated into mandarin (translation was concluded by March 30, 2018); the status of the final
report of the feasibility study for the project, as of these presences, is on hold due (awaiting feedback from the federal government
of Union of the Comoros).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 29, 2018, Comoros&#8217;s President
Sem Azali Assoumani declared that a referendum on amending the country&#8217;s Constitution would be held in July 2018. The results
of the referendum were in favor of changing the constitution, and one of the issues of address was federal consolidation of powers,
and as such, the Federal Government of the Union of the Comoros, would now be the new Intervening Party to the Concessions and
Power Purchase Agreements, as well as the Deed of Assignment pursuant to a Public-Private Partnership (PPP), in lieu of the Governorate
of the Autonomous Island of Grande Comore.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the months of September and November,
2018, BioCrude sent a delegation to the Union of the Comoros in order to clarify and document the transition of the Federal Government&#8217;s
intervention, and as such, the Federal Government of the Union of the Comoros has yet to issue to BioCrude the following Amending
Declarations:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Amending Declaration to the Concessions and Power Purchase Agreements, as well as the Deed of Assignment pursuant to a Public-Private Partnership (PPP), by the Ministry of Finance, Economy, Budget, Investment and Foreign Trade of the Union of the Comoros, whereby they Federal Government of the Union of the Comoros acknowledges same, as well as declare that the Federal Government of the Union of the Comoros is the new intervening party to contracts, more particularly, with respect to honoring all of the Government&#8217;s obligations within the signed engagements with BioCrude, as well as the Sovereign Guarantees attached to same.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Amending Declaration to the Concessions and Power Purchase Agreements, as well as the Deed of Assignment pursuant to a Public-Private Partnership (PPP), by the Ministry of Production, Environment, Energy, Industry and Crafts of the Union of the Comoros, whereby the Federal Government of the Union of the Comoros acknowledges same, as well as declare that the Federal Government of the Union of the Comoros is the new intervening party to contracts, more particularly, with respect to honoring all of the Government&#8217;s obligations with the issuance of all necessary permits, and clearances for the development of BioCrude&#8217;s Waste to Energy project in Moroni, Grande Comore, Union of the Comoros.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.1pt; text-align: justify">BioCrude also requested from
the Federal Government of the Union of the Comoros&#8217; legal division, a legal opinion of the Concessions and Power Purchase
Agreements, as well as the Deed of Assignment pursuant to a Public-Private Partnership (PPP), incorporating the change of the Contracting/Intervening
Party. The Federal Government of the Union of the Comoros&#8217; legal division has yet to issue same.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.1pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of these presences, BioCrude has
yet to receive the amending declarations, and legal opinion from the Federal Government of the Union of the Comoros, as well as
a signing date for the aforementioned expansion of works of waste treatment for the Governorates of Moheli and Anjouan, and for
the Waste Collection, and Street and Public Spaces Cleaning for the whole country of the Union of the Comoros (Autonomous Islands
of Grande Comore, Moheli and Anjouan).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Going Concern</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The future of the Company is dependent
upon its ability to obtain financing and upon future profitable operations. Management has plans to seek additional capital through
private placements and a public offering of its common stock, if necessary. Although, historically, the Company had continuous
losses and negative working capital issues, there are doubts about the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s ability to become
a profitable operating company is dependent upon its ability to generate revenues and/or obtain financing adequate to fulfill our
requirements to complete evaluations of Concession acquisitions and development of same opportunities and to achieve a level of
revenues adequate to support our cost structure has raised substantial doubts about our ability to continue as a going concern.
We plan to attempt to raise additional equity capital by selling shares in this offering and, if necessary, through one or more
private placement or public offerings. However, the doubts raised, relating to our ability to continue as a going concern, may
make our shares as an unattractive investment for potential investors. These factors, among others, may make it difficult to raise
any additional capital.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Plan of Operation</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">With the signing of the Concession Agreements
with the countries of the Union of the Comoro, the Company, during the next twelve months, will be able to aggressively implement
the building of its corporate infrastructure by adding a few key senior managers to oversee the control of the management of the
Complexes and the general management of the Company. In addition, technical staff experienced in the management of the Engineering,
Procurement, and Construction (&#8220;EPC&#8221;) activities, a key component in the controlling the successful creation of a Complex,
will also be hired. The anticipated cost for accomplishing this is approximately twenty million United States dollars (20,000,000
USD), which includes the provisions for infrastructure development of the Company (construction, fixed assets and equipment procurement),
human resource staffing and working capital. The anticipation of raising funds through a common share offering will further allow
the Company to comfortably expand operations (with enhanced Research and Development), in sync, with the essence of BioCrude&#8217;s
mission, as elaborated within these presents.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The crucial factor to the financial
success is the rapid successful signing of additional concession agreements. Each such agreement requires an immediate investment
in the capital stock of the legal entity created for the purpose of building and subsequently operating the Complex. Additional
investments in the capital stock of each Complex totaling ten percent (10%) of the capital expenditure for a given complex must
be made in conjunction with the securing of long-term debt provided by financial institutions (made possible by the sovereign guarantees
included in the Concession Agreements). The legal entities created for the Complexes in a given country take a wholly owned subsidiary
of a joint venture owned fifty per cent (50%) each by the Company and the local government providing the sovereign guarantee. The
Company anticipates the creation of a total of eight (8) subsidiaries and two (2) joint ventures requiring a total of approximately
$46 million (note: each joint venture entity requires the upfront payment of a licensing fee on the part of the Company&#8217;s
joint venture partner, partially offsetting the Company&#8217;s investment in the Complex and providing a portion of the funds
required to operate the Company and make further investments in additional Complexes).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Asset Management</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude&#8217;s capital strategy will
be focused in two main areas:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Implementing operating programs that improve capital efficiency and asset utilization; and</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Pursuing selective strategic investment opportunities in waste transformation and resource optimization.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">BioCrude seeks to selectively invest
growth capital in high-return opportunities that will enhance its ability to support emerging customer and market needs in waste
transformation and resource optimization. The investment strategy seeks to leverage core competencies in materials processing to
create additional value from the waste stream.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Revenue Streams</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has identified five (5)
main revenue streams. Revenues derived from each Complex (Plant Operating Revenue) are the largest and most secure as this relies
on the long-term Concession Agreements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Plant Operating Revenues</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This revenue stream is comprised of
the following four (4) elements;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Tipping Fees</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In exchange for the provided environmental
services, municipalities have to pay a tipping fee per ton of waste delivered by the city to the MSW-Energy Complexes (&#8220;<b>Tipping
Fees</b>&#8221;) based on the long-term Concession Agreement on a &#8220;<b>Put or Pay</b>&#8221; (for full face value) basis.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sales of Power</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the W2E plant, the waste is processed
in RDF (Refuse Derived Fuel) and Biomethanation processes to yield marketable by-products. The RDF and the biogas are used for
power generation. The power is sold to the grid based on a long-term contract (Power Purchase Agreement) on a &#8220;<b>Take or
Pay</b>&#8221; (for full face value) basis.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sales of Carbon Credits</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The carbon credits gained by reducing
the green gas emission and by producing power based on renewable energy (&#8220;<b>Clean Design Mechanism</b>&#8221; (CDM)) are
sold on the carbon credit market.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sales of By-Products </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The by-products of recycled materials
and fertilizer will be marketed and sold to third parties:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Compost will be sold to the farming industry (which, in certain instances, is subsidized by the government), at spot market prices, less 15%. BioCrude may sell any excess product outside of the municipality and/or country.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Ash can be sold to resellers of construction materials.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 107%">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Processed inerts (primary feedstock for building materials) can be sold to entities (local and foreign) engaged in that processing milieu.&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">&#9658;</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Recyclables can be sold to entities (local and foreign) engaged in that processing milieu.</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the unlikely event MSW feedstock
is not delivered to the Complex, the MSW Agreement ensures that BioCrude is compensated for any shortfall in revenue derived from
the sale of electricity and by-products of Compost, ash and recyclables produced by the complex.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Engineering, Procurement and Construction
Fees</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">To ensure that the planned benefits
contained in the design of each Complex is realized BioCrude undertakes to supervise the entire EPC process and is compensated
accordingly, adhering to industry norms for such expertise.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Servicing Fees</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Once the Complex is commercially operational,
BioCrude is responsible for the ongoing operation and maintenance of the related facilities. The Company is compensated for supervising
this activity in accordance with the terms of the contracts agreed to and signed prior to the commissioning of each Complex.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Licensing Fees</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">To accelerate the proliferation of the
Company&#8217;s presence in the W2E market and at the same time reduce the demand on its cash resources, BioCrude is willing to
license its technology, to selected third parties in the form of joint ventures, resulting in another potential source of revenue.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Results of Operations</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>For the six months period ended
June 30, 2021 and 2020</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Revenue</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We did not generate revenue during the
six months period ended June 30, 2021 and 2020.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Costs and Expenses</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months period ended June
30, 2021 there were $314,853 of operating expenses consisting of general and administrative expenses. Operating expenses for the
prior year ended December 31, 2020 was $283,752 consisting of general and administrative.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Liquidity and Capital Resources</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As at June 30, 2021, the Company had
$80,412 in cash and did not have any other cash equivalents. The following table provides detailed information about our net cash
flow for the six months period ended June 30, 2021 and 2020. To date, we have financed our operations through the issuance of stock
and borrowings.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In summary, our cash flows were as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended June 30,<br /> 2021</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December&#160;31,<br /> 2020</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Net cash used in operating activities</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(236,724</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(279,584</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">207,165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">389,250</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Effect of exchange rate changes on cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase (decrease) in Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29,559</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,666</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cash, beginning of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">109,971</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">305</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Cash, end of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">80,412</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">109,971</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to the limited nature of the Company&#8217;s
operations to date, the Company does not believe that past performance is any indication of future performance. The impact on the
Company&#8217;s revenues of recognized trends and uncertainties in our market will not be recognized until such time as the Company
has had sufficient operations to provide a baseline.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Operating activities</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities
was $236,724 for the six months period ended June 30, 2021 and $279,584 for the year ended December 31, 2020.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Investing activities</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in investing activities
was $ Nil and $ Nil for the six months period ended June 30, 2021 and the year ended December 31, 2020, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Financing activities</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash provided by financing activities
was $207,165 and $389,250 for the six months ended June 30, 2021 and the year ended December 31, 2020, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Since inception, we have financed our
cash flow requirements through issuance of common stock and related party advances. As we expand our activities, we may, and most
likely will, continue to experience net negative cash flows from operations, pending receipt of listings or some form of advertising
revenues. Additionally, we anticipate obtaining additional financing to fund operations through common stock offerings, to the
extent available, or to obtain additional financing to the extent necessary to augment our working capital. In the future we need
to generate sufficient revenues from sales in order to eliminate or reduce the need to sell additional stock or obtain additional
loans. There can be no assurance we will be successful in raising the necessary funds to execute our business plan.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We anticipate that we will incur operating
losses in the next twelve months. Our lack of operating history makes predictions of future operating results difficult to ascertain.
Our prospects must be considered in light of the risks, expenses and difficulties frequently encountered by companies in their
early stage of development, particularly companies in new and rapidly evolving markets. Such risks for us include, but are not
limited to, an evolving and unpredictable business model and the management of growth.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">To address these risks, we must, among
other things, obtain a customer base, implement and successfully execute our business and marketing strategy, continually develop
and upgrade our website, respond to competitive developments, and attract, retain and motivate qualified personnel. There can be
no assurance that we will be successful in addressing such risks, and the failure to do so can have a material adverse effect on
our business prospects, financial condition and results of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Off-Balance Sheet Arrangements</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have any off-balance sheet
arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material
to investors.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Critical Accounting Policies</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The methods, estimates and judgments
we use in applying our accounting policies have a significant impact on the results we report in our financial statements, which
we discuss under the heading &#8220;Results of Operations&#8221; following this section of our MD&amp;A. Some of our accounting
policies require us to make difficult and subjective judgments, often as a result of the need to make estimates of matters that
are inherently uncertain.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We set forth below those material accounting
policies that we believe are the most critical to an investor&#8217;s understanding of our financial results and condition and
that require complex management judgment.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for all share-based
payment awards made to employees and directors, based on their fair value. The Company measures share-based compensation to consultants
by recognizing the fair value of the awards over the period the services are rendered or goods are provided.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Critical Accounting Policies</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In Financial Reporting Release No. 60,
&#8220;Cautionary Advice Regarding Disclosure About Critical Accounting Policies&#8221; (&#8220;FRR 60&#8221;), the Securities
and Exchange Commission suggested that companies provide additional disclosure and commentary on their most critical accounting
policies. In FRR 60, the SEC defined the most critical accounting policies as the ones that are most important to the portrayal
of a company&#8217;s financial condition and operating results, and require management to make its most difficult and subjective
judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition,
our most critical accounting policies include: non-cash compensation valuation that affects the total expenses reported in the
current period and the valuation of shares and underlying mineral rights acquired with shares. The methods, estimates and judgments
we use in applying these most critical accounting policies have a significant impact on the results we report in our financial
statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Available Information</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are subject to the informational
requirements of the Securities Exchange Act of 1934, as amended. All of our reports are able to be reviewed through the SEC&#8217;s
Electronic Data Gathering Analysis and Retrieval System (EDGAR) which is publicly available through the SEC&#8217;s website (<span style="text-decoration: underline">http://www.sec.gov</span>).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to furnish to our stockholders,
annual reports containing financial statements audited by our independent certified public accountants and quarterly reports containing
reviewed unaudited interim financial statements for the first three-quarters of each fiscal year. You may contact the Securities
and Exchange Commission at (800) SEC-0330 or you may read and copy any reports, statements or other information that we file with
the Securities and Exchange Commission at the Securities and Exchange Commission&#8217;s public reference room at the following
location:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Public Reference Room</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">100 F. Street N.W.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Washington, D.C. 2054900405</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Telephone: (800) SEC-0330</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_004"></span><span style="text-decoration: underline">ITEM 3</span>. QUANTITATIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is not exposed to market
risk related to interest rates or foreign currencies.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_005"></span><span style="text-decoration: underline">ITEM 4</span>. CONTROLS AND PROCEDURES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Evaluation of Disclosure Controls
and Procedures </i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As required by Rule 13a-15 under the
Securities Exchange Act of 1934 (the &#8220;1934 Act&#8221;), as of December 31, 2019, we carried out an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures. This evaluation was carried out under the supervision and
with the participation of our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal
financial officer), who concluded, that our disclosure controls and procedures were effective as at September 30, 2020.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Disclosure controls and procedures are
controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted
under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities
and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures
designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated
to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely
decisions regarding required disclosure.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="a_006"></span>PART II OTHER INFORMATION</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_007"></span><span style="text-decoration: underline">ITEM 1</span>. LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is not a party to any legal
proceedings.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_008"></span><span style="text-decoration: underline">ITEM 1A</span>. RISK FACTORS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no material changes
in the risk factors set forth in the Company&#8217;s 10-K/A (2020) filed February 16, 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_009"></span><span style="text-decoration: underline">ITEM 2</span>. UNREGISTERED SALES
OF EQUITY SECURITIES AND USE OF PROCEEDS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no sales of unregistered
equity securities during the covered time period.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_010"></span><span style="text-decoration: underline">ITEM 3</span>. DEFAULTS UPON SENIOR
SECURITIES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_011"></span><span style="text-decoration: underline">ITEM 4</span>. SUBMISSION OF MATTERS
TO A VOTE OF SECURITY HOLDERS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_012"></span><span style="text-decoration: underline">ITEM 5</span>. OTHER INFORMATION</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_013"></span><span style="text-decoration: underline">ITEM 6</span>. EXHIBITS AND REPORTS
ON FORM 8-K</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">The following documents are included or incorporated by reference as exhibits to this report:</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit No.</b></span></td>
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 10%; text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext">31.1</span></td>
    <td style="width: 1%; text-align: justify; line-height: 107%">&#160;</td>
    <td style="width: 89%; text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><a href="e2911_ex31-1.htm">Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
<tr style="vertical-align: top; background-color: white">
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext">31.2</span></td>
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><a href="e2911_ex31-2.htm">Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext">32.1</span></td>
    <td style="text-align: justify; line-height: 107%">&#160;</td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: none; color: windowtext"><a href="e2911_ex32-1.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td>
    <td style="text-align: justify; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">REPORTS ON FORM 8-K</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with Section 13 or 15
(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td colspan="2" style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Date: <span>August 2 2021</span></span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 50%; line-height: 107%">&#160;</td>
    <td style="width: 5%; line-height: 107%">&#160;</td>
    <td style="width: 45%; line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: none">Biocrude Technologies USA, Inc.</span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td colspan="2" style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Registrant</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1pt solid; line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">/s/ John Moukas</span></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 107%">&#160;</td>
    <td>&#160;</td>
    <td style="line-height: 107%"><span style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</span></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">32</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="margin: 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
[{"type": "10-Q", "sequence": "1", "filename": "e2911_10-q.htm", "description": "FORM 10-Q", "secsgml_size_bytes": 574398}]
{"company-data": {"conformed-name": "BioCrude Technologies USA, Inc.", "cik": "0001690384", "assigned-sic": "4953", "irs-number": "812924160", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "10-Q", "act": "34", "file-number": "000-55818", "film-number": "211136793"}, "business-address": {"street1": "1255 PHILLIPS SQUARE, SUITE 605", "city": "MONTREAL", "state": "A8", "zip": "H3B 3G5", "phone": "514-962-0070"}, "mail-address": {"street1": "1255 PHILLIPS SQUARE, SUITE 605", "city": "MONTREAL", "state": "A8", "zip": "H3B 3G5"}}
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
(Mark
One)
☒
Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934
For
the quarterly period ended
June 30, 2021
or
☐
Transition Report under Section 13 or 15(d) of the Exchange Act
For
the Transition Period from ________to __________
Commission File Number:
000-55818
BioCrude Technologies USA, Inc.
(Exact Name of Registrant as Specified
in its Charter)
Nevada
81-2924160
(State of incorporation)
(I.R.S. Employer Identification No.)
1255 Phillips Square
,
Suite 605
Montreal
,
Quebec
,
Canada
H3B 3G5
(Address of principal executive
offices)
514
-
840-9719
(Registrant's telephone number
including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Class
Trading Symbol
Name of each exchange on which registered
Indicate
by check mark whether the issuer (1) filed all reports required to be filed by Section13 or 15(d) of the Exchange Act of 1934
during the past 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.
Yes ☐
No
☒
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of "large accelerated filer", "an accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer
☐
AcceleratedFiler
☐
Non-Accelerated Filer
☐
Smaller Reporting
    Company
☒
Emerging Growth
    Company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐
No
☒
As of
June 30, 2021
,
the issuer had
50,710,386
shares of common stock issued and outstanding.
TABLE OF CONTENTS
Page
PART I – FINANCIAL INFORMATION
Item 1.
Financial Statements- Unaudited
1
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operation
8
Item 3.
Quantitative and Qualitative Disclosures about Market Risk
30
Item 4.
Controls and Procedures
30
PART II – OTHER INFORMATION
Item 1.
Legal Proceedings
31
Item 1A.
Risk Factors
31
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
31
Item 3.
Defaults Upon Senior Securities
31
Item 4.
Submission of Matters to a Vote of Security Holders
31
Item 5.
Other Information
31
Item 6.
Exhibits
31
i
PART I – FINANCIAL INFORMATION
ITEM 1
. FINANCIAL STATEMENTS
BIOCRUDE TECHNOLOGIES USA, INC.
CONSOLIDATED BALANCE SHEETS
(EXPRESSED IN US DOLLARS)
(UNAUDITED)
UNAUDITED
June 30,
2021
AUDITED
December 31,
2020
ASSETS
CURRENT ASSETS
Cash
$
80,412
$
109,971
Property, plant and equipment
18,048
19,697
TOTAL ASSETS
$
98,460
$
129,668
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable and accrued liabilities
$
3,172
$
21,400
Accounts payable and accrued liabilities - related parties (Note 6)
16,017
104,727
Convertible notes (Note 3)
—
—
Loans payable (Note 4)
138,671
152,169
TOTAL LIABILITIES
$
157,860
$
278,296
STOCKHOLDERS' DEFICIT
Common stock, $
0.001
par value,
75,000,000
shares authorized,
50,710,386
and outstanding (December 31, 2020 -
50,621,336
)
$
50,711
$
50,622
Additional paid in capital
8,523,756
8,167,646
Subscription receivable
—
(
50,000
)
Accumulated other comprehensive income
28,660
28,654
Deficit
(
8,660,918
)
(
8,343,939
))
TOTAL STOCKHOLDERS' DEFICIT ATTRIBUTALBLE TO   EQUITY SHAREHOLDERS OF THE COMPANY
(
57,791
)
(
147,017
)
NON-CONTROLLING INTEREST
$
(
1,609
)
$
(
1,611
)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT
$
98,460
$
129,668
The accompanying notes are an integral
part of these consolidated financial statements.
1
BIOCRUDE TECHNOLOGIES USA, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS
FOR THE THREE AND SIX MONTHS ENDED
JUNE 30, 2021 AND 2020
(EXPRESSED IN US DOLLARS)
(UNAUDITED)
For the three months ended
For the six months ended
June 30, 2021
June 30, 2020
June 30, 2021
June 30, 2020
REVENUE
$
—
$
—
$
—
$
—
OPERATING EXPENSES
General and administrative
152,158
21,955
314,853
42,396
Total operating expenses
152,158
21,955
314,853
42,396
LOSS FROM OPERATIONS
(
152,158
)
(
21,955
)
(
314,853
)
(
42,396
)
Interest expense
(
1,025
)
(
1,240
)
(
2,126
)
(
2,483
)
Income tax expense
—
—
—
—
NET LOSS
$
(
153,183
)
$
(
23,195
)
$
(
316,979
)
$
(
44,879
)
OTHER COMPREHENSIVE LOSS
Exchange differences on translating foreign operations
(
4
)
89
6
(
19
)
Exchange differences on translating non-controlling interest
(
2
)
38
2
(
8
)
TOTAL COMPREHENSIVE LOSS
$
(
153,189
)
$
(
23,068
)
$
(
316,971
)
$
(
44,906
)
NET LOSS ATTRIBUTABLE TO
Equity shareholders of the Company
$
(
153,183
)
$
(
23,195
)
$
(
316,979
)
$
(
44,879
)
Non-controlling interest
—
—
—
—
NET LOSS
$
(
153,183
)
$
(
23,195
)
$
(
316,979
)
$
(
44,879
)
TOTAL COMPREHENSIVE LOSS ATTRIBUTABLE TO
Equity shareholders of the Company
$
(
153,187
)
$
(
23,106
)
$
(
316,973
)
$
(
44,898
)
Non-controlling interest
(
2
)
38
2
(
8
)
TOTAL COMPREHENSIVE LOSS
$
(
153,189
)
$
(
23,068
)
$
(
316,971
)
$
(
44,906
)
Net loss per common share   basic and diluted
$
(
0,00
)
$
(
0.00
)
$
(
0.00
)
$
(
0.00
)
Weighted average number of common shares outstanding   basic and diluted
50,604,735
50,492,243
50,604,735
50,492,243
See accompanying
notes to unaudited interim consolidated financial statements
2
BIOCRUDE TECHNOLOGIES USA, INC.
CONSOLIDATED STATEMENTS OF CHANGES
IN STOCKHOLDERS' DEFICIT
(EXPRESSED IN
US DOLLARS)
(UNAUDITED)
Number of
    shares
Par Value
Additional
    Paid-in Capital
Accumulated
Other Comprehensive Income
Deficit
Total equity
attributable to
equity
shareholders
of the Company
Non-
    controlling interest
Total
Balance at December 31, 2020
50,621,336
$
50,622
$
8,167,646
$
28,654
$
(
8,343,939
)
$
(
147,017
)
$
(
1,611
)
$
(
148,628
)
Stock issued for services
16,550
17
66,183
—
—
66,200
—
66,200
Subscription receivable
—
—
—
—
—
50,000
—
50,000
Stock issued for cash
42,500
43
169,957
—
—
170,000
—
170,000
Foreign currency translation loss
—
—
—
10
—
10
4
14
Net loss
—
—
—
—
(
163,796
)
(
163,796
)
(
163,796
)
Balance at March 31, 2021
50,680,386
$
50,681
$
8,403,786
$
28,664
$
(
8,507,735
)
$
(
24,604
)
$
(
1,607
)
$
(
26,211
)
Stock issued for services
30,000
30
119,970
—
—
120,000
—
120,000
Stock issued for convertible debts
—
—
—
Stock issued for cash
—
—
Foreign currency translation
—
—
—
(
4
)
—
(
4
)
(
2
)
(
6
)
Net loss
—
—
—
—
(
153,183
)
(
153,183
)
(
153,183
)
Balance at June 30, 2021
50,710,386
$
50,711
$
8,523,756
$
28,664
$
(
8,660,918
)
$
(
57,791
)
$
(
1,609
)
$
(
59,400
)
The accompanying notes to unaudited interim
consolidated financial statements
3
BIOCRUDE TECHNOLOGIES USA, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE & SIX MONTHS ENDED JUNE
30, 2021 AND 2020
(EXPRESSED IN US DOLLARS)
(UNAUDITED)
UNAUDITED
June 30, 2021
UNAUDITED
June 30,
    2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
$
(
316,979
)
$
(
44,480
)
Adjustments to reconcile net loss to net cash used in operating activities
Accretion and interest expenses
2,127
2,484
Amortization
1,649
1,697
Stock issued for services
186,198
40,000
Forgiveness accrued interest
—
Foreign exchange
(
2,781
)
(
239
)
Changes in operating assets and liabilities
Prepaid expenses
—
—
Accounts payable and accruals
(
18,228
)
7,258
Accounts payable and accrued liabilities - related party
(
88,710
)
(
35,860
)
Net cash used in operating activities
(
236,724
)
(
29,540
)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible debt
Proceeds from private placement
220,000
20,000
(Repayment) Proceeds of loans payable
(
12,835
)
9,250
Net cash provided by financing activities
207,165
29,250
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment
—
—
Net cash used in financing activities
—
—
Effect of exchange rate changes on cash
—
CHANGE IN CASH DURING THE PERIOD
(
29,559
)
(
290
)
CASH BEGINNING
109,971
305
CASH ENDING
$
80,412
$
15
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
$
—
$
—
Interest paid
$
—
$
—
Noncash investing and financing activities:
Beneficial conversion feature discount related to the issuance of convertible debt
$
—
$
—
Conversion of convertible debt to common stock
$
—
$
—
Stock issued for services
$
120,000
$
—
Forgiveness accrued interest
$
—
$
—
See accompanying notes to unaudited interim
consolidated financial statements
4
BIOCRUDE TECHNOLOGIES USA,
INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 1
–
ORGANIZATION AND BASIS OF PRESENTATION
Nature of Operations
Biocrude Technologies USA, Inc. (the
"Company") was incorporated under the laws of the State of Nevada on December 29, 2015. The Company's principal
business objective is to provide resource management expertise and services, catering to commercial, municipal, and industrial
customers, primarily in the areas of solid waste management and recycling services.
Interim Financial Statements
The unaudited interim consolidated financial
statements of the Company have been prepared in accordance with United States generally accepted accounting principles ("GAAP")
for interim financial information and the rules and regulations of the Securities and Exchange Commission ("SEC").
They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein,
there have been no material changes in the information disclosed in the notes to the financial statements for the year ended December
31, 2020 included in the Company's 2020 annual report on Form 10-K, filed with the SEC. The unaudited interim consolidated
financial statements should be read in conjunction with those financial statements included in Form 10-K. In the opinion of management,
all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made.
Operating results for the six-month period ended June 30, 2021 are not necessarily indicative of the results that may be expected
for the year ending December 31, 2021.
Going Concern
The Company's consolidated financial
statements are prepared on a going concern basis in accordance with United States generally accepted accounting principles ("US
GAAP") which contemplate the realization of assets and discharge of liabilities and commitments in the normal course of business.
The Company has not generated operating revenues to date and has accumulated losses of $
8,660,918
since inception. The Company
has funded its operations through the issuance of capital stock, convertible debt, loans, and advances from related parties. Management
plans to raise additional funds through equity and/or debt financings. There is no certainty that further funding will be
available as needed. These factors raise substantial doubt about the ability of the Company to continue operating as a going concern.
The Company's ability to continue its operations as a going concern, realize the carrying value of its assets, and discharge
its liabilities in the normal course of business is dependent upon its ability to raise new capital sufficient to fund its commitments
and ongoing losses, and ultimately on generating profitable operations.
NOTE 2 –
SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES
Basis of presentation and Principles
of Consolidation
These consolidated financial statements
and related notes are presented in accordance with US GAAP and are presented in United States dollars.
The accompanying consolidated financial
statements include the accounts of its
70
% owned subsidiary, Biocrude Technologies (Hong Kong) Limited ("Biocrude HK").
All significant inter-company transactions and balances have been eliminated upon consolidation.
Use of Estimates
The preparation of financial statements
in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Significant areas requiring management's estimates
and assumptions include determining the fair value of transactions involving shares common stock. Actual results could differ
from those estimates.
Fair Value Measurements
The Company adopted the provisions of
ASC Topic 820, "Fair Value Measurements and Disclosures", which defines fair value as used in numerous accounting pronouncements,
establishes a framework for measuring fair value and expands disclosure of fair value measurements.
The estimated fair value of certain
financial instruments, including cash and cash equivalents, payables to related parties, and accounts payable and accrued expenses
are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.
ASC 820 defines fair value as the exchange
price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes
a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. ASC 820 describes three levels of inputs that be used to measure fair value:
5
Level 1 - quoted prices in active markets
for identical assets or
Level 2 - quoted prices for similar
assets and liabilities in active markets or inputs that are observable
Level 3 - inputs that are unobservable
(for example cash flow modeling inputs based on assumptions)
The Company's financial assets
and liabilities are subsequent measured at amortized cost, but their carrying amount approximates their fair value due to the short
period of time until maturity.
Foreign Currency Translation and
Transaction
The Company's presentation currency
is the U.S dollar. The functional currency of Biocrude USA and Biocrude HK is U.S dollar and Hong Kong dollar, respectively. Assets
and liabilities of the foreign operations are translated to the U.S dollar using the exchange rate at period end, and income, expenses
and cash flow items are translated using the rate approximates the exchange rates at the dates of the transactions (i.e., the average
rate for the period). All resulting exchange differences recognized directly in other comprehensive income (loss).
Transactions in currencies other than
the entity's functional currency are recorded at the rates of exchange prevailing at the dates of the transactions. At each
statement of financial position date, monetary assets and liabilities are translated using the period end foreign exchange rate.
Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. Non-monetary assets
and liabilities that are stated at fair value are translated using the historical rate on the date that the fair value was determined.
All gains and losses on translation of these foreign currency transactions are included in profit or loss.
Cash and cash equivalents
Cash and cash equivalents consist of
cash balances and highly liquid instruments with an original maturity of three months or less. As at June 30, 2021, the Company
does not have cash equivalents.
Property, plant and equipment
Property, plant, and equipment are recorded
at cost and depreciated to its estimated residual values using the straight-line method over its estimated useful lives of
8
years.
Share-based Expense
ASC 718, "
Compensation –
Stock Compensation
", prescribes accounting and reporting standards for all share-based payment transactions in which
employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and
other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees,
including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair
values. That expense is recognized over the period during which an employee is required to provide services in exchange for the
award, known as the requisite service period (usually the vesting period).
The Company accounts for stock-based
compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, "
Equity –
Based Payments to Non-Employees."
Measurement of share-based payment transactions with non-employees is based on the
fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued.
The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance
completion date.
Income Taxes
Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income for the years in which those differences are expected
to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income
statement in the period that includes the date of enactment. Additionally, ASC 740: Income Taxes, requires the Company to recognize
in its financial statements the impact of a tax position that is more likely than not to be sustained upon examination based on
the technical merits of the position.
Leases
Effectively January 1, 2018, the Company
adopted ASC Leases which requires a lessee to recognize the assets and liabilities that arise from leases, including operating
leases. Under the new requirements, a lessee will recognize in the balance sheet a liability to make lease payments (the lease
liability) and the right-of-use asset representing the right to the underlying asset for the lease term. For leases with a term
of twelve months or less, the lessee is permitted to make an accounting policy election not to recognize lease assets and lease
liabilities by class of underlying assets. The Company did not enter into any significant operating leases for the six months period
ended June 30, 2021 and did not have any significant leases as at December 31, 2020. Adoption of this standard does not have material
impact on the Company's interim consolidated financial statements.
Earnings Per Share Information
FASB ASC 260, "Earnings Per Share"
provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes
no dilution and is computed by dividing net loss available to common shareholders by the weighted average common shares outstanding
for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an
entity similar to fully diluted earnings per share. Basic and diluted loss per share were the same, at the reporting dates, as
there were no common stock equivalents outstanding.
6
NOTE 3 –
CONVERTIBLE NOTES
As at June 30, 2021, there are
no
outstanding
convertible loans.
NOTE 4 –
LOANS PAYABLE
As at June 30, 2021, the Company has
loans payable of $
110,856
(December 31, 2020 – $
126,481
) in principal and accrued interest of $
27,815
(December 31, 2020
- $
25,688
) outstanding. These loans bear an average interest rate of
4
%, are unsecured and have extended maturities until December
31, 2022. Included in the balance of loans payable as at June 30, 2021, $
25,383
(December 31, 2020 - $
32,291
) was due to a director
of the Company.
NOTE 5 -
RELATED PARTY TRANSACTIONS
As at June 30, 2021, the "CEO"
of the Company and a director had advanced the Company a cumulative $
16,017
(December 31, 2020 - $
104,727
) net of repayments for
the payment of the Company's operating expenses. These amounts are unsecured, without interest and payable on demand and
are included in accounts payable and accrued liabilities – related parties.
NOTE 6
–
SHARE CAPITAL
The Company is authorized to issue up
to
75,000,000
shares of common stock at par value $
0.001
per share. As at June 30, 2021, the Company had
50,710,386
(December 31,
2020 -
50,621,336
) shares of common stock issued and outstanding, respectively.
In Q2 2021, the Company issued
30,000
shares of the Company's common stock, with a fair value of $
120,000
, for services rendered..
NOTE 7
–
SUBSEQUENT
EVENTS
There are no subsequent events.
7
ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward-Looking Statements
This Form 10-Q includes "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included or incorporated by reference
in this Form 10-Q which address activities, events or developments which the Company expects or anticipates will or may occur in
the future, including such things as future capital expenditures (including the amount and nature thereof); finding suitable merger
or acquisition candidates; expansion and growth of the Company's business and operations; and other such matters are forward-looking
statements. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its
perception of historical trends, current conditions and expected future developments, as well as other factors it believes are
appropriate under the circumstances. However, whether actual results or developments will conform with the Company's expectations
and predictions is subject to a number of risks and uncertainties, including general economic, market and business conditions;
the business opportunities (or lack thereof) that may be presented to and pursued by the Company; changes in laws or regulation;
and other factors, most of which are beyond the control of the Company.
These forward-looking statements can
be identified by the use of predictive, future-tense or forward-looking terminology, such as "believes," "anticipates,"
"expects," "estimates," "plans," "may," "will," or similar terms. These
statements appear in a number of places in this Filing and include statements regarding the intent, belief or current expectations
of the Company, and its directors or its officers with respect to, among other things: (i) trends affecting the Company's
financial condition or results of operations for its limited history; (ii) the Company's business and growth strategies;
and, (iii) the Company's financing plans. Investors are cautioned that any such forward-looking statements are not guarantees
of future performance and involve significant risks and uncertainties, and that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors. Such factors that could adversely affect actual results
and performance include, but are not limited to, the Company's limited operating history, potential fluctuations in quarterly
operating results and expenses, government regulation, technological change and competition.
Consequently, all of the forward-looking
statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results
or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected
consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking
statements.
General Business Development
The Company was formed on August 4,
2015 in the State of Nevada, under the name of "BioCrude Technologies, Inc. On November 8, 2016, the Company received its
"Certificate of Amendment to Articles of Incorporation" pursuant to NRS 78.385 and 78.390 to its request for a name
change from "BioCrude Technologies, Inc." to "BioCrude Technologies USA, Inc.", whilst doing business as
"BioCrude Technologies, Inc.", as well. All of the afore-stated have been filed with SEC as part of the Company's
S-1(/A) registration statement(s).
Business Strategy
The Company is a resource management
expertise and services provider, catering to commercial, municipal, and industrial customers, primarily in the areas of solid waste
management and recycling services.
BioCrude Technologies USA, Inc. has
developed efficient, cost-effective, and environmentally friendly products, processes and systems for the reformation of waste
material, waste management and creation of renewable energy.
The versatility and potential of the
BioCrude Technologies USA, Inc. has been demonstrated by the many uses that our R&D department has already tested and verified.
The avenues they have explored include sustainable and cost-efficient methods that will enlarge composting and biomethanation yields
and rates of decomposition while increasing output and providing a higher quality of end product. Their focus is on waste treatment
protocols for Municipal Solid Waste ("MSW"), cellulose, all organic waste and all manure types; renewable energy sources
such as biogas, ethanol and biodiesel; waste water treatment, and multiple other applications.
One very important area that BioCrude
Technologies USA, Inc. excels in is the reformation of MSW into renewable energy and marketable end-by-products, using its intrinsic
intellectual property and know how in its "Integrated Municipal Solid Waste to Energy Proposed Complexes" for municipal
applications. Understanding the non-homogenous nature and characteristics of the waste, we can define distinct processes to optimally
handle the procurement of the varied categories of waste (MSW can be classified into organics, fuels, recyclables, inerts and others),
once segregated with an efficient separation process and materials recovery facility ("MRF"). There is no intellectual
property protection as of yet. BioCrude will be filing for certain Intellectual property and know how protection via a patent for
"Integrated Municipal Solid Waste to Energy Systems". In addition to patent applications, the Company will apply for
trademark protection where appropriate.
8
The long-term vision of the organization
is to be a world leader in the management of solid waste. Our business model will be to transform solid waste streams into renewable
energy resources and marketable by-products. Conventionally, people, entities, etc.…, view solid waste streams as not only
worthless refuse requiring monetary resources in order to get rid of. BioCrude, on the contrary, views this so-called refuse "as
a valuable commodity", with a negative product cost, i.e., PRODUCT COST is ZERO, with an implicit REVENUE received PER UNIT
OF WASTE given for disposal (people, governments will pay entities/companies in order to get rid of the undesired waste, in the
form of a "Tipping" or "Gate" fee.
Global competition for limited resources is, the Company believes,
creating significant business opportunities
for companies
that can sustain and extract value in the form of renewable energy
and other marketable by-products, i.e., fertilizer, raw materials (primary feedstock for building materials), etc.…, from
resources previously considered an irretrievable waste stream.
BioCrude's business strategy has been firmly tied to creating
a sustainable resource management model and the Company continues to be rooted in these same tenets today. Each day the Company
strives to create long-term value for all stakeholders: customers, employees, communities, and shareholders, by helping customers
and communities manage their resources in a sustainable and financially sound manner.
The Company intends to achieve successful
market penetration, with distinction, in numerous segments of the industry, generating escalating positive cash flows on an annual
basis so that the Company becomes a competitive leading participant in the industry. Management will look to have its Integrated
Municipal Solid Waste to Energy Complexes widely implemented across Africa, Asia, the Balkans and North America with a view to
expanding to other international markets (Latin America), while continuing to pursue Concession Agreements under private license/joint
ventures and other conventional arrangements.
Municipal Solid Waste Management is
the collection, transport, processing (waste treatment), recycling or disposal of waste materials, usually ones produced by human
activity, in an effort to reduce their effect on human health or local aesthetics or amenity.
Municipal Solid Waste Management ("MSWM")
is a major responsibility for local government. It is a complex task which requires appropriate organizational capacity and cooperation
between numerous stakeholders in the private and public sectors.
The first goal of MSWM is to protect
the health of the population, particularly that of low-income groups. Other goals include promotion of environmental quality and
sustainability, support of economic productivity and employment generation.
Waste-to-energy ("
W2E
")
or energy-from-waste ("
EfW
") is the process of creating energy in the form of electricity or heat from the incineration
of waste source.
Conventional Municipal Solid Waste Management
employs one or more of the following processes:
►
Waste prevention, including reuse of products
►
Recycling, including composting
►
Combustion with energy recovery
►
Disposal through land-filling
Landfilling is one of the most common
ways of municipal solid waste disposal in developing countries. Air pollutants emitted from landfills contributes to the emission
in the atmosphere of greenhouse gases and cause serious problems to human health.
Methane emissions from landfills are
a serious environmental global concern, as it accounts for approximately 15% of current greenhouse gas emissions. Landfilling
is a significant contributor to greenhouse gas emissions (GHG) accountable for approximately 5% of total GHG releases which consists
of methane from anaerobic decomposition of solid waste and carbon dioxide from wastewater decomposition.
The past 20 years has seen a change
in how we look at our environment. There has been a greater understanding of the economic, social and environmental risks of not
managing waste.
The main drivers of the W2E market are
environmental factors, regulations and legislation and economic factors.
9
Environmental Factors
The Stern report, published in 2006, created
an authoritative and eye-opening scientific report on the challenges of climate change. The report highlighted the need to decarbonize
the power sector by 60% and reduce CO
2
emissions by 80% of current levels to ensure increases in global temperature
do not exceed two degrees Celsius.
Regulations and Legislation
Scientific evidence, public awareness
and increased levels of participation in environmental campaigning have led to governments' worldwide implementing regulations
and legislation. Examples include:
●
EU Landfill Diversion Directive
●
recycling targets
●
climate change regulations
Nota Bene
: It is only in the
last two decades that governments world wide have been working together to come to a consensus of standardized, environmentally
friendly waste management directives, in order to become recognized and implemented practices.
Economics
Economic drivers to developing the waste
and renewable energy sector have included:
●
waste disposal and landfill gate fees/landfill tax
●
penalties/avoidance schemes (e.g., landfill allowance schemes and fines, carbon trading)
●
energy prices
Waste to Energy Market
Size and Trend
Renewable Energy:
According to
the most recent data available from the International Energy Agency, global waste to energy power production from municipal and
industrial wastes increased from 283 terawatt hours to 383 terawatt hours, a 35% increase over that period. In-depth analyses of
the global market, forecasts the market will increase from approximately $27 billion in 2018 to $450 billion by 2030.
MSW Management (Tipping/Gate fees):
As long as there are people in our world, there will be waste generation. Depending on the demographics of people clusters
(nations), the amount of waste generated on a per capita (person) basis can vary from 0.6 kg (persons in destitute third world
countries (e.g., Niamey [Niger], Juba [South Sudan], Freetown [Sierra Leone], Port-au-Prince [Haiti])) to 1.8 kg (advanced societies
with flourishing economies (e.g., New York City [US], Toronto [Canada], Paris [France], Dubai [UAE]) per person per day. With an
approximate current world population (census 2020) of 7.8 billion persons, there is a minimum quantum (weighted average) of about
6,000,000 tons of waste generated on a per day basis. Depending on the national budget for the level of waste management treatment
implemented by a certain nation, analyses of the global market, forecasts the market will increase from approximately $45 billion
in 2020 to $60 billion by 2030.
Nota Bene
: The Market potential
for Waste Management is not only "HUGE", but at its infancy stage, ready to "EXPLODE", with few credible
corporations, capable of servicing same!
Source
: http://www.waste-management-world.com
10
Competition
The market for Waste-to-Energy is dominated
manly by Germen, French, American and British companies. Ex.: AE&E Group GmbH, Axpo Kompogas AG, Babcock & Wilcox Volund
A/S, Bedminster International Ltd., BiogenGreenfinch, BTA International GmbH, Community Power Corporation, CNIM, Covanta Holding
Corporation, EcoCorp Inc., Keppel Integrated Engineering Ltd., North American Power Group Ltd., Organic Waste Systems NV, STRABAG
Umweltanlagen GmbH, Veolia Environmental Services, Waste Management Inc., and Wheelabrator Technologies Inc., among others.
Nota Bene
: If you compare
the technology of the
Competition
in
juxtaposition
to
BioCrude's (further elaborated upon, hereinunder,
you will be able see why "
BioCrude is the logical choice for the present and the future
".
Defining Waste Management
for Municipal Applications
The provision of municipal solid waste
services is a costly and troubling problem for local authorities everywhere. In many cities, service coverage is low, resources
are insufficient, and uncontrolled dumping is widespread, with resulting environmental and health related problems, which are recognized
worldwide, and cannot be neglected! Moreover, substantial inefficiencies are typically observed. Typically, worldwide, governmental
waste management ordinance, surprisingly enough, encompasses inefficient waste collection, landfilling until over exhaustion, and
incineration
.
Out of concern for the quality of life
of their residents, local municipalities bear primary responsibility for waste management. Municipalities will work with other
municipal levels to identify the best collection, transportation, treatment and disposal methods for their respective jurisdictions.
This includes identifying suitable sites for municipal, or regional waste management facilities, and managing and operating collection,
transportation and treatment systems. To increase the environmental and economic efficiency of waste management, local municipalities
will be responsible for planning waste management infrastructure and systems at the urban community and regional county municipality
levels.
Biocrude, with its upgraded technologically
advanced systems, can improve quality of environment, ergo, life.
Waste management planning, as well as
the production of renewable energy resources, are vital issues facing any city or municipality today. We are at a time where all
level of governments recognize the importance and need for waste management. Be it for financial, environmental, or health issues.
Room for improvement exists for the following:
1.
Reduction, and eventually, the elimination of landfilling, as opposed to over exhausting (substituting proposed landfill sites with other forms of development (commercial, industrial, residential, agricultural, and community developments, amongst others – real estate value).
2.
Reduction of Greenhouse Gases, and environmental pollutants with reference to ground and surface water contamination
(percolation of contaminated leachate)
alongside with the elimination of odors.
3.
Further enhanced separation process for MSW, which could prelude to a more optimal recycling program.
Nota Bene
: Landfilling
is NOT a solution (contaminates the land forever, cost of construction, waste creation), but a deferral of a problem for future
generation to handle. In essence, it is what it is; a PRACTICE that has been utilized for the longest period of time! Nothing more!
The myth that landfilling is a cost-effective
solution is what it is; a myth. There are long term ramifications, especially when the landfills are not proper "Scientific
Landfills" (environmental implications; rainfall, leachate, percolation, contamination (soil and water table). Even the fact
that, if a Scientific Landfill is deployed (with membrane linings) at an astronomical cost (the cost of construction of a Scientific
landfill, which could host approximately 2,000 TPD of waste for 25 years could costs approximately 100 MUSD), after a few earth
tremors or shifting of land, the membrane could crack, or over time, the membrane will deteriorate, thus yielding the same negative
environmental impacts, only deferred in time.
Another issue to address is the continual
use of landfills. As time goes on, and waste is continuously generated by the populous and its activities, more and more landfills
have to be created, to a point where a good part of the country will become a cemetery for garbage. Municipalities/governments
must plan to integrate their waste management from a strategic and financial perspective.
BioCrude, having set as its objective
the "PROFITABILITY" of the activities inherent within the realms of this sector, whilst building business relationships
and addressing social implications within the collectivity's / communities that BioCrude is called upon to serve, beyond
the environmental and social implications, and beyond the business imperatives, has set as one of its priorities, the optimization
of waste management and, treatment thereof, all in conformity to the boundaries of economies, efficiency and adherence to environmental
wellbeing initiatives.
BioCrude has been involved in the R&D of Environmental Technologies, both process and product based,
whereby it has enhanced and optimized conventional technology, thus giving credence to environmental, economic, social and technological
well-beings, too numerous to mention (all can be referenced, in its entirety, within BioCrude's Integrated MSW-Energy Proposal.
Shortlists of the aforesaid well-beings are summarized herein under:
11
1.
Secure, cost effective long-term processing capacity for recyclables and organics.
2.
Improvement of effectiveness and efficiency of current waste systems/practices.
3.
Elimination of MSW from going to landfills.
4.
Procurement of Renewable Energy and Marketable by-products (fertilizer, primary feedstock for building materials, etc.…) from the exploitation of the calorific value inherent within the realms of the MSW
5.
Reduction of Greenhouse Gases and other environmental pollutants emitted into the atmosphere.
6.
Municipalities do not have to undergo cost of implementation; privatized via BOOT (Build, Own, Operate & Transfer), whereby BioCrude Technologies USA, Inc. will be lobbying to get the MSW, Land, Sewage treated Effluent and Resale of Electricity Concessions (with Sovereign Guaranties from the Ministry of Finance of the Government in question).
7.
Due to the profitability of the proposal, significant savings could be passed onto the Municipalities, to reduce their day to day on going expenses for Municipal Waste Management, for the duration of the BOOT (30 years), by approximately 50% per annum, via MSW Tipping (Gate) Fees (favorably outbidding the competition and still having better bottom lines than same) and the Transport of the MSW to neighboring cities/provinces (states), without forgetting to mention the reduced GHG emissions from the substitution effect of BioCrude's Integrated MSW to Energy proposal from landfilling and/or incineration. This surplus in savings can be used for other municipal social and infrastructural programs.
8.
Employment opportunities are created during the EPC (Engineering, Procurement & Construction) phase of the project (a few hundred jobs) and for the day-to-day operations of the project (approximately 86 jobs per shift per 2,000 TPD Plant plus 11 persons for administration X 3 shifts per day, equating to a total quantum of a minimum of 269 persons).
9.
The proposed solution is an integrated MSW management system based on energy recovery that respects the norms of a Clean Design Mechanism ("CDM") inherent within the realms of article 12 of the Kyoto Protocol ("UNFCCC") or any future proposed legislation regarding same, and qualifies for Carbon Emissions Reduction Credits ("CER's").
Municipal Solid Waste
All solid waste generated in an area
except industrial and agricultural wastes, typically from residences, commercial or retail establishments. Sometimes includes construction
and demolition debris and other special wastes that may enter the municipal waste stream. The EPA (1998c) defined municipal solid
waste as "a subset of solid waste and as durable goods (e.g., appliances, tires, and batteries), non-durable goods (e.g.,
newspapers, books, and magazines), containers and packaging, food wastes, yard trimmings, and miscellaneous organic wastes from
residential, commercial and industrial non-process sources.
The MSW can be classified in the following
categories:
a)
Organics
b)
Fuels
c)
Recyclables
d)
Inerts
e)
Miscellaneous
Each category has its own distinct composite
classification. To achieve an optimal Waste to Energy procurement, one has to analyze separately the inherent category contributions
to energy yield and its correlated technological process of extraction in obtaining same in the most economical sense available;
thus, the importance of segregating the MSW into the appropriate categories of distinct feedstock is of principal importance for
optimal performance in the appropriate technological processes.
In BioCrude's MSW-Energy initiative,
BioCrude Technologies USA, Inc. incorporated the following technologies in the Integrated Municipal Waste Processing (Waste to
Energy) Complex in order to optimize the treatment process in an environmentally friendly manner by whilst optimizing the Revenue
Model of same, and in turn, pass some of the savings back to the municipalities while still earning an impressive bottom line in
juxtaposition to what the competition has to offer with regards to landfilling and incineration:
1.
Separation of Waste Facility (Materials Recovery Facility)
2.
Refuse Derived Fuel ("RDF") Plant in order to handle the fuels of the MSW and produce Energy with an ash by-product
3.
Bio-Methanation Plant in order to handle the organic fraction of the MSW (OFMSW) to produce Energy with a fertilizer by-product
4.
Composting Facility (maximum 50 TPD) in order to handle a percentage of the OFMSW alongside with the small particles (plastics, ceramics...) that could not be efficiently separated within the separation process of the MSW (fuels in the Bio Methanation plant (plug flow digester) inhibit the process). The economies are no longer apparent in Composting facilities surpassing the 50 TPD capacities.
5.
Power Plant
12
With BioCrude's Integrated MSW
to Energy proposal/initiative, BioCrude attempts to service each category of the MSW in order to optimally utilize all renewable
resources from same to procure renewable energy and marketable by-products (fertilizer, ash, etc.).
It is very important to note that the
Separation Process of the MSW into the appropriate feedstock categories for each distinct process (organics for biomethanation
(as well as for composting), and polymer based hydro-carbons and cellulose based products for RDF process) is of the utmost importance.
Failure to do so can lead to complications and inevitable failure of each process in question. Evidence of Success and failure
stories (especially with biomethanation plants, whereby the feedstock generated from MSW (organic fraction) had traces of more
than 10% of polymer based products and/or inerts, thus inhibiting and/or limiting the viability of same) as can be found all over
the world, and each outcome, in essence, can be summarized by Plant Technology Implementation and Feedstock Preparation (do not
mix up technology viability with technology implementation and operation).
Nota Bene
: With
gasification and/or incineration (mass burn), MSW is dumped into the boiler "as is" and combusted at temperatures ranging
from 800 – 12000C (minimum; plasma arc gasification temperatures range from 7,000 – 10,0000C). All waste is burned
yielding an approximate net yield of energy for reuse (after self-consumption) of 30 – 40%. The organic fraction of the MSW
(OFMSW) is burned, whereby the fertilizer potential via a biomethanation process (cooking) is substituted for an ash from the gasification/incineration
process (es). Let us not even entertain what happens to the methane potential of same via gasification/incineration in lieu of
biomethanation; LOST! Bottom line, "
Potential Revenues
" lost and operational costs of gasification/incineration
processes are increased dramatically, up to the point where one has to substitute more energy (fuel) in order to sustain continuity
of operation and/or to substitute the self-consumption energy requirements of the processes when the varying calorific value of
a sample of the waste is deficient for same. One can do their own sensitivity analysis to evaluate same and come to their own conclusions!
BioCrude's Integrated MSW-Energy Solution evolves from first principles of Science, Chemistry, Engineering, Economics and
Common Sense!
The
Organics
portion of the MSW
is treated via a
biomethanation
process, whereby all methane gas is extracted for the eventual realization of renewable
energy creation, and a fertilizer procured as an additional by-product, which can be marketed to the agricultural industry.
The
polymer-based
(hydro-carbon chain), cellulose
and textiles portion of the MSW will be treated via an
RDF
process (a derivative of gasification, but with the incorporation
of a Materials Recovery Facility (MRF) [Separation process], where we have the luxury of operating at lower temperatures (350 –
400
0
C) because of the separation of the MSW, i.e. lower temperatures reflects less operational self-consumption, hence
more outputs (energy) for resale), whereby the thermal combustion will generate renewable energy and the by-product of ash can
be marketed to the construction industry for the following purposes:
●
Concrete production, as a substitute material for Portland cement and sand
●
Embankments and other structural fills (usually for road construction)
●
Grout and Flowable fill production
●
Waste stabilization and solidification
●
Cement clinkers production - (as a substitute material for clay)
●
Mine reclamation
●
Stabilization of soft soils
●
Road sub base construction
●
As Aggregate substitute material (e.g. for brick production)
●
Mineral filler in asphaltic concrete
●
Agricultural uses: soil amendment, fertilizer, cattle feeders, soil stabilization in stock feed yards, and agricultural stakes
●
Loose application on rivers to melt ice
●
Loose application on roads and parking lots for ice control
●
Other applications include cosmetics, toothpaste, kitchen counter tops, floor and ceiling tiles, bowling balls, flotation devices, stucco, utensils, tool handles, picture frames, auto bodies and boat hulls, cellular concrete, geopolymers, roofing tiles, roofing granules, decking, fireplace mantles, cinder block, PVC pipe, Structural Insulated Panels, house siding and trim, running tracks, blasting grit, recycled plastic lumber, utility poles and cross arms, railway sleepers, highway sound barriers, marine pilings, doors, window frames, scaffolding, sign posts, crypts, columns, railroad ties, vinyl flooring, paving stones, shower stalls, garage doors, park benches,
The fly ash can also be marketed to
the agricultural industry for the following purposes:
●
It improves permeability status of soil
●
Improves fertility status of soil (soil health) / crop yield
●
Improves soil texture
●
Reduces bulk density of soil
●
Improves water holding capacity / porosity
●
Optimizes pH value
●
Improves soil aeration and reduces crust formation
●
Provides micro nutrients like Fe, Zn, Cu, Mo, B, Mn, etc.
●
Provides macro nutrients like K, P, Ca, Mg, S etc.
13
●
Works as a part substitute of gypsum for reclamation of saline alkali soil and lime for reclamation of acidic soils
●
Surface cover of bio reclaimed vegetated ash pond get stabilized and can be used as recreational park
●
Ash ponds provides suitable conditions and essential nutrients for plant growth, helps improve the economic condition of local inhabitants
●
Works as a liming agent
●
Helps in early maturity of crop & improves the nutritional quality of food crop
●
Reduces pest incidence
There is a definite market for the fly
ash by-product; the industry players in the global market place have to be clearly identified for the realization of commercialization.
BioCrude can even offer this ash by-products pro-bono to the industry or landfill, for there is no environmental hazard of same.
The recyclables can be easily sold to the recyclable industry
milieu (metals, glass, ceramics, etc.)
The balance of the inerts (Construction
and Demolition Debris, gravel, sand, bricks, etc.) can either be landfilled with no negative environmental impacts, or crushed
and given to companies specializing in the fabrication of construction materials (if a market is identified, BioCrude can offer
them these by-products (crushed or uncrushed).
BioCrude's Integrated MSW
to Energy Complex for Municipal Applications
BioCrude's solution of an Integrated
Municipal Solid Waste to Energy complex is in line with the present trends in the Municipal Solid Waste ("MSW") industry
and the main advantage of same is that it is comprised of a Materials Recovery Facility ("MRF") and different modular
waste treatment processes (Composting, Bio-methanation and Refuse Derived Fuel ("RDF")) and a power station, in order
to treat the MSW and procure renewable energy and other marketable by-products (compost, ash and certain recyclables) with the
added implication of practically zero-landfill policy (less certain inerts which have zero negative environmental impact, if landfilled).
The material components (modules) of
an Integrated Municipal Solid Waste to Energy Complex are detailed as follows:
1.
Entrance to complex
: Kiosk and weighbridge (reception/departure and weighing of garbage trucks (pre-and-post deposit of MSW at the MSW Storage facility).
2.
MSW Storage facility
: Closed and properly ventilated warehouse facility for receiving and storing just in time (JIT) 3 days' inventory of MSW. MSW is moved from the storage facility and moved via machinery and conveyor belts to the Materials Recovery facility.
3.
Materials Recovery facility (MRF)
: a properly ventilated facility that houses different types of machinery/equipment (either procured from suppliers or built in-situ according to plan specifications) requisite for different facets of the separation process of the MSW into the distinct categories of the waste (organics, hydro-carbon polymer based, cellulose, inerts, miscellaneous (batteries, cadavers, etc.…)) and prepare same as the distinct feedstock for the different waste treatment processes (Composting, Biomethanation and Refuse Derived Fuel (RDF)), as well as separate the recyclables for resale and the inerts (elements of construction and demolition debris that are not recyclable) for landfilling or to be crushed and given/sold (negligible in nature in comparison to the revenue model established by the tipping fees, and resale of electricity and compost) to the secondary markets for the manufacturing of building materials.
4.
Composting facility
: A portion of the land concession will host a type of composting system (Windrow [with procured mechanical mixing machinery (trucks) like compost turners or tub/horizontal grinders] or Static Aerated Piles [aeration system such as installed perforated piping to ensure steady oxygen supply (forced air) for the microorganisms and to reduce moisture content]), depending on BioCrude's evaluation of the waste analysis. A fertilizer will be procured, dried and stored in a warehousing facility for by-products.
5.
Biomethanation facility
: Modular digesters are constructed in series and synchronized in operation in order to receive organics and process same to extract and capture the methane gas which will be piped to the Biogas – RDF power plant (will be combusted for the procurement of renewable energy) and in addition, yield a cured fertilizer which will be dried and stored in the warehousing facility for by-products.
6.
RDF facility
: A refuse derived fuel system (gasification derivative) will be procured and installed. The RDF facility will receive the hydro-carbon polymer and cellulose based waste products that will be used to make RDF pellets (compressed and dried) that will be used as the feedstock for combustion within same to generate renewable energy within the Biogas – RDF power plant.
7.
RDF – Biogas power plant
: will be procured and installed within a certain section of the Complex with a dedicated Distributed Control System (DCS) for the MSW-Energy (RDF & Biogas based) power plant & fuel processing plant (controls & instrumentation for the boiler and turbine, instrumentation for the balance of the power plant and control room).
8.
Internal roads
: will be constructed within the complex for vehicle/truck transport/passage within the complex.
9.
Green Belt
: will be developed for aesthetic purposes and municipal environmental conformities.
14
Business Model
The Company's business model is
designed to create a profitable revenue stream through the direct acquisition of Concession Agreements from different Governments
for the implementation of BioCrude's integrated MSW-Energy Complexes. Our products, processes and services, marketed to the
relevant target audience, enable us, to generate multiple revenue streams and consistent profitability derived from the high gross
profit inherent within the realms of our proprietary products, services and applications.
By acquiring the necessary Concession
(MSW, Land and Supply of Treated Effluent) and Power Purchase Agreements (PPA), from the respective governmental authorities of
a certain country, with Sovereign Guarantees (with right of subrogation), the Company will develop its Integrated Municipal Solid
Waste to Energy Complex, under "
BOOT"
(Build, Own, Operate & Transfer) basis.
The following contractual understandings are the key prerequisite
elements for establishing a mutual meeting of the minds, by and between BioCrude Technologies USA, Inc. and the governmental authorities
of a municipality/country, for the successful realization of BioCrude's MSW-Energy Complexes:
1.
MSW Concession
for the guaranteed delivery of MSW to the Complex with an implied base tipping fee per tonne ("Put or Pay") with annual escalations for the term (30 years) of the project with an option of renewal for an additional term (30 years) and Sovereign Guarantees from the Minister of Finance endorsing same.
2.
Land Lease Concession
for the delivery of the required amount of land for project term (30 years), at an annual symbolic lease rate of $1/amount of land delivered/annum, with an option of renewal for an additional term (30 years).
3.
Supply of Treated Effluent Concession
whereby the governmental authorities will supply the necessary treated water in order to fulfill the operational requirements of the MSW to Energy complex at a negligible symbolic annual rate for the term of the project with an option of renewal for an additional term (30 years).
4.
Power Purchase Agreement (PPA)
[resale of procured electricity to the Power Corporation of the country in question], whereby the Power Corporation of a certain country will buy back the electricity produced by the MSW to Energy Complex at a base rate per kW-hr ("Take or Pay"), with annual escalations for the term (30 years) of the project with an option of renewal for an additional term (30 years) and Sovereign Guarantees from the Minister of Finance endorsing same.
15
5.
Assistance from the Appropriate Governmental Ministries and Municipalities in obtaining all necessary permits and clearances for the Construction and Operation of the MSW-Energy Complex (stipulations in contracts).
Nota Bene
: Depending on
country policy on foreign investment, the Company may request or be granted an exemption of taxes, levies, duties and all other
relevant taxes applicable to the importation of all plant, materials, equipment and rolling stock for the Construction of the MSW-Energy
complex, from the appropriate Ministries, related thereto.
All of the aforesaid Concession agreements
have to be granted at the same time in order for BioCrude to successfully realize the development (Engineering, Procurement and
Construction) and operation of the MSW to Energy complex (the "Sovereign Guarantees" and right of subrogation are critical
and paramount for the funding requirements of the MSW to Energy complex).
Target Market
The global Waste to Energy segment of
the waste management industry is the target market BioCrude addresses. Management is confident it will succeed in having its integrated
systems and processes widely implemented across Africa, Asia, the Balkans, the GULF and North America with a view to expanding
to other international markets (Latin America). The Company's first step in penetrating its target market has been taken
with the signing of Concession Agreements with the country of the Union of the Comoros (Autonomous Island of Grande Comore); signed
January 11, 2016.
Strategies of the Company
BioCrude's strategy is designed
to create a "PROFITABLE" revenue stream through the direct acquisition of Concession Agreements from different Governments,
for the implementation of BioCrude's integrated MSW-Energy Complexes, or through the establishment of unique and strategic
alliances via licensing arrangements and/or joint ventures within the industry milieu.
BioCrude has developed what we believe
is a highly effective marketing strategy, built on a proactive direct marketing campaign with Government, large corporate facility
management that target the sector for waste product treatment and reformation.
The Company believes that this will result in
a development of a marketing and distribution network with extensive coverage of the Company's target market at a minimal
expense, allowing the Company to reach profitability.
We believe that our marketing strategy will permit us to generate an
extensive customer/end user base; however, there can be no assurance that our estimate regarding acceptance of our products and
services will be correct.
The Company's long-term strategy
is to create economically beneficial uses for waste streams through resource transformation solutions. Since the value of marketable
by-products (commodities; renewable energy, fertilizer, primary feedstock for building materials, etc.…), after processing
costs, is a significant and absolute amount, in juxtaposition to disposal options (ZERO), such as landfilling or incineration,
the Company believes this strategy is effective long-term. The Company believes that as carbon taxes or cap and trade systems are
implemented and the demand for commodities rises, economics will further favor this strategy. The Company is also focusing on lowering
the cost of resource transformation solutions by reducing its recycling processing operating costs, examining ways to mitigate
commodity price fluctuations (forward contracts for marketable by-products), and developing new processing technologies. These
steps will help to build an effective business model at lower commodity pricing levels.
The Company is focused on four main
areas to improve the performance of base operations and hence, increase cash flow generation. They are Pricing initiatives, Cost
controls and operating efficiencies, Integrated Waste to Energy development initiatives with long term Concession Agreements and,
Asset Management.
BioCrude has developed a number of Lobbying
(Sales/Solicitation) programs and the standardization of same. We believe that the pricing logic used in our fee structures, with
implied "
Put or Pay
" and "
Take or Pay
" provisions for the supply of feedstock and resale
of outputs (renewable energy), respectively, is not only reasonable, but competitive. We expect to continue to add valued ameliorations
to our structured fee-based pricing of products and services. The goal of our pricing program is to generate price increases in
excess of CPI, whilst being competitive in nature. BioCrude will derive revenues from a combination of commodity sales (Marketable
by-products – fertilizer and energy resale), carbon credits (CER's under the auspices of a "
Clean Development
Mechanism
" (CDM project)) and tipping (gate) and material processing fees. Fluctuations in commodity pricing are managed
by a number of risk mitigation strategies including: financial hedging instruments (transfer of foreign exchange risk), floor prices,
forward sales contracts, and index purchases. The goal is to optimize and stabilize the revenue stream, while still being competitive,
net of cost of operations, and generate consistent positive cash flows.
The Company continues to search for
the best continuous improvement practices and programs as solutions to then implement as part of its corporate governance. The
goals of these practices and programs are to enhance customer service, increase safety for employees, and to reduce operating and
administrative costs. The Company has implemented continuous improvement strategies, and as such, as of date, the Company has introduced
select operating efficiency initiatives in safety, productivity, maintenance, customer service, environmental compliance, and procurement.
16
Prior Activities of BioCrude Canada
Within certain countries, if an entity
wants to pursue certain specialized works, it is recommended that the entity establish a presence within same (establish a corporation
with a civic address). As an example, in 2009, this was done in Romania with the anticipation that BioCrude Canada would be successful
in acquiring the concession agreements from the governmental authorities of Romania. BioCrude was not successful in meeting its
objective in Romania for same and stopped its lobbying works for the pursuit of said engagement by and between the Governmental
authorities of Romania and BioCrude for the implementation of BioCrude's proposed MSW to Energy complex in Romania, closed
its preliminary office and the corporation became dormant.
Since July 2008, BioCrude Canada has
taken the initiative to market and promote its intellectual property and specialized technical expertise throughout the market
place, both nationally and globally (we have introduced our technology to Governments and major Conglomerates in the Waste to Energy
sector) in over 30 Countries worldwide, whereby BioCrude has successfully opened up dialogue with Governmental Authorities and
respectable corporations for near future contractual negotiations.
In December, 2007, Jaipuria Advanced
Technologies, Inc. (http://www.jaipuria-group.com and http://www. smvjaipuria.com/waste.php) of India, and BioCrude Canada, announced
their formation of a new division dedicated to Waste Reformation and Energy Procurement for the purpose of pursuing contracts in
India. In many areas of the country, waste management and energy shortages are a serious problem. With Jaipuria's construction
and large project experience, and with the use of the intellectual property supplied by BioCrude in terms of waste management and
production of renewable energy, we have, in January, 2008, submitted a bid, in response to a tender for a Waste to Energy plant
(2,000 TPD) in Okhla and Tymarpur, India (we were not the selected candidate) and Indore, India (Collection and Treatment of municipal
waste; 600 TPD; we were not the selected candidate).
During this time, we have also negotiated
with "Pepsi Co India" to build a 50 TPD prototype in the city of Panipat, India, in a strategic joint venture alliance.
A few months later, Pepsi Co India's New President/CEO had a change of corporate venue and put aside the Waste to Energy
initiative. Ever since then, BioCrude Technologies, Inc. (Canada) decided not to pursue any more works in India.
The Company, through its commercialization
efforts, has established good relationships with governments and ministries in more than 70 countries in North America, Latin America,
Asia, Africa and Europe and received a positive reception when presented with its waste to energy solution for their waste management
dilemmas. This produced dozens of Letters of Interest, submitted to BioCrude, by different divisions of Governments (federal/municipal)
from different countries, worldwide.
2009 –
2020 -
Marketing and Commercialization
: BioCrude presented its waste to energy solution to governments and ministries
from USA, Canada and Mexico in North America, Costa Rica, Panama, Ecuador, Argentina, Peru, Brazil, Dominican Republic, Haiti,
Colombia, Venezuela, Guatemala, Honduras, Jamaica, El Salvador, Cuba, Uruguay, Bahamas and Trinidad & Tobago in Latin America,
China, Hong Kong, Mongolia, Kazakhstan, Vietnam, Indonesia, Philippines, India, Bangladesh, and Pakistan in Asia, Kingdom of Saudi
Arabia, United Arab Emirates, Kuwait, Qatar, Jordan, Oman, and Bahrain in the Middle East, Portugal, Luxembourg, Belgium, Hellenic
Republic, Malta, Corsica, Albania, Bulgaria, Romania, Serbia, FYROM (Macedonia), Spain, Montenegro, Kosovo, Belarus, Ukraine, Georgia,
Latvia, Armenia, amongst other countries, in Europe, Ivory Coast, Burkina Faso, Ghana, Togo, Senegal, Benin, Angola, Niger, Guinea,
Mali, Uganda, Burundi, Rwanda, Morocco, Tunisia, Algeria, Egypt, Libya, Kenya, Ethiopia, Democratic Republic of the Congo (Kinshasa),
Republic of the Congo (Brazzaville), amongst other countries in Africa.
Pricing initiatives
BioCrude has developed a number of sales/solicitation
programs and the standardization of the sales/solicitation process and standardized the sales/solicitation process. We believe
that the pricing logic used in our fee programs, with implied "
Put or Pay
" and "
Take or Pay
"
provisions for the supply of feedstock and resale of outputs (renewable energy), respectively, is reasonable and competitive. We
expect to continue to add to our fee-based pricing through additional administrative fees, recycling fees, late charges and further
improvements to our existing fee structures. The goal of our pricing program is to generate price increases in excess of CPI. BioCrude
will derive revenues from a combination of commodity sales (Marketable by-products – fertilizer and energy resale), carbon
credits (CER's under the "
Clean Development Mechanism
" established pursuant to article 12 of the "
Kyoto
Protocol
" (CDM project)) and tipping fees paid for material processing. Fluctuations in commodity pricing are managed
by a number of risk mitigation strategies including: financial hedging instruments (transfer of foreign exchange risk), Sovereign
Guarantees, floor prices, forward sales contracts, index purchases, and tipping fees. The goal is to smooth revenue, net of cost
of products purchased, and generate consistent cash flows.
Cost controls and operating efficiencies
The Company continues to search for
the best practices throughout the entire organization and then implements these solutions through standardized continuous improvement
programs. The goals of these programs are to enhance customer service, increase safety for employees, and to reduce operating and
administrative costs. The Company has implemented continuous improvement strategies and the introduction of select operating efficiency
initiatives in safety, productivity, maintenance, customer service, environmental compliance, and procurement.
17
Integrated Waste to Energy development
initiatives with long term Concession Agreements
BioCrude excels is the reformation of
MSW using its intrinsic intellectual property as well as its expertise in Integrated Waste to Energy Processing Complexes. BioCrude
has and will continue to invest time, effort and valuable resources in the pursuit of Governmental Concession (MSW, Land, Supply
of Treated Effluent and Power Purchase Agreements (PPA)) Agreements, for the duration of twenty-five to thirty years, for the implementation
of same. The essence of the Concession Agreements, not only guarantees the MSW and implied tipping fees, related thereto (with
annual indexing), but the resale of the marketable by-products (energy to grid via PPA) for the duration of the term, with Sovereign
Guarantees. Investments in Waste to Energy facilities position the Company well for the evolution of the industry from waste management
to resource management.
Company milestones and plan of execution
During the past 10 years, BioCrude has
developed a reputation in waste management, a result of R&D of Environmental Technologies (both process and product based)
whereby it has enhanced and optimized conventional technologies, augmented by its fungal technology that increases the rate of
decomposition of organics. This led to the development of efficient, cost-effective, and environmentally friendly products, processes
and systems for the reformation of waste material and the creation of renewable energy and marketable by-products.
BioCrude's MSW to Energy initiative
is, by definition, an "en suite" of waste management and energy procurement, whereby the latter is a marketable byproduct
derived from the intrinsic processes of the treatment of the MSW by procuring the necessary constituent feedstock (primary material)
to produce the renewable energy in the modular section for power generation of the Integrated MSW to Energy complex. In order to
realize an integral MSW to Energy complex, as defined in the "Business Model" of the registration statement, all Concession
Agreements (guarantee of MSW supply, Land and Supply of Treated Effluent) as well as a Power Purchase Agreement must be contracted
concurrently, for they are "ALL" necessary constituent elements for the development of an integrated MSW to Energy
complex i.e., you cannot have some or most of the agreements (Concessions/PPA) in place, but must have "ALL" in place,
at the same time, simply because of the nature of the project in question.
BioCrude's revenue model is based
on revenue generation from the following: i) the operation of MSW to Energy complexes (tipping fees, resale of renewable energy,
resale of other marketable by-products (compost, recyclables) and potential carbon credits, ii) Joint Venture license fees, whereby
the prospective Joint Venture partner will buy a license from BioCrude (payment to be effected immediately after signature) for
their participation in the consortium and will infuse its prorated share of equity capital for the potential MSW to Energy complex,
and iii) EPC ("Engineering, Procurement & Construction) management fees (general contracting fees, approximately 20%
of the capital cost of the project).
In order to realize an integrated MSW
to Energy complex, as defined in the "Business Model", all Concession Agreements (guarantee of MSW supply, Land and
Supply of Treated Effluent) as well as a Power Purchase Agreement must be contracted concurrently, for they are "ALL"
necessary constituent elements for the development of an integrated MSW to Energy complex.
In order to acquire the concessions
for Biocrude waste management (MSW to Energy), major lobbying must be done in all levels of government and ministries (e.g., Biocrude's
waste management project is an environmental project thus requiring the intervention of the Ministry of Environment, renewable
energy is procured, hence requiring the intervention of the Ministry of Energy/Power and Power Corporation (usually crown corporation),
the municipalities usually are responsible for the granting of the MSW, Land and Supply of Treated Effluent Concessions and the
Ministry of Finance is responsible for the signing of the Sovereign Guarantees, and in some instance, countries might have other
intervening governmental agencies).
BioCrude has positioned itself, through
its continual lobbying efforts (ongoing), for potential Joint Ventures (JV) with certain governments (countries/clients). Should
any of these Joint Ventures prove to be realized because of the persistent lobbying activities, not only will BioCrude be able
to realize the EPC management fee for the development of the MSW to Energy complex(es), but it will also receive its prorate share
(50%) of the revenue stream of the developed MSW to Energy complex(es), with similar time frame frequencies as mentioned above,
as well as a license fee (BioCrude already submitted offers) immediately following signature of the Joint Venture engagement and
the Concession and Power Purchase agreements. BioCrude anticipates, that if the prospective JV partner(s) take the initiative to
implement (not only entertain) a waste management solution for their country, possible engagement can be realized within 6 to 12
months following that initiative (being cognizant of bureaucracy and red tape procedures of government).
As part of BioCrude's marketing
strategy, BioCrude invests time, effort and resources in order to prepare tailor made prefeasibility studies, presentations &
educational literature for municipalities worldwide, and sends corporate delegations to these places for presentation of same,
at no expense to these governmental institutions. This attribute of BioCrude's direct marketing campaign has proven to be
very successful. Governments worldwide were not only receptive, but appreciative of BioCrude's formal and professional address.
These efforts have given BioCrude a profound understanding of the challenges faced by governments at all levels in their dealings
with waste management issues.
A vote of confidence has been bestowed
to BioCrude by the governmental authorities of the Autonomous Island of Grande Comore on its proposed integrated waste management
solution for the Autonomous Island of Grande Comore through the awarding of the necessary Concession Agreements (delivery of MSW,
Land and Supply of Treated Effluent) for 30 years (with a renewal option of 30 years) with Sovereign Guarantees for the implementation
(design, build, finance and operate) of a 700 TPD Municipal Solid Waste to Energy Complex, in the city of Moroni, Autonomous Island
of Grande Comore, Union of the Comoros. Furthermore, a Power Purchase Agreement has been signed with the "Le Gestion de l'Eau
et de l'Électricité aux Comores (MA-MWE)" whereby same will buy back all procured renewable energy from
the MSW to Energy complex for the term of the Concessions (and renewal option).
BioCrude, subject to its contractual
engagement with the Government of the Autonomous Island of Grande Comore for the implementation of a 700 TPD MSW to Energy complex
in Moroni, Grande Comore, through the financing provisions of the MSW to Energy project, will earn the EPC management/general contracting
fee of approximately twenty percent (20%) of the capital cost of the MSW to Energy project (prorated over the duration of the construction
period), i.e., commencing within 6 to 8 months from these presences.
18
Nota Bene
: For the Union
of the Comoros, the Company is still awaiting documents from the Federal Governmental Authorities stating that the Federal Government
is the new Intervening Party to the Concession(s) agreements previously signed with the Governorate (province; autonomous region)
of Moroni, after the outcome of the Federal Referendum, whereby through same, contracting and economic powers are transferred from
the Governorate (Province) level to that of Federal level. The Referendum outcome favored the Federal Government over that of the
Governorate (Autonomous) Region of Moroni, i.e., authorizing documents are still pending.
BioCrude, as well, is looking at approximately
24 to 26 months (development time frame for the realization of MSW to Energy complex) before it can start generating absolute,
guaranteed revenues from the operation of the MSW to Energy complex(es) (tipping fees/fees from the resale of marketable by-products
(compost, ash, primary feedstock for building materials (inerts), recyclables, etc.…), resale of renewable energy and carbon
emission reduction credits [CERs]), servicing the waste management needs of the Government of the Union of the Comoros, as per
the provisions and stipulations of the contractual engagements with the government (with implied sovereign guarantees), for a minimum
guaranteed term of 30 years (and an option for an additional 30 years).
BioCrude is evaluating additional options
for funding (capital markets, financial institutions, contracting companies, pension funds, etc.…amongst other financially
engineered hybrid scenarios thereof) and has already opened up dialogue regarding same. BioCrude has received a term sheet for
the funding of the MSW to Energy project for the Union of the Comoros, ergo, BioCrude will shortly be able to commence works for
ground breaking and start receiving its (Engineering, Procurement and Construction) EPC management fee as its first projected revenue
stream on a prorate schedule subject to a disbursement schedule in accordance to the terms and stipulations of the expected offer
of funding.
BioCrude, with confidence, aims to be
a leader in waste management, having set as its objective, the profitability inherent within the realms of the activities issued
of this sector, while building business relationships and social implications within the collectivity's/communities that
BioCrude is called upon to serve, beyond the environmental and social implications, and beyond the business imperatives.
BioCrude has adopted a directive, as
part of its corporate governance, to routinely undertake innovative strategic planning initiatives in order to design and implement
integrated solid waste systems that are responsive to dynamic demographic and industrial growth needs of municipalities. Strategic
planning starts with the formulation of long-term goals based on the local urban needs, followed by a medium and short-term action
plan to meet these goals. The strategy and action plans should identify a clear set of integrated actions, responsible parties
and needed human, physical and financial resources as part of the waste management solution.
BioCrude has not only demonstrated its
proven ability to open up dialogue and develop relationships with the various divisions of Governments worldwide (Administrative
and Technical) but has also developed confidence in same for potential and eventual engagement. BioCrude's Public Relations
and Business Development divisions have demonstrated their lobbying abilities as highly effective, efficient and productive in
yielding results and establishing goodwill for BioCrude.
At present, the provisioning for waste
treatment and "
green
" reformation of these products into renewable energy sources is regionalized and within
a given geographic region of operations, can be competitive. However, we believe that there are no other entities that provide
turnkey solutions targeted to all types and sizes of users. However, there are waste treatment providers that may elect to enter
into this designated market if our model is successful. We compete on the basis of engineering uniqueness, quality, cost-effectiveness
and the increasingly comprehensive and specialized nature of our services, along with the expertise, technology and professional
support we offer. While we believe that we will have a competitive cutting-edge advantage by being the most specialized in the
market, there can be no assurance that our assumptions regarding our competitive position will be proven correct.
We will require additional capital to
meet our liquidity needs. Currently, the Company has determined that its anticipated monthly cash flow needs should not exceed
$30,000 per month for twelve months following the filing date of these financial statements.
The Company's projected capital
needs and its projected increase in expenses are based upon the Company's projected acquisition of Municipal Solid Waste,
Land and Supply of Treated Effluent Concessions and Power Purchase Agreements ("PPA") per facility interests over the
coming twelve months; however, in the event that the full offering proceeds are not raised, the Company would acquire the Municipal
Solid Waste, Land and Supply of Treated Effluent Concessions and PPA per facility at a slower pace and/or focus its energies on
the refinement of existing properties to maximize their productivity. The Company's success does not depend on a scheduled
acquisition and therefore it has flexibility to scale back its expenses to meet actual sources of cash.
We anticipate that we will receive sufficient
proceeds from investors through this offering, to continue operations for at least the next twelve months; however, there is no
assurance that such proceeds will be received and there are no agreements or understandings currently in effect from any potential
investors. It is anticipated that the Company will receive increasing revenues from operations in the coming year; however, since
the Company has a short history of revenues, it is difficult to anticipate what those revenues might be, if any, and therefore,
management has assumed for planning purposes only that it may need to sell common stock, take loans or advances from officers,
directors or shareholders or enter into debt financing agreements in order to meet our cash needs over the coming twelve months.
The Issuer has no agreements or understandings for any of the above-listed financing options.
19
The Use of Proceeds section includes
a detailed description of the use of proceeds over the differing offering scenarios of 100%, 75%, 50% and 25%. As the Company's
expenses are relatively stable, not incorporating elements of severe force majeure, the Company believes it can fund its present
operations with projected revenues together with offering proceeds under any of the offering scenarios. The Company will consider
raising additional funds during 2021 through sales of equity, debt and convertible securities, if it is deemed necessary.
The Company's belief is based
on its business model, which in turn is based on assumptions, which may prove to be incorrect. As a result, the Company's
financial resources may not be sufficient to satisfy its capital requirements for this period, and may need to raise additional
funds. If additional funds are raised through the issuance of equity, equity-related or debt securities, such securities may have
rights, preferences or privileges senior to those of the rights of the common stock and the Company's shareholders may experience
additional dilution. Management cannot be certain that additional financing will be available on favorable terms, when required,
if at all. If adequate funds are not available or not available on acceptable terms, the Company may not be able to fund its expansion,
promote its brand as desired, take advantage of unanticipated acquisition opportunities, develop or further enhance and/or optimize
its products and services or respond to competitive pressures.
BioCrude's revenue model is based
on revenue generation from the following: i) the operation of the MSW to Energy complexes (tipping fees, resale of renewable energy,
resale of other marketable by-products (compost, recyclables) and potential carbon credits, ii) Joint Venture license fees, whereby
the prospective Joint Venture partner will buy a license from BioCrude (payment to be effected immediately after signature) for
their participation and will infuse its prorated share of equity capital for the potential MSW to Energy complex, and iii) EPC
("Engineering, Procurement & Construction) management fees (general contracting fees, approximately 20% of the capital
cost of the project). In essence, these fees have to be paid regardless, and BioCrude management will execute and capture remuneration
for same.
Hereunder is a schedule of events (agenda)
for the realization (full execution) of the MSW to Energy project in Moroni, Autonomous Island of Grande Comore (inclusive: contract
realization process), in order for BioCrude to start realizing revenues as an ongoing concern, not taking into account any prospective
joint ventures in the works.
Different facets and schedule of
events for the pursuit and realization of MSW to Energy projects (excluding lobbying activities)
Contract Conclusion, Engineering,
Procurement& Construction
A. Signature of the following Accords
necessary for the realization of the MSW-Energy Complex in Moroni, Autonomous Island of Grande Comore
1.
Deed of Assignment Agreement ("Protocol of Engagement") by and between the Government of the Autonomous Island of Grande Comore and BioCrude Technologies USA, Inc. Contract was signed January 11, 2016.
2.
The signing of the Concession Agreement for the Municipal Solid Waste, Land Lease Agreement and Agreement for the supply of treated Municipal Water on January 11, 2016
3.
The signing of the Power Purchase Agreement (PPA) with the "Le Gestion de l'Eau et de l'Électricité aux Comores (MA-MWE)" [ Power Corporation of the Autonomous Island of Grande Comore] on January 11, 2016
4.
Opening of a new Comorian Corporation (in the country in question) totally owned by BioCrude Technologies USA, Inc., opening of bank account and execution of all party obligations contained in the Deed of Assignment. This was done on January 12, 2016
5.
Reception of letter from new governmental administration of the Autonomous Island of the Grande Comore (after elections on May 2016) reaffirming their initiative and will to fully respect and execute the engagements signed on January 11, 2016; August 25, 2016
6.
Site selection (site Identification and legal designation (Cadastral, Lot, etc. ...)) for the MSW-Energy Complex, preparation of legal documents to annex same to the Land Lease Agreement and Assignment of selected parcel of land to BioCrude, as per the stipulations of the Land Concession agreement on November 12, 2016.
7.
Incorporating agreed to amendments and/or modifications to the contractual engagements of January 11, 2016 into the new agreements replacing those of January 11, 2016: December 9, 2016.
8.
Granting of a Treasury Guarantee to BioCrude from the governmental administration of the Autonomous Island of the Grande Comore, as per the stipulations of the Concession and Power Purchase Agreements: December 10, 2016
(Fully executed; timeline:
it took approximately
8 months
)
B. Organizational Matrix: Construction, Management, Operations
and Maintenance of Project
1.
Flowchart of management staff
2.
Organization of the Waste Management (Collection, Transportation, Sorting and Treatment)
20
3.
Flowchart of Engineering, Procurement and Construction
4.
Flowchart of Operations Complex and Maintenance
5.
Flowchart for the influx of feedstock and the out flux (distribution) of by-products
(
Fully executed; timeline:
The
tasks identified above in B are part and parcel of the submitted preliminary proposal, which included the "
Prefeasibility
Study & Detailed Project Report
" and the "
Business Plan (with financial metrics)
", to the Governmental
Authorities of the Autonomous Island of Grande Comore (September 2015) for the realization of the Concession and Power Purchase
Agreements in accordance to the provisions of the Deed of Assignment pursuant to a Public-Private Partnership (PPP)).
C. Project implementation plan for
the Integrated Municipal Solid Waste to Energy Complex
1.
Opening of the office in Moroni, Autonomous Island of Grande Comore: expected completion date September 2021
2.
Recruitment and training of human resources in Moroni, Autonomous Island of Grande Comore (for engineering, management, operation and maintenance): expected completion date September 2021 (preliminary core)
3.
Recruitment of human resources in Canada (for key management positions): expected completion date September 2021
4.
Preliminary Engineering: completed in preliminary proposal (generic)
5.
Analysis of Municipal Solid Waste: expected completion date September 2021
6.
Study of the site and soil studies: expected completion date October 2021
7.
Detailed Engineering plans: expected completion date October 2021
8.
Detailed plan of the development strategy of the complex: expected completion date October 2021
9.
Hiring of project manager(s) and subcontractors (either through reference or through tender): expected completion date September 2021
10.
Recruitment of Material and Equipment specialist suppliers, via reputation in the market place or tender: expected completion date October 2021
(Timeline:
6 to 8 months from time = present)
D. Human Resource List for Project Implementation
1.
Project management
3.
Structural Engineers
4.
Electrical Engineers
5.
Mechanical Engineers
6.
Environmental Engineers
7.
Geological Engineers
8.
Designers
9.
Architects
10.
Planners
11.
Buyers
12.
Supply Agents
13.
Cost Controllers
14.
Training Coach
(Timeline:
2 to 4 months from time = present
)
21
E. Development and implementation of the EPC project guide
(Engineering, Procurement and Construction)
1.
Program Implementation Plan (
Project Execution Plan
"
PEP
") Completed
2.
Preparation of studies and preliminary engineering plans Completed
3.
Preparation of studies and detailed engineering design 3 months following task D
4.
Planning and timetable for the project (Gantt Chart) 3 months following task D
5.
Obtaining permits and governmental approvals and clearances for the construction and operation of the complex 2 months following submission of detailed engineering plans to the related Governmental Agencies of the Union of the Comoros (timeline provision in agreements and signed off by the Governmental Authorities of the Union of the Comoros)
6.
Construction 10 to 14 months following the execution of E.5. above incorporating a startup synchronization period of approximately 1 to 2 months
7.
Operation and Maintenance Complex NA for Development timeline
F. Project Management and Control: Project Implementation
Plan (PIP)
1.
A preliminary feasibility study and a detailed report of the complex Completed
2.
Strategic planning and economic analysis Completed
3.
The selection of the field Completed
4.
Preliminary engineering Completed
►
Economic analysis and project risks
►
The estimate of the total capital investment as well as operating and maintenance costs
►
The preliminary assessment of environmental impact and permitting requirements
►
The technology research, analysis and conceptualization
5.
Reliability analysis Completed
6.
The technology selection, project configuration
and sizing Concurrently with task E.3. and its timeline
7.
The studies and engineering plans for the environmental permitting Concurrently with task E.3. and its timeline
8.
Research Techniques Concurrently with task C and its timeline
9.
The strategy and planning for the reduction of emissions of greenhouse gases (GHG) Concurrently with task C and its timeline
10.
The preparation of the Clean Design Mechanism documents for submission to the CDM program (literature and the detailed report for project compliance with the standards and requirements established by the UNFCCC) Concurrently with task C and its timeline
11.
Carbon capture and storage Concurrently with task C and its timeline
12.
The carbon credit analysis Concurrently with task C and its timeline
13.
Energy efficiency Concurrently with task C and its timeline
14.
The analysis of the applicable regulations Concurrently with task C and its timeline
15.
The economic and financial analysis (Business Plan) for the preparation of the application for funding Completed; we have already opened up dialogue with an EPC firm for not only engaging same for the EPC works, but also financing same under the proviso of BioCrude subrogating its right to the Sovereign Guarantees; waiting for proforma proposal from EPC firm
16.
The selection for the companies to carry out the civil works, and procure materials and equipment required for the development of the project (initiate works) Completed; we have already opened up dialogue with an EPC firm for not only engaging same for the EPC works, but also financing same under the proviso of BioCrude subrogating its right to the Sovereign Guarantees; awaiting proforma proposal from EPC firm
17.
The management and supervision of the project 10 to 14 months; duration of EPC works
18.
The operation and maintenance of the MSW-Energy complex NA for Development timeline
19.
The invoice, receipt and payment collection NA for Development timeline
20.
Organization of briefings to the public NA for Development timeline
22
G. Environmental Impacts Analysis
The evaluation process:
1.
The assessment of critical elements used in the development of the project, emissions harmful to the environment, leaching into soil, drainage, etc.…
2.
Potential erosion, the effects of the use and release of public waters on the tributaries, the adjacent ecological systems to the site, etc.…
3.
The number of vehicles (trucks, cars, etc.…) and emissions of pollutants
4.
The energy used in the complex and cooling of various buildings
5.
Materials used for the manufacture of the floor
6.
Building materials used for roofs
7.
Management and treatment of municipal solid waste (MSW)
8.
The quality of water and air
9.
The negative environmental impacts and mitigation, thereof
10.
Analysis of existing site and the impact of adverse effects thereon, for the development of the MSW-Energy complex so as to minimize the impact thereof
11.
Effect of development on sensitive regional systems sent by either air or by ground water systems
(Fully executed; timeline:
Part
and parcel of the submitted preliminary proposal ("
Prefeasibility Study & Detailed Project Report
" incorporating
an "
Environmental Impact Analysis
") to the Governmental Authorities of the Autonomous Island of Grande Comore
for the realization of the Concession and Power Purchase Agreements in accordance to the provisions of the Deed of Assignment pursuant
to a Public-Private Partnership (PPP); the Environmental Impact Analysis was acceptable to the Governmental Authorities of the
Autonomous Island of Grande Comore, hence no caveats, provisions or stipulations related thereto are within the signed contractual
agreements).
Planning and Timetable for the Project
The Summary forecast for the following tasks of the project
planning encompasses a timeline of 6 to 8 months:
►
Analysis of the composition and characteristics of municipal solid waste,
►
Study and preparation of plans for the preliminary engineering,
►
Study and preparation of detailed plans of Engineering.
The Summary forecast for the Construction
& synchronization of different modules in the MSW to Energy complex of the project planning encompasses a timeline of 16 to
18 months (incorporating approximately 4 months for project preparation for ground breaking ceremony).
Material Agreements
We have filed (with SEC as part of the
Company's S-1(/A) registration statement(s)) our Material Agreements (the Deed of Assignment pursuant to a Public-Private
Partnership (PPP), the Power Purchase Agreement (PPA), and MSW, Land and Supply of Treated Effluent Concession Agreements), with
SEC as part of the Company's S-1(/A) registration statement(s), respectively by and between the Governmental Authorities
of the Grande Comore and BioCrude.
January 2016 –
Concluded Engagements
:
signed Deed of Assignment pursuant to a Public-Private Partnership (PPP), MSW, Land and Supply of Treated Effluent Concession Agreements
and a Power Purchase Agreement (PPA), by and between the Government of the Autonomous Island of Grande Comore and BioCrude Technologies
USA, Inc., for the implementation of the first Waste to Energy complex in the municipality of Moroni, which are as follows:
►
Deed of Assignment pursuant to a Public-Private Partnership (PPP):
exclusively assigning the rights of waste management treatment to BioCrude via the inter-related specific concession vehicles, all defining protocol and mode of engagement as well as rights, interests and obligations of each engaging entity for the term of engagement (30 years) with an option of renewal for an additional term (30 years). Contract was signed January 11, 2016 and amended on December 9, 2016.
23
►
MSW Concession*
for the guaranteed delivery of MSW to the Complex with an implied base tipping fee per ton of MSW ("
Put or Pay
" for the minimum MSW guarantee of 700 TPD) with annual escalations for the term (30 years) of the project with an option of renewal for an additional term (30 years) and Sovereign Guarantees from the Minister of Finance endorsing same. Contract was signed January 11, 2016 and amended on December 9, 2016.
►
Land Lease Concession
for the delivery of the required amount of land for project term (30 years), at an annual symbolic lease rate of $1/amount of land delivered/annum, with an option of renewal for an additional term (30 years). Contract was signed January 11, 2016 and amended on December 9, 2016.
►
Supply of Treated Effluent Concession
whereby the governmental authorities will supply the necessary treated water in order to fulfill the operational requirements of the MSW to Energy complex at a negligible symbolic annual rate for the term of the project with an option of renewal for an additional term (30 years). Contract was signed January 11, 2016 and amended on December 9, 2016.
►
Power Purchase Agreement (PPA)*
[resale of procured electricity to the Power Corporation of the country in question], whereby the Power Corporation of a certain country will buy back the electricity produced by the MSW to Energy Complex at a base rate per kW-hr ("
Take or Pay
" for all of the renewable energy procured less the self-consumption needs of the MSW-Energy complex), with annual escalations for the term (30 years) of the project with an option of renewal for an additional term (30 years) and Sovereign Guarantees from the Minister of Finance endorsing same. Contract was signed January 11, 2016 and amended on December 9, 2016.
*
A Revolving Letter of Credit (RLC)
,
replenished quarterly (for the duration of the term of the contractual engagements) will be issued by the Governmental Authorities
of the Autonomous Island of the Grande Comore (a temporary Treasury bond has been issued to BioCrude on December 10, 2016, which
will be replaced by the RLC), as per the provisions and stipulations of the contractual engagements (submitted to the SEC), as
a default payment mechanism guarantee, in the event of nonpayment of the tipping fees or for the purchase of the renewable energy,
which can immediately, after default, be drawn upon, to remedy default. The face value of the RLC is to cover the tipping fees
and resale of electricity payments for a whole year, multiplied by a factor of 1.5.
* On July 27, 2017, the Governmental
Authorities of the Autonomous Island of the Grande Comore have issued to BioCrude a "
Treasury Bond
", with supporting
literature (indenture, resolutions, etc.…; as filed with SEC as part of the Company's S-1(/A) registration statement(s),
as well as other in other Form filings) baring a face value of twenty million United States Dollars (20,000,000 USD), in lieu of
a "Revolving Letter of Credit (RLC)", replenished quarterly (for the duration of the term of the contractual engagements),
as per the provisions and stipulations of the contractual engagements (Concessions and Power Purchase Agreements). This Treasury
Bond serves as a default payment mechanism guarantee, in the event of nonpayment of the Governmental Authorities of the Autonomous
Island of the Grande Comore's financial contractual obligations (tipping fees and/or fees due for the purchase of the renewable
energy), which same can immediately, after default, be executed upon by BioCrude, to remedy default.
Nota Bene
: The parties
(the Governmental Authorities of the Grande Comore and BioCrude), following discussions, agreed to enforce amendments discussed
and reflect same within the agreements and agreed to sign these new agreements, as amended, on December 9, 2016, replacing all
of the agreements signed on the 11
th
of January 2016. The principal points of amendment were to incorporate the identified
land concession which was assigned to BioCrude, by governmental decree, on November 12, 2016 and to reflect the new governmental
administration that was elected into office as the representatives for the Governmental divisions of the Grande Comore that engaged
with BioCrude.
For the Union of the Comoros, the Company
is still awaiting documents from the Federal Governmental Authorities stating that the Federal Government is the new Intervening
Party to the Concession(s) agreements previously signed with the Governorate (province; autonomous region) of Moroni, after the
outcome of the Federal Referendum, whereby through same, contracting and economic powers are transferred from the Governorate (Province)
level to that of Federal level. The Referendum outcome favored the Federal Government over that of the Governorate (Autonomous)
Region of Moroni, i.e., authorizing documents are still pending.
Nota Bene
:
The following
contractual attributes are intrinsic to the aforesaid contractual (Concessions) agreements:
►
Contracts are backed by Government Sovereign Guarantees
►
Law and Jurisdiction of Dispute Arbitration (Canada)
►
Law of Contract execution immunized against change of law with Grandfather clause
►
Government issuance of (USD 20 Million) Treasury Bond; covers any interim financial defaults – replenished quarterly
►
Government payments are in US dollars (foreign exchange rate risk eliminated)
►
Zero Income Taxes, VAT's and no levies & duties of imported materials, equipment, rolling stock, etc.… for duration of contract (30 years)
►
Assignment of contracts/change of control clauses benefiting BioCrude (to its discretion)
►
Land Lease Concession: Symbolic $1 US per 25 hectares per year, for 30 years (term), and for additional 30-year renewal term (no escalations / changes)
24
►
Supply of Effluent Concession: Symbolic $1 US per 7,000 kL of Effluent (water) per day, for 30 years (term), and for additional 30-year renewal term (no escalations / changes)
►
Supply of primary feedstock (waste): 700 tons per day not only at zero cost, but at either a "gate fee" [government pays BioCrude this tipping fee]
►
Government buys back all procured renewable energy (net of self-consumption of complex) via a Power Purchase Agreement for the duration of the 30-year term and renewal option thereof
►
BioCrude is beneficiary of all Certified Emissions Reduction Credits (CERs) due to the MSW to Energy project
►
BioCrude's management and its Joint-Venture Partner, China Machinery Industry Construction Group Inc. (SINOCONST), have BONIFIDE credentials to execute the Engineering, Procurement, and Construction ("EPC") of the MSW to Energy project, as well as the management of the operations to same*
* On April 4th, 2017, China Machinery
Industry Construction Group Inc.'s (SINOCONST) and BioCrude Technologies, Inc. have signed a strategic Partnership (JV) Agreement
which embodies the understood exclusive engagement by and between the participants of the JV Consortium (SINOCONST and BioCrude)
for any present and future Waste to Energy Project(s) acquired by any party worldwide. SINOCONST will be responsible for the EPC
works (for the development of the Project(s) [Design and Build]) as well as securing the financing for the Project(s), while BioCrude
will be the operator (Operation and management).
China
Machinery Industry Construction Group Inc. (SINOCONST), is one of the earliest large state-owned construction enterprises in
China, having Class A general construction contracting certification and Class A design certification approved by the
Ministry of Housing and Urban-Rural Development, and having AAA credit standing and foreign trade license granted by the
Ministry of Commerce. SINOCONST has passed the certification of ISO9001 Quality Management System, ISO14001 Environmental
Management System and GB/T 28001 Occupational Health and Safety Management System. Presently, SINOCONST has 15 wholly owned
subsidiaries, 4 Business Division divisions, 19 branch companies, 8 joint-stock companies and 1National Exemplary Technician
Institute. It boasts more than 10,000 employees, including 3,000 various engineers.
During the past 60 years since its establishment,
SINOCONST has successively undertaken hundreds of large and medium key projects involving different sectors, such as machinery,
automobile, building materials, metallurgy, electric power, chemical, petroleum, electronics, light industry, broadcasting &
TV, environmental protection, municipal, public and civil buildings etc., with projects performed throughout the country. SINOCONST
has made great contribution to China's industrial development and modernization.
SINOCONST will be responsible for the
EPC works (for the development of the Project(s) [Design and Build]) as well as securing the financing for the Project(s), while
BioCrude will be the operator (Operation and management). Both SINOCONST and BioCrude will engage with SPV's/SPE's,
with Contract (Project) Agreements and Operation and management Agreements.
As a caveat for securitizing payment
of the contract price for Engineering, Procurement and Construction ("EPC") works, via the financing mechanism established
by SINOCONST, JV Consortium will set up "Special Purpose Vehicle's/Entity's" ("SPV/SPE") for
each and every acquired Project. The JV Consortium's mission and ethos for creating an SPV/SPE of each well-defined Project
is to enable direct securitization of financially engineered loans (and other receivables) against direct assets. SINOCONST's
association (equity participation) into every SPV/SPE will be provisional, in a sense where same will have a certain stake in the
shareholdings (Common Stock) of the SPV/SPE (as defined in the Capital Structure of the SPV/SPE, as referenced below and in the
Memorandum and Articles of Association of same, refer to Annex I), until such time that the loans vested for the development (Design,
Building of Project by SINOCONST) of the Project are fully paid back by the JV Consortium from the proceeds of the receivables
(for services rendered to client by the Project (SPV/SPE)), and all shares of Common Stock held by SINOCONST are transferred (sold
to BioCrude for Project loan(s) repayment, only) to BioCrude as full and final settlement for the loan (that paid for the contract
price of said development to SINOCONST). As part and parcel to the securitization of the loans in the SPV/SPE, BioCrude shall assign
and/or subrogate its rights to its assets of that distinct Project (Concessions and Power Purchase Agreements, Sovereign Guarantees,
Revenues of Operation, etc.…) to the SPV/SPE ("JV Consortium"), and same shall be subject to Charges (Mortgage,
privilege, etc..) for financing (funding), only.
On April 4, 2017, SINOCONST and BioCrude
have commissioned the services of B & W INT'L SECRETARY LIMITED (Honk Kong, China) [law firm] to establish an SPV/SPE,
"
BioCrude Technologies, (Hong Kong) Limited
" [JV Corporation], as the development vehicle for the MSW to Energy
project for the Autonomous Island of the Grande Comore, Union of the Comoros (BioCrude Technologies, (Hong Kong) Limited; filed
as an exhibit with the SEC). The "SPV/SPE" possesses the following characteristics:
1.
Memorandum and Articles of Association
: "The Companies Ordinance (Cap. 622) [Hong Kong, China]" for "Private Company Limited by Shares" is utilized as the base Memorandum and Articles of Association and enhanced / modified as per the terms, conditions and stipulations of the JV Agreement by and between SINOCONST and BioCrude ("
Memorandum and Articles of Association
"; filed as an exhibit with the SEC).
2.
Organization and Capital Structure
: as per the stipulations of the Memorandum and Articles of Association, and modified to reflect the following, as well:
25
BioCrude will account for seventy
percent (70.0%) of the total issued and outstanding shares of Common Stock at an issue price of 1 HKD per share for an aggregate
issue price of 700 HKD, and at Closing Date;
SINOCONST will account for
thirty per cent (30.0%) of the total issued and outstanding shares of Common Stock, at an issue price of 1 HKD per share for an
aggregate issue price of 300 HKD, and at Closing Date and issued only once financing (funding) for the Project has been put in
place, and will be holder of same until such time that financing (funding) has been paid back, in full, whereby all shares of Common
Stock will have been transferred to BioCrude, as full and final settlement for loan repayment and shares of Common Stock acquisition.
Nota Bene
: The
financing (funding) secured by SINOCONST for the Project and accepted by the JV Consortium will bare an amortization of approximately
five (5) years, with a negotiated mechanism for the repayment schedule of principal and interest. Every year end (from the beginning
of operations of the Project, i.e., after project completion in accordance to the terms, conditions and stipulations of SINOCONST's
engagement (Contract (Project) Agreement) with SPV/SPE), relative to the amount of capital paid down from the original outstanding
loan on that year, a pro rata amount of shares of Common Stock will be given (transferred) back to BioCrude in that year, until
the full repayment of the loan, whereby the balance of the shares of Common Stock outstanding as shareholdings of SINOCONST are
transferred back to BioCrude, and BioCrude is one hundred per cent (100.0%) shareholder of all of the issued and outstanding shares
of Common Stock.
3.
Management (Board of Directors, Officers)
: as per the stipulations of the Articles of Association, modified to reflect the terms, provisions and stipulations of the JV Agreement by and between BioCrude and SINOCONST.
On April 4th, 2017, SINOCONST's
General Manager of the Group Business Development Department, Mr. Zhou Tao, and BioCrude Technologies (Comoros), LTD. [Hong Kong
SPV established by SINOCONST and BioCrude, as a JV Partnership], Chairman and CEO, Mr. John Moukas, have signed a Construction
(EPC) Contract Agreement which embodies SPV's engagement of SINONST to Design, Construct, and Finance BioCrude's Municipal
Solid Waste (MSW) to Energy Complex in the municipality of Moroni, Autonomous Island of the Grande Comore, Union of the Comoros,
to treat MSW and procure renewable energy and other marketable by-products (organic fertilizer, ash, primary feedstock for building
materials, etc.…) within the conforms of BioCrude's acquired Concession and Power Purchase Agreements, as well as
BioCrude's Deed of Assignment pursuant to a Public-Private Partnership with the Governmental Authorities of the Autonomous
Island of Grande Comore, Union of the Comoros.
On September 1, 2017, BioCrude, in joint
with SINOCONST ("JV Consortium"), have had a work session (in Beijing, China) with China Export and Credit Insurance
Corporation ("SINOSURE"), to clarify particulars regarding BioCrude's Municipal Solid Waste (MSW) to Energy Complex
("Project") in the municipality of Moroni, Autonomous Island of the Grande Comore, Union of the Comoros, more particularly,
the Concessions and Power Purchase Agreements and the Deed of Assignment pursuant to a Public – Private Partnership. Thereafter,
BioCrude and SINOCONST, on behalf of BioCrude Technologies, (Hong Kong) Ltd ("SPV/SPE"), have submitted an application
to SINOSURE requesting loan insurance for the Project. As part and parcel to the loan insurance application, an independent third-party
feasibility study for the Project was requested. The JV Consortium has taken the initiative to solicit same for the execution of
the required works.
On September 5, 2017, JV Consortium,
on behalf of SPV/SPE, had a work session (in Beijing, China) with the Industrial and Commercial Bank of China Limited ("ICBC"),
and shortly therewith, submitted to same, an application for funding for BioCrude's Project. We are awaiting feedback regarding
the indicative terms and conditions ("term sheet") for the Project funding.
On October 5, 2017, BioCrude received
from ICBC, the indicative terms and conditions ("term sheet") for the Project funding (term of validity was six months).
On April 8, 2018, BioCrude received from ICBC, a renewal of the "term sheet", extending the term of validity for another
six months.
On January, 2018, BioCrude, in joint
with SINOCONST ("JV Consortium"), have commissioned out the works related to the feasibility study of the Municipal
Solid Waste (MSW) to Energy Complex ("Project") in the municipality of Moroni, Autonomous Island of the Grande Comore,
Union of the Comoros, to China International Electronic Commerce Center ("CIECC"), an independent engineering firm
in China, acceptable to SINOSURE's shortlist of accredited and acceptable suppliers for same.
On January 23, 2018, BioCrude, in joint
with SINOCONST ("JV Consortium"), had a work session (in Beijing, China) with CIECC. CIECC had requested that all of
BioCrude's literature be translated into mandarin (translation was concluded by March 30, 2018); the status of the final
report of the feasibility study for the project, as of these presences, is on hold due (awaiting feedback from the federal government
of Union of the Comoros).
On April 29, 2018, Comoros's President
Sem Azali Assoumani declared that a referendum on amending the country's Constitution would be held in July 2018. The results
of the referendum were in favor of changing the constitution, and one of the issues of address was federal consolidation of powers,
and as such, the Federal Government of the Union of the Comoros, would now be the new Intervening Party to the Concessions and
Power Purchase Agreements, as well as the Deed of Assignment pursuant to a Public-Private Partnership (PPP), in lieu of the Governorate
of the Autonomous Island of Grande Comore.
26
In the months of September and November,
2018, BioCrude sent a delegation to the Union of the Comoros in order to clarify and document the transition of the Federal Government's
intervention, and as such, the Federal Government of the Union of the Comoros has yet to issue to BioCrude the following Amending
Declarations:
1.
Amending Declaration to the Concessions and Power Purchase Agreements, as well as the Deed of Assignment pursuant to a Public-Private Partnership (PPP), by the Ministry of Finance, Economy, Budget, Investment and Foreign Trade of the Union of the Comoros, whereby they Federal Government of the Union of the Comoros acknowledges same, as well as declare that the Federal Government of the Union of the Comoros is the new intervening party to contracts, more particularly, with respect to honoring all of the Government's obligations within the signed engagements with BioCrude, as well as the Sovereign Guarantees attached to same.
2.
Amending Declaration to the Concessions and Power Purchase Agreements, as well as the Deed of Assignment pursuant to a Public-Private Partnership (PPP), by the Ministry of Production, Environment, Energy, Industry and Crafts of the Union of the Comoros, whereby the Federal Government of the Union of the Comoros acknowledges same, as well as declare that the Federal Government of the Union of the Comoros is the new intervening party to contracts, more particularly, with respect to honoring all of the Government's obligations with the issuance of all necessary permits, and clearances for the development of BioCrude's Waste to Energy project in Moroni, Grande Comore, Union of the Comoros.
BioCrude also requested from
the Federal Government of the Union of the Comoros' legal division, a legal opinion of the Concessions and Power Purchase
Agreements, as well as the Deed of Assignment pursuant to a Public-Private Partnership (PPP), incorporating the change of the Contracting/Intervening
Party. The Federal Government of the Union of the Comoros' legal division has yet to issue same.
As of these presences, BioCrude has
yet to receive the amending declarations, and legal opinion from the Federal Government of the Union of the Comoros, as well as
a signing date for the aforementioned expansion of works of waste treatment for the Governorates of Moheli and Anjouan, and for
the Waste Collection, and Street and Public Spaces Cleaning for the whole country of the Union of the Comoros (Autonomous Islands
of Grande Comore, Moheli and Anjouan).
Going Concern
The future of the Company is dependent
upon its ability to obtain financing and upon future profitable operations. Management has plans to seek additional capital through
private placements and a public offering of its common stock, if necessary. Although, historically, the Company had continuous
losses and negative working capital issues, there are doubts about the Company's ability to continue as a going concern.
The Company's ability to become
a profitable operating company is dependent upon its ability to generate revenues and/or obtain financing adequate to fulfill our
requirements to complete evaluations of Concession acquisitions and development of same opportunities and to achieve a level of
revenues adequate to support our cost structure has raised substantial doubts about our ability to continue as a going concern.
We plan to attempt to raise additional equity capital by selling shares in this offering and, if necessary, through one or more
private placement or public offerings. However, the doubts raised, relating to our ability to continue as a going concern, may
make our shares as an unattractive investment for potential investors. These factors, among others, may make it difficult to raise
any additional capital.
Plan of Operation
With the signing of the Concession Agreements
with the countries of the Union of the Comoro, the Company, during the next twelve months, will be able to aggressively implement
the building of its corporate infrastructure by adding a few key senior managers to oversee the control of the management of the
Complexes and the general management of the Company. In addition, technical staff experienced in the management of the Engineering,
Procurement, and Construction ("EPC") activities, a key component in the controlling the successful creation of a Complex,
will also be hired. The anticipated cost for accomplishing this is approximately twenty million United States dollars (20,000,000
USD), which includes the provisions for infrastructure development of the Company (construction, fixed assets and equipment procurement),
human resource staffing and working capital. The anticipation of raising funds through a common share offering will further allow
the Company to comfortably expand operations (with enhanced Research and Development), in sync, with the essence of BioCrude's
mission, as elaborated within these presents.
The crucial factor to the financial
success is the rapid successful signing of additional concession agreements. Each such agreement requires an immediate investment
in the capital stock of the legal entity created for the purpose of building and subsequently operating the Complex. Additional
investments in the capital stock of each Complex totaling ten percent (10%) of the capital expenditure for a given complex must
be made in conjunction with the securing of long-term debt provided by financial institutions (made possible by the sovereign guarantees
included in the Concession Agreements). The legal entities created for the Complexes in a given country take a wholly owned subsidiary
of a joint venture owned fifty per cent (50%) each by the Company and the local government providing the sovereign guarantee. The
Company anticipates the creation of a total of eight (8) subsidiaries and two (2) joint ventures requiring a total of approximately
$46 million (note: each joint venture entity requires the upfront payment of a licensing fee on the part of the Company's
joint venture partner, partially offsetting the Company's investment in the Complex and providing a portion of the funds
required to operate the Company and make further investments in additional Complexes).
27
Asset Management
BioCrude's capital strategy will
be focused in two main areas:
●
Implementing operating programs that improve capital efficiency and asset utilization; and
●
Pursuing selective strategic investment opportunities in waste transformation and resource optimization.
BioCrude seeks to selectively invest
growth capital in high-return opportunities that will enhance its ability to support emerging customer and market needs in waste
transformation and resource optimization. The investment strategy seeks to leverage core competencies in materials processing to
create additional value from the waste stream.
Revenue Streams
The Company has identified five (5)
main revenue streams. Revenues derived from each Complex (Plant Operating Revenue) are the largest and most secure as this relies
on the long-term Concession Agreements.
Plant Operating Revenues
This revenue stream is comprised of
the following four (4) elements;
Tipping Fees
In exchange for the provided environmental
services, municipalities have to pay a tipping fee per ton of waste delivered by the city to the MSW-Energy Complexes ("
Tipping
Fees
") based on the long-term Concession Agreement on a "
Put or Pay
" (for full face value) basis.
Sales of Power
In the W2E plant, the waste is processed
in RDF (Refuse Derived Fuel) and Biomethanation processes to yield marketable by-products. The RDF and the biogas are used for
power generation. The power is sold to the grid based on a long-term contract (Power Purchase Agreement) on a "
Take or
Pay
" (for full face value) basis.
Sales of Carbon Credits
The carbon credits gained by reducing
the green gas emission and by producing power based on renewable energy ("
Clean Design Mechanism
" (CDM)) are
sold on the carbon credit market.
Sales of By-Products
The by-products of recycled materials
and fertilizer will be marketed and sold to third parties:
►
Compost will be sold to the farming industry (which, in certain instances, is subsidized by the government), at spot market prices, less 15%. BioCrude may sell any excess product outside of the municipality and/or country.
►
Ash can be sold to resellers of construction materials.
►
Processed inerts (primary feedstock for building materials) can be sold to entities (local and foreign) engaged in that processing milieu.
►
Recyclables can be sold to entities (local and foreign) engaged in that processing milieu.
In the unlikely event MSW feedstock
is not delivered to the Complex, the MSW Agreement ensures that BioCrude is compensated for any shortfall in revenue derived from
the sale of electricity and by-products of Compost, ash and recyclables produced by the complex.
Engineering, Procurement and Construction
Fees
To ensure that the planned benefits
contained in the design of each Complex is realized BioCrude undertakes to supervise the entire EPC process and is compensated
accordingly, adhering to industry norms for such expertise.
Servicing Fees
Once the Complex is commercially operational,
BioCrude is responsible for the ongoing operation and maintenance of the related facilities. The Company is compensated for supervising
this activity in accordance with the terms of the contracts agreed to and signed prior to the commissioning of each Complex.
Licensing Fees
To accelerate the proliferation of the
Company's presence in the W2E market and at the same time reduce the demand on its cash resources, BioCrude is willing to
license its technology, to selected third parties in the form of joint ventures, resulting in another potential source of revenue.
28
Results of Operations
For the six months period ended
June 30, 2021 and 2020
Revenue
We did not generate revenue during the
six months period ended June 30, 2021 and 2020.
Costs and Expenses
During the six months period ended June
30, 2021 there were $314,853 of operating expenses consisting of general and administrative expenses. Operating expenses for the
prior year ended December 31, 2020 was $283,752 consisting of general and administrative.
Liquidity and Capital Resources
As at June 30, 2021, the Company had
$80,412 in cash and did not have any other cash equivalents. The following table provides detailed information about our net cash
flow for the six months period ended June 30, 2021 and 2020. To date, we have financed our operations through the issuance of stock
and borrowings.
In summary, our cash flows were as follows:
For the year ended June 30,
2021
For the year ended December 31,
2020
Net cash used in operating activities
$
(236,724
)
$
(279,584
)
Net cash used in investing activities
—
—
Net cash provided by financing activities
207,165
389,250
Effect of exchange rate changes on cash
—
—
Net increase (decrease) in Cash
(29,559
)
109,666
Cash, beginning of year
109,971
305
Cash, end of year
$
80,412
$
109,971
Due to the limited nature of the Company's
operations to date, the Company does not believe that past performance is any indication of future performance. The impact on the
Company's revenues of recognized trends and uncertainties in our market will not be recognized until such time as the Company
has had sufficient operations to provide a baseline.
Operating activities
Net cash used in operating activities
was $236,724 for the six months period ended June 30, 2021 and $279,584 for the year ended December 31, 2020.
Investing activities
Net cash used in investing activities
was $ Nil and $ Nil for the six months period ended June 30, 2021 and the year ended December 31, 2020, respectively.
Financing activities
Net cash provided by financing activities
was $207,165 and $389,250 for the six months ended June 30, 2021 and the year ended December 31, 2020, respectively.
Since inception, we have financed our
cash flow requirements through issuance of common stock and related party advances. As we expand our activities, we may, and most
likely will, continue to experience net negative cash flows from operations, pending receipt of listings or some form of advertising
revenues. Additionally, we anticipate obtaining additional financing to fund operations through common stock offerings, to the
extent available, or to obtain additional financing to the extent necessary to augment our working capital. In the future we need
to generate sufficient revenues from sales in order to eliminate or reduce the need to sell additional stock or obtain additional
loans. There can be no assurance we will be successful in raising the necessary funds to execute our business plan.
We anticipate that we will incur operating
losses in the next twelve months. Our lack of operating history makes predictions of future operating results difficult to ascertain.
Our prospects must be considered in light of the risks, expenses and difficulties frequently encountered by companies in their
early stage of development, particularly companies in new and rapidly evolving markets. Such risks for us include, but are not
limited to, an evolving and unpredictable business model and the management of growth.
To address these risks, we must, among
other things, obtain a customer base, implement and successfully execute our business and marketing strategy, continually develop
and upgrade our website, respond to competitive developments, and attract, retain and motivate qualified personnel. There can be
no assurance that we will be successful in addressing such risks, and the failure to do so can have a material adverse effect on
our business prospects, financial condition and results of operations.
29
Off-Balance Sheet Arrangements
We do not have any off-balance sheet
arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material
to investors.
Critical Accounting Policies
The methods, estimates and judgments
we use in applying our accounting policies have a significant impact on the results we report in our financial statements, which
we discuss under the heading "Results of Operations" following this section of our MD&A. Some of our accounting
policies require us to make difficult and subjective judgments, often as a result of the need to make estimates of matters that
are inherently uncertain.
We set forth below those material accounting
policies that we believe are the most critical to an investor's understanding of our financial results and condition and
that require complex management judgment.
Stock-Based Compensation
The Company accounts for all share-based
payment awards made to employees and directors, based on their fair value. The Company measures share-based compensation to consultants
by recognizing the fair value of the awards over the period the services are rendered or goods are provided.
Critical Accounting Policies
In Financial Reporting Release No. 60,
"Cautionary Advice Regarding Disclosure About Critical Accounting Policies" ("FRR 60"), the Securities
and Exchange Commission suggested that companies provide additional disclosure and commentary on their most critical accounting
policies. In FRR 60, the SEC defined the most critical accounting policies as the ones that are most important to the portrayal
of a company's financial condition and operating results, and require management to make its most difficult and subjective
judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition,
our most critical accounting policies include: non-cash compensation valuation that affects the total expenses reported in the
current period and the valuation of shares and underlying mineral rights acquired with shares. The methods, estimates and judgments
we use in applying these most critical accounting policies have a significant impact on the results we report in our financial
statements.
Available Information
We are subject to the informational
requirements of the Securities Exchange Act of 1934, as amended. All of our reports are able to be reviewed through the SEC's
Electronic Data Gathering Analysis and Retrieval System (EDGAR) which is publicly available through the SEC's website (
http://www.sec.gov
).
We intend to furnish to our stockholders,
annual reports containing financial statements audited by our independent certified public accountants and quarterly reports containing
reviewed unaudited interim financial statements for the first three-quarters of each fiscal year. You may contact the Securities
and Exchange Commission at (800) SEC-0330 or you may read and copy any reports, statements or other information that we file with
the Securities and Exchange Commission at the Securities and Exchange Commission's public reference room at the following
location:
Public Reference Room
100 F. Street N.W.
Washington, D.C. 2054900405
Telephone: (800) SEC-0330
ITEM 3
. QUANTITATIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK
The Company is not exposed to market
risk related to interest rates or foreign currencies.
ITEM 4
. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls
and Procedures
As required by Rule 13a-15 under the
Securities Exchange Act of 1934 (the "1934 Act"), as of December 31, 2019, we carried out an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures. This evaluation was carried out under the supervision and
with the participation of our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal
financial officer), who concluded, that our disclosure controls and procedures were effective as at September 30, 2020.
Disclosure controls and procedures are
controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted
under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities
and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures
designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated
to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely
decisions regarding required disclosure.
30
PART II OTHER INFORMATION
ITEM 1
. LEGAL PROCEEDINGS
The Company is not a party to any legal
proceedings.
ITEM 1A
. RISK FACTORS
There have been no material changes
in the risk factors set forth in the Company's 10-K/A (2020) filed February 16, 2021.
ITEM 2
. UNREGISTERED SALES
OF EQUITY SECURITIES AND USE OF PROCEEDS
There were no sales of unregistered
equity securities during the covered time period.
ITEM 3
. DEFAULTS UPON SENIOR
SECURITIES
None.
ITEM 4
. SUBMISSION OF MATTERS
TO A VOTE OF SECURITY HOLDERS
None.
ITEM 5
. OTHER INFORMATION
None.
ITEM 6
. EXHIBITS AND REPORTS
ON FORM 8-K
(a)
The following documents are included or incorporated by reference as exhibits to this report:
Exhibit No.
Description
31.1
Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
(b)
REPORTS ON FORM 8-K
None.
31
SIGNATURES
In accordance with Section 13 or 15
(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date:
August 2 2021
Biocrude Technologies USA, Inc.
Registrant
By:
/s/ John Moukas
Chief Executive Officer
32